var title_f32_22_33120="Terbinafine: Drug information";
var content_f32_22_33120=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Terbinafine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34358?source=see_link\">",
"       Terbinafine (systemic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/47/6900?source=see_link\">",
"       Terbinafine (topical): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9677 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C80C007BE0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_22_33120=[""].join("\n");
var outline_f32_22_33120=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34358?source=related_link\">",
"      Terbinafine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/47/6900?source=related_link\">",
"      Terbinafine (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_22_33121="Elbow arthrocentesis";
var content_f32_22_33121=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F70018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F70018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Elbow arthrocentesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The landmarks for injection or aspiration of the elbow joint are the radial head, lateral epicondyle, and tip of the olecranon. A needle inserted into the center of the triangle penetrates only the anconeus muscle and capsule before entering the joint. The patient is supine with the elbow flexed to 90 degrees and the hand tucked under the buttock. A triangle is made with points at the lateral epicondyle, radial head, and olecranon process. The needle is inserted in the center of the triangle, perpendicular to the skin and parallel to the radial head, 3/4 to 1 inch deep.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_22_33121=[""].join("\n");
var outline_f32_22_33121=null;
var title_f32_22_33122="Supplemental oxygen on commercial airlines";
var content_f32_22_33122=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Supplemental oxygen on commercial airlines (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?32/22/33122/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/22/33122/contributors\" id=\"au5969\">",
"       James K Stoller, MS, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?32/22/33122/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/22/33122/contributors\" id=\"se5257\">",
"       Peter J Barnes, DM, DSc, FRCP, FRS",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?32/22/33122/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/22/33122/contributors\" id=\"de1810\">",
"       Helen Hollingsworth, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?32/22/33122?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     As air travel has become more common, travel opportunities have increased for people with serious medical conditions. This includes passengers with lung disease who require supplemental oxygen during air travel. Commercial air carriers' policies regarding in-flight oxygen vary considerably, potentially leading to a great deal of confusion for travelers.",
"    </p>",
"    <p>",
"     This topic review provides an overview of the potential effects of air travel; measures to determine who may require in-flight oxygen; and steps to help patients plan ahead so that traveling with oxygen can be achieved safely, comfortably, and relatively easily.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      EFFECTS OF AIRLINE TRAVEL",
"     </span>",
"    </p>",
"    <p>",
"     Traveling by airplane exposes people to decreased air pressure and lower than normal oxygen levels. For most people, these changes are not noticeable. However, for patients with certain underlying lung conditions, small atmospheric changes can have significant and potentially severe effects.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Cabin pressure",
"     </span>",
"     &nbsp;&mdash;&nbsp;Air pressure drops as altitude increases. Thus, as an airplane ascends, the air pressure inside the plane is reduced. Inside commercial airplanes, pressurization of the cabin limits the fall of pressure. This allows the airplane to cruise at altitudes up to 40,000 feet without exposing travelers to dangerously low levels of air pressure.",
"    </p>",
"    <p>",
"     Cabin pressurization levels vary by the type of airplane. The United States Federal Aviation Administration (FAA) requires that the cabin pressure on commercial airplanes be maintained at levels equivalent to the atmospheric pressure below 8,000 feet. The FAA allows for brief drops in air pressure for safety purposes only, such as to avoid bad weather conditions. The minimum air pressure to which travelers could be exposed for short periods of time is equal to that encountered 10,000 feet above sea level.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Risks of exposure to low air pressure",
"     </span>",
"     &nbsp;&mdash;&nbsp;The effects of increased altitude and associated reductions in air pressure can result in expansion of the air or gas trapped within the body. Trapped air or gas can be located in many different places, including:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Nasal sinuses",
"      </li>",
"      <li>",
"       Tubes within the ear",
"      </li>",
"      <li>",
"       Abnormal pockets within the lung (bullae)",
"      </li>",
"      <li>",
"       The space between the outer layer of the lung and the inner layer of the chest wall; air trapped in this region is referred to as a pneumothorax",
"      </li>",
"      <li>",
"       Internal organs in the abdominal cavity",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     As atmospheric pressure drops, trapped air expands. This explains the \"ear-popping\" with which most travelers are familiar. When air is trapped in the chest, gas expansion can be life-threatening.",
"    </p>",
"    <p>",
"     Low air pressure during air travel also decreases the amount of oxygen in the air. This effect is modest and generally not noticeable for healthy travelers. For patients with significant lung disease, a small decrease in available oxygen can cause significant symptoms, especially with exercise. Although air travelers usually remain sitting and are relatively inactive during flight, even modest exertion (eg, walking to lavatory) under these conditions can cause low oxygen levels in up to 80 percent of people with lung disease.",
"    </p>",
"    <p>",
"     Despite the theoretical risks associated with air travel, studies indicate that medical emergencies and deaths are uncommon in people with long-standing (chronic) lung disease who fly. Most studies suggest that medical emergencies occur in about one in every 19,000 to 40,000 travel episodes and that deaths occur in approximately one in every 3,200,000 travel episodes.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      WILL I REQUIRE IN-FLIGHT SUPPLEMENTAL OXYGEN?",
"     </span>",
"    </p>",
"    <p>",
"     Patients with diseases that can cause low oxygen levels, particularly chronic obstructive pulmonary disease (COPD), may need oxygen supplementation in-flight. This is true even if the person does not use oxygen at home. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=see_link\">",
"      \"Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Predictive tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;The evaluation often includes measurement of the blood oxygen level using a finger oximeter and general tests of lung function. If you require supplemental oxygen on a daily basis, you may need an increased flow rate in-flight. If you do not require oxygen on a daily basis, but have borderline lung function, other tests may be recommended to calculate oxygen requirements during in-flight conditions. These include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Breathing a gas mixture with lower than normal levels of oxygen",
"      </li>",
"      <li>",
"       Testing in a special chamber where air pressure is lowered to simulate flight",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Experts generally recommend supplemental oxygen for any patient whose in-flight oxygen level is predicted to fall below a certain point and for anyone who is known to have low oxygen levels on the ground.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      PREPARING FOR AIRLINE TRAVEL",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Visit your doctor",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who are at risk for low oxygen levels should discuss their condition with a clinician well in advance of the planned departure date. Here are some suggestions to make this process as efficient as possible:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Determine if supplemental oxygen is needed several weeks to months before leaving. The studies necessary to determine the need for oxygen are best performed when your health is stable, within several weeks before the actual travel date. Most airlines require notification of the need for in-flight oxygen at least 48 hours before the trip, making it necessary to undergo such testing at least three days before travel.",
"      </li>",
"      <li>",
"       Learn what your oxygen requirements will be while flying, as well as during layovers and at the final destination (for those who require supplemental oxygen on the ground). Airlines do not provide oxygen for ground use. Speak with your doctor or other members of the healthcare team about arrangements to supply oxygen for each part of the trip. A local oxygen provider might be able to help with such arrangements.",
"      </li>",
"      <li>",
"       Obtain documentation of the need for oxygen from your doctor. Most airlines require a letter on the doctor's letterhead with his or her name and contact information, your specific underlying lung condition, approval for air travel, verification of need for in-flight oxygen, and information specifying the required oxygen flow rate in liters per minute, as well as duration of use (",
"       <a class=\"graphic graphic_figure graphicRef71862 \" href=\"UTD.htm?9/40/9856\">",
"        figure 1",
"       </a>",
"       ). Be sure to bring enough copies of this letter for all flights.",
"      </li>",
"      <li>",
"       Make sure that you have an adequate supply of your usual medications for the trip.",
"      </li>",
"      <li>",
"       Some doctors will prescribe an emergency supply of certain medications, such as an antibiotic in case of a bacterial lung infection or an oral glucocorticoid (eg, prednisone) to prevent or reduce inflammation. Keep such medications in their original containers and be sure to pack them in carry-on luggage.",
"      </li>",
"      <li>",
"       Gather copies of prescriptions for your medications. You should carry multiple copies in case the luggage is delayed, lost, or stolen. Consider keeping copies in the carry-on luggage rather than in checked baggage.",
"      </li>",
"      <li>",
"       Obtain a list of recommended physicians at your destination(s) and along your travel route.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4335337\">",
"     <span class=\"h2\">",
"      Obtaining oxygen for air travel",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Federal Aviation Administration does not allow travelers to carry their own oxygen&nbsp;tanks or liquid oxygen aboard commercial aircraft. Instead, most patients can use a Department of Transportation approved battery-powered portable oxygen concentrator. Airlines landing in the United States are now required to allow use of these devices throughout the flight.",
"    </p>",
"    <p>",
"     You can get portable oxygen concentrators for short-term rental from an oxygen supply company. Examples of portable oxygen concentrators include AirSep Free Style, AirSep Life Style, Inogen One, Inogen One G2, Respironics EverGo, Sequal Eclipse, Delphi Medical Systems RS-00400, Invacare Corporation XPO2, DeVilbiss Healthcare iGo, International Biophysics Corporation Life Choice, and Oxlife Independence Oxygen Concentrator. You can use these on the ground and carry them onto the plane. These machines are battery-operated, so you need to bring enough 12-cell batteries for one and half times the anticipated duration of the flight. While you are in the airport waiting for boarding, you might be able to plug the portable oxygen concentrator into an electrical outlet to save your battery power.",
"    </p>",
"    <p>",
"     Alternatively, some airlines provide oxygen that is supplied in an oxygen canister packaged in a flame proof \"super box.\"",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      \"Shop around\" for an appropriate airline",
"     </span>",
"     &nbsp;&mdash;&nbsp;Oxygen policies and charges can be very different, depending upon the airline. It is important to obtain the most up-to-date information about an airline&rsquo;s specific requirements to make sure that your needs will be met. The Airline Oxygen Council of American web site (",
"     <a class=\"external\" href=\"file://www.airlineoxygencouncil.org/\">",
"      www.airlineoxygencouncil.org",
"     </a>",
"     ) lists various airlines' policies regarding in-flight oxygen use and equipment. The European Lung Foundation has compiled information on European airlines, whose rules and charges regarding in&ndash;flight oxygen may differ from those of American carriers (",
"     <a class=\"external\" href=\"file://www.european-lung-foundation.org/\">",
"      www.european-lung-foundation.org",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     When contacting the airlines, begin by asking if they have a special services office, medical department, or a help desk to help travelers who need in-flight oxygen. The following is a list of suggested questions that may be helpful in clarifying a specific air carrier's oxygen policies:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Does your airline accept passengers who require supplemental oxygen?",
"      </li>",
"      <li>",
"       Are portable oxygen concentrators acceptable or is oxygen supplied by the airline?",
"      </li>",
"      <li>",
"       How much notice do you require before the flight? Many airlines require 48- to 72-hour advance notice. However, some air carriers may require several days, one to two weeks, or as much as one month advance notice. This is particularly true of international flights.",
"      </li>",
"      <li>",
"       What documentation is required from my doctor? All carriers require some notification from the passenger's personal doctor concerning oxygen needs, usually a written prescription or an airline authorization form, although sometimes verbal notification is sufficient.",
"      </li>",
"      <li>",
"       Do you allow passengers to bring their empty oxygen equipment? Due to safety reasons, the Federal Aviation Administration (FAA) prohibits travelers from carrying their own partially- or completely-filled oxygen tank or liquid oxygen tank aboard commercial aircraft. However, some air carriers permit passengers to bring",
"       <strong>",
"        empty",
"       </strong>",
"       personal oxygen equipment on board or as checked baggage.",
"      </li>",
"      <li>",
"       Are there specific seat requirements? Some air carriers assign certain seats to oxygen-using passengers to accommodate their equipment.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If the airline will be supplying the oxygen:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       What do you charge for supplying in-flight oxygen and how is the charge determined? Specific price structures vary among carriers. Some carriers supply oxygen for free, while others charge varying rates, often ranging from about $100 to $250. However, fees may be as low as $50 or as high as $1,500. Charges may be based on a flat fee, the number of travel legs, the number of oxygen cylinders needed, or total air time. It is important to be aware that airlines may charge for each separate flight. Because health insurance may not cover such charges, it is important to consider the expense of in-flight oxygen when selecting among air carriers that serve the same destinations.",
"      </li>",
"      <li>",
"       Are passengers required to purchase an additional seat if they will need more than a certain number of oxygen cylinders?",
"      </li>",
"      <li>",
"       What liter flow options are available? The liter flow capability offered among different air carriers varies. For example, liter flow options may range from only one or two choices (eg, either 2 or 4 liters per minute) to an adjustable range of 1 to 15 liters per minute.",
"      </li>",
"      <li>",
"       Do you provide nasal cannulas or masks? A nasal cannula is a device that delivers oxygen via two small tubes inserted in the nostrils. Air carriers may offer nasal cannulas or masks only, or a choice between the two. In addition, they may allow you to bring and use your own cannula or mask.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Verify the arrangements",
"     </span>",
"     &nbsp;&mdash;&nbsp;After deciding on an appropriate airline, be sure to make reservations as far in advance as you can. If there are any questions or concerns about the information you received while originally talking with the airline, call again to verify the information. In addition, make it a point to confirm your in-flight oxygen arrangements a few days before your flight, and be sure to arrive early.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Take appropriate precautions when aboard",
"     </span>",
"     &nbsp;&mdash;&nbsp;Before your plane leaves the gate, you should also take certain additional precautions. You should make sure that:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       The oxygen equipment is working properly",
"      </li>",
"      <li>",
"       You have plenty of batteries for your portable oxygen concentrator; you need enough to last the whole flight comfortably",
"      </li>",
"      <li>",
"       For oxygen canisters in a &ldquo;super box,&rdquo; check that the cylinders are full",
"      </li>",
"      <li>",
"       The flow meter has been set to the proper liter flow per minute",
"      </li>",
"      <li>",
"       You have access to all of your medicines, including inhalers",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If you have any questions or problems, notify a flight attendant immediately.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32164556\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32164564\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/42/27298?source=see_link\">",
"      Patient information: Staying healthy when you travel (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/59/5043?source=see_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/48/15107?source=see_link\">",
"      Patient information: Chronic bronchitis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32164608\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"     <br/>",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=see_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32164623\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"     <br/>",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=see_link\">",
"      Ear barotrauma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16042?source=see_link\">",
"      High altitude, air travel, and heart disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13737?source=see_link\">",
"      Patient assessment for air travel",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28840?source=see_link\">",
"      Traveling with oxygen aboard commercial air carriers",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Lung Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.lungusa.org/\">",
"      www.lungusa.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Alpha-1 Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.alphaone.org/\">",
"      www.alphaone.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Airline Oxygen Council of America",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.airlineoxygencouncil.org/\">",
"      www.airlineoxygencouncil.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       European Respiratory Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ersnet.org/\">",
"      www.ersnet.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Association for Respiratory Care",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aarc.org/\">",
"      www.aarc.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Home Oxygen Patients Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.homeoxygen.org/airline-travel-with-oxygen\">",
"      www.homeoxygen.org/airline-travel-with-oxygen",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Transportation Security Administration",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.tsa.dhs.gov/travelers/airtravel/specialneeds/editorial_1374.shtm\">",
"      www.tsa.dhs.gov/travelers/airtravel/specialneeds/editorial_1374.shtm#2",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?32/22/33122/abstract/1,2\">",
"      1,2",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 24, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?32/22/33122?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33122/abstract/1\">",
"      British Thoracic Society Standards of Care Committee. Managing passengers with respiratory disease planning air travel: British Thoracic Society recommendations. Thorax 2002; 57:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33122/abstract/2\">",
"      Lyznicki JM, Williams MA, Deitchman SD, et al. Medical oxygen and air travel. Aviat Space Environ Med 2000; 71:827.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f32_22_33122=[""].join("\n");
var outline_f32_22_33122=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           EFFECTS OF AIRLINE TRAVEL",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           WILL I REQUIRE IN-FLIGHT SUPPLEMENTAL OXYGEN?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           PREPARING FOR AIRLINE TRAVEL",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/40/9856\" title=\"figure 1\">",
"           O2 prescription air travel",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f32_22_33123="Dimethyl sulfoxide: Drug information";
var content_f32_22_33123=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dimethyl sulfoxide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33827?source=see_link\">",
"    see \"Dimethyl sulfoxide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F160865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rimso-50&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F160866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dimethyl Sulfoxide Irrigation, USP;",
"     </li>",
"     <li>",
"      Kemsol&reg;;",
"     </li>",
"     <li>",
"      Rimso-50&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F160881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Urinary Tract Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F160867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interstitial cystitis: Instill 50 mL directly into bladder and allow to remain for 15 minutes; repeat every 2 weeks until symptoms are relieved, then increase intervals between treatments",
"     <b>",
"      or",
"     </b>",
"     50 mL directly into bladder for 15-20 minutes every 1-2 weeks for 4-8 treatments (Chancellor, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F160868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F160858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intravesical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rimso-50&reg;: 50% (50 mL) [500 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F160849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F160860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Not for I.V. or I.M. use.",
"     </b>",
"     Intravesical: Instill directly into the bladder via catheter or syringe. To reduce bladder spasm it is recommended to apply an analgesic lubricant (eg, lidocaine jelly) to urethra prior to catheter insertion; belladonna and opium suppositories may be of benefit.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F160859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of interstitial cystitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F16562878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dimethyl sulfoxide may be confused with dimethyl fumarate",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F160879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Garlic-like breath (may persist for up to 72 hours), garlic-like taste (may persist for several hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Cystitis (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Discomfort (moderate-to-severe)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Skin odor (may persist for up to 72 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Contact dermatitis, eosinophilic cystitis, hypersensitivity reactions, lens deposits",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5683959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5683960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: May cause hypersensitivity reactions (rare).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ophthalmic effects: Lens changes and opacities have been observed in animal studies; precaution is advised in humans and eye exams (prior to use and periodically) are recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Urinary tract malignancy: Use with caution in patients with urinary tract malignancy; may be harmful due to vasodilatory effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate administration: For bladder instillation only; do not administer I.V./I.M.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F160854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexrazoxane: Dimethyl Sulfoxide may diminish the therapeutic effect of Dexrazoxane.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulindac: Dimethyl Sulfoxide may decrease the metabolism of Sulindac. Specifically, the concentrations of the active sulfide metabolite are decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F160855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13841189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F160870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F160862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Rimso-50 Intravesical)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50% (50 mL): $113.43",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5683993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, liver and renal function tests about every 6 months; eye examinations and slit lamp examinations (baseline and periodically)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F160863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Demsodrox (ES);",
"     </li>",
"     <li>",
"      Dermialgida Liquido (ES);",
"     </li>",
"     <li>",
"      Dolobene (PL);",
"     </li>",
"     <li>",
"      Intran DMSO-Losung (AT);",
"     </li>",
"     <li>",
"      Rheumabene (DE);",
"     </li>",
"     <li>",
"      Rimso-50 (GB)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5683985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exact mechanism unknown; reported to induce and alter inflammatory tissue responses, modulate collagen disposition, influence nerve conduction and neurotransmission, and alter cell proliferation in fibroblasts and hepatocytes; thus exerting an anti-inflammatory, analgesic, and muscle relaxant effect. It may also interact with free radicals forming formaldehyde, possibly contributing to fixative effect on biological tissues.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5683987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Well absorbed (topical administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Body fluids and tissues (topical administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Oxidation to dimethyl sulfone; reduction to dimethyl sulfide",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine and feces (as unchanged drug and dimethyl sulfone); skin and lungs (dimethyl sulfoxide)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abramov Y, Goldberg RP, McGuire M, et al, &ldquo;Eosinophilic Cystitis After Bladder Instillation With Dimethyl Sulfoxide,&rdquo;",
"      <i>",
"       Urology",
"      </i>",
"      , 2004, 63(6):1182-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/22/33123/abstract-text/15183980/pubmed\" id=\"15183980\" target=\"_blank\">",
"        15183980",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chancellor MB and Yoshimura N, &ldquo;Treatment of Interstitial Cystitis,&rdquo;",
"      <i>",
"       Urology",
"      </i>",
"      , 2004, 63(Suppl 1):85-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/22/33123/abstract-text/15013658/pubmed\" id=\"15013658\" target=\"_blank\">",
"        15013658",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Melchior D, Packer CS, Johnson TC, et al, &ldquo;Dimethyl Sulfoxide: Does it Change the Functional Properties of the Bladder Wall?,&rdquo;",
"      <i>",
"       J Urol",
"      </i>",
"      , 2003, 170(1):253-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/22/33123/abstract-text/12796699/pubmed\" id=\"12796699\" target=\"_blank\">",
"        12796699",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nishimura M, Takano Y, Toshitani S, &ldquo;Systemic Contact Dermatitis Medicamentosa Occurring After Intravesical Dimethyl Sulfoxide Treatment For Interstitial Cystitis,&rdquo;",
"      <i>",
"       Arch Dermatol",
"      </i>",
"      , 1988, 124(2):182-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/22/33123/abstract-text/2963596/pubmed\" id=\"2963596\" target=\"_blank\">",
"        2963596",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perez-Marrero R, Emerson LE, and Feltis JT, &ldquo;A Controlled Study of Dimethyl Sulfoxide in Interstitial Cystitis,&rdquo;",
"      <i>",
"       J Urol",
"      </i>",
"      , 1988, 140(1):36-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/22/33123/abstract-text/3288775/pubmed\" id=\"3288775\" target=\"_blank\">",
"        3288775",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rowley S and Baer R, &ldquo;Lens Deposits Associated With RIMSO-50 (Dimethylsulphoxide),&rdquo;",
"      <i>",
"       Eye",
"      </i>",
"      , 2001, 15(pt 3):332-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/22/33123/abstract-text/11450733/pubmed\" id=\"11450733\" target=\"_blank\">",
"        11450733",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8898 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-188.40.116.55-F65976BBC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_22_33123=[""].join("\n");
var outline_f32_22_33123=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160865\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160866\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160881\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160867\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160868\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160858\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160849\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160860\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160859\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16562878\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160879\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5683959\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5683960\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299206\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160854\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160855\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841189\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160870\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160862\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5683993\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160863\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5683985\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5683987\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8898\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8898|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33827?source=related_link\">",
"      Dimethyl sulfoxide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_22_33124="Closure of minor skin wounds with staples";
var content_f32_22_33124=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Closure of minor skin wounds with staples",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/22/33124/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/22/33124/contributors\">",
"     Rana Kronfol, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/22/33124/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/22/33124/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/22/33124/contributors\">",
"     Allan B Wolfson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/22/33124/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/22/33124/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/22/33124/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost 12 million wounds are treated annually in emergency departments in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33124/abstract/1\">",
"     1",
"    </a>",
"    ]. Management of minor wounds has two goals: hemostasis and achievement of a functional scar that is cosmetically acceptable [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33124/abstract/2\">",
"     2",
"    </a>",
"    ]. Suturing is the most common method of wound closure for minor lacerations; stapling and tissue adhesives (eg, Dermabond&reg;) are acceptable alternatives.",
"   </p>",
"   <p>",
"    The use of staples for wound closure is reviewed here. Wound preparation and other wound closure methods and the assessment and management of scalp lacerations are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link\">",
"     \"Minor wound preparation and irrigation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=see_link\">",
"     \"Closure of skin wounds with sutures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41478?source=see_link\">",
"     \"Superficial wound repair with tissue adhesives\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/9/30872?source=see_link\">",
"     \"Assessment and management of scalp lacerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For many minor wounds, suturing is the standard method of closure. Staples are an acceptable alternative for linear lacerations through the dermis that have straight, sharp edges and are located on the scalp, trunk, arms, and legs [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33124/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Scalp lacerations are particularly suitable for closure with staples. For these injuries, randomized trials suggest that closure of scalp wounds with staples is faster and less costly than with similar infection rates, healing time, and cosmetic outcomes when compared to sutures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/9/30872?source=see_link&amp;anchor=H4199768#H4199768\">",
"     \"Assessment and management of scalp lacerations\", section on 'Surgical staples'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because staples can be placed more rapidly than can sutures [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33124/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], they are especially useful in mass casualty situations [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33124/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. In such situations, staples may be safer because the risk of accidental needle-stick injury is eliminated [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33124/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because staples do not permit meticulous cosmetic repair, the clinician should avoid staple use on the face or neck [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33124/abstract/1,5,6\">",
"     1,5,6",
"    </a>",
"    ]. Also, discomfort makes staples a poor choice for wound closure in the hands or feet. In addition, staples should not be used in patients who may require computed tomography or magnetic resonance imaging as part of their acute care because they produce scan artifacts and may be avulsed by the powerful magnetic field.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local anesthesia using topical agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    -epinephrine-tetracaine [LET] gel)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infiltrative anesthesia (eg, buffered lidocaine) provides adequate pain control in most patients. In children, anxiety and pain response may often be decreased with distraction techniques and use of a child life specialist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=see_link&amp;anchor=H2#H2\">",
"     \"Topical anesthetics in children\", section on 'LET'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=see_link&amp;anchor=H2#H2\">",
"     \"Infiltration of local anesthetics\", section on 'Lidocaine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Wound assessment and irrigation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wound irrigation, foreign body removal, and necrotic tissue debridement should occur prior to staple placement. The preparation of a skin wound for closure is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link\">",
"     \"Minor wound preparation and irrigation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Materials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assemble the following materials:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sterile gloves for the provider",
"     </li>",
"     <li>",
"      Sterile 4 x 4 inch gauze, tubular gauze bandage, and tape for dressing",
"     </li>",
"     <li>",
"      Sterile drapes",
"     </li>",
"     <li>",
"      Irrigation solution (eg, sterile normal saline)",
"     </li>",
"     <li>",
"      30 to 60 mL syringe with 18 to 19 gauge IV catheter or irrigation device with splash shield (eg, Zerowet&reg;)",
"     </li>",
"     <li>",
"      Staple device",
"     </li>",
"     <li>",
"      Skin forceps",
"     </li>",
"     <li>",
"      Antibiotic ointment (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6469?source=see_link\">",
"       Bacitracin",
"      </a>",
"      &reg;)",
"     </li>",
"     <li>",
"      Staple remover",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many stapling devices are commercially available. Units which hold between 5 and 25 staples can be purchased. The 10-staple unit suffices for most lacerations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;After wound assessment and preparation with appropriate local anesthesia, the clinician performs staple closure as follows (",
"    <a class=\"graphic graphic_figure graphicRef69979 \" href=\"UTD.htm?6/5/6226\">",
"     figure 1",
"    </a>",
"    )&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link\">",
"     \"Minor wound preparation and irrigation\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H5\">",
"     'Analgesia'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33124/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Staple placement",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximate the adjacent skin margins with eversion of the skin edges using Adson forceps (forceps with teeth) or the thumb and forefinger. Eversion is necessary to avoid the tendency of the stapler to invert the edges of the wound, which can cause a less aesthetically pleasing scar. Eversion of the wound edges by an assistant may permit more accurate staple positioning.",
"     </li>",
"     <li>",
"      Place the stapler firmly on the skin surface but without indenting the skin.",
"     </li>",
"     <li>",
"      Align the center mark on the stapler with the center of the wound margin.",
"     </li>",
"     <li>",
"      Gently squeeze the staple handle to eject the staple into the skin.",
"     </li>",
"     <li>",
"      If the stapler does not automatically release, then release the staple from the stapler by pulling the stapler back. When properly placed, the crossbar of the staple is elevated a few millimeters above the skin surface.",
"     </li>",
"     <li>",
"      Place staples about 0.5 to 1 cm apart.",
"     </li>",
"     <li>",
"      Place enough staples to allow for proper apposition of the wound edges.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Wound care",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the wound is stapled, apply an antibiotic ointment to minimize dressing adherence, and either cover the wound with a sterile dressing (eg, leg, arm, and trunk wounds) or leave it open to the air (eg, scalp wounds). The patient may remove the dressing and gently clean the wound in 24 to 48 hours. The patient may then continue wound care until the staples are removed as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Apply antibiotic ointment daily to the wound.",
"     </li>",
"     <li>",
"      Apply a dressing to the wound, unless it was originally left open.",
"     </li>",
"     <li>",
"      Do not soak the wound (eg, swimming, bathing), although showering is acceptable",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The interval between application and removal of the staple is the same as that for standard suture placement and removal, although healing is more rapid (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=see_link&amp;anchor=H39#H39\">",
"     \"Closure of skin wounds with sutures\", section on 'Suture removal'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Scalp &ndash; 7 to 14 days",
"     </li>",
"     <li>",
"      Trunk and upper extremities &ndash; 7 to 10 days",
"     </li>",
"     <li>",
"      Lower extremities &ndash; 10 to 14 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Staple removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The procedure for staple removal is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Position the prongs of the staple remover under the staple.",
"     </li>",
"     <li>",
"      Depress the handle of the staple remover so that the staple is bent outward in the midline, easing it out of the skin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients describe a pinching sensation during removal [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33124/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the patient is following up elsewhere for staple removal, provide a staple remover to the patient to ensure that the follow-up provider has the proper equipment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications related to staple closure occur infrequently and at a rate that appears equivalent to that of sutured wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33124/abstract/7,9\">",
"     7,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Scarring",
"      </strong>",
"      &ndash; As with sutures, staples can cause scarring. In patients who scar easily, the scar that results from staples may be more pronounced than one produced by sutures, particularly if the staples are left in place for prolonged periods (&gt;5 to 15 days, depending upon the location) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33124/abstract/3,11\">",
"       3,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Difficult removal",
"      </strong>",
"      &ndash; Embedding of the staples in the skin and rotation of the staples may lead to difficulty in removal. Proper depth and symmetry of initial staple placement, as well as timely removal, should avoid this problem in most patients [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33124/abstract/12\">",
"       12",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      For partially embedded staples, the remover can be placed as far under the staple as possible and toggled back and forth until the staple loosens. On occasion, it is easier to grasp and toggle the staple with a hemostat.",
"      <br/>",
"      <br/>",
"      Rarely, staples may become completely lodged within the skin. In this situation, radiographs may be necessary to determine the orientation of the buried staple. After local anesthesia, an incision can be made over the buried staple so that removal can occur.",
"     </li>",
"     <li>",
"      <strong>",
"       Wound dehiscence",
"      </strong>",
"      &ndash; Wound dehiscence may occur if hemostasis is not ensured prior to staple placement or if the wound is not apposed completely during closure [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33124/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/51/6962?source=see_link\">",
"       \"Patient information: Stitches (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Staples are suitable for closure of linear lacerations through the dermis that have straight, sharp edges and are located on the scalp, trunk, arms, or legs. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because staples do not permit meticulous cosmetic repair, the clinician should avoid staple use on the face or neck. Also, discomfort makes staples a poor choice for wound closure in the hands or feet. In addition, staples should not be used in patients who may require computed tomography or magnetic resonance imaging as part of their acute care. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Proper wound preparation prior to stapling requires appropriate analgesia, wound assessment, irrigation, and debridement and does not differ significantly from the approach to wounds undergoing suture placement. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Analgesia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link\">",
"       \"Minor wound preparation and irrigation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The needed materials and procedure for staple placement, wound care, and staple removal are described above (",
"      <a class=\"graphic graphic_figure graphicRef69979 \" href=\"UTD.htm?6/5/6226\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Materials'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30149427\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Nawar, EW, Niska, RW, Xu, J. National Hospital Ambulatory Medical Care Survey: 2005 Emergency Department Summary. Advance data from vital health Statistics, no. 386. National Center for Health Statistics, Hyattsville, MD 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33124/abstract/2\">",
"      Hollander JE, Singer AJ. Laceration management. Ann Emerg Med 1999; 34:356.",
"     </a>",
"    </li>",
"    <li>",
"     Lammers L. Principles of wound management. In: Clinical Procedures in Emergency Medicine, Roberts J.  (Ed), WB Saunders, St. Louis 1988. p.533.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33124/abstract/4\">",
"      George TK, Simpson DC. Skin wound closure with staples in the Accident and Emergency Department. J R Coll Surg Edinb 1985; 30:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33124/abstract/5\">",
"      Edlich RF, Rodeheaver GT, Thacker JG, et al. Revolutionary advances in the management of traumatic wounds in the emergency department during the last 40 years: part II. J Emerg Med 2010; 38:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33124/abstract/6\">",
"      Forsch RT. Essentials of skin laceration repair. Am Fam Physician 2008; 78:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33124/abstract/7\">",
"      Kanegaye JT, Vance CW, Chan L, Schonfeld N. Comparison of skin stapling devices and standard sutures for pediatric scalp lacerations: a randomized study of cost and time benefits. J Pediatr 1997; 130:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33124/abstract/8\">",
"      MacGregor FB, McCombe AW, King PM, Macleod DA. Skin stapling of wounds in the accident department. Injury 1989; 20:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33124/abstract/9\">",
"      Ritchie AJ, Rocke LG. Staples versus sutures in the closure of scalp wounds: a prospective, double-blind, randomized trial. Injury 1989; 20:217.",
"     </a>",
"    </li>",
"    <li>",
"     McNamara R, DeAngelis M. Laceration repair with sutures, staples, and wound closure tapes. In: Textbook of Pediatric Emergency Procedures, 2nd, King C, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. p.1034.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33124/abstract/11\">",
"      Stockley I, Elson RA. Skin closure using staples and nylon sutures: a comparison of results. Ann R Coll Surg Engl 1987; 69:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33124/abstract/12\">",
"      Kanegaye JT, McCaslin RI. Pediatric scalp laceration repair complicated by skin staple migration. Am J Emerg Med 1999; 17:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33124/abstract/13\">",
"      Brickman KR, Lambert RW. Evaluation of skin stapling for wound closure in the emergency department. Ann Emerg Med 1989; 18:1122.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6320 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-8F853297CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_22_33124=[""].join("\n");
var outline_f32_22_33124=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Analgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Wound assessment and irrigation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Materials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Staple placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Wound care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Staple removal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30149427\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6320\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6320|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/5/6226\" title=\"figure 1\">",
"      Skin stapling",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/9/30872?source=related_link\">",
"      Assessment and management of scalp lacerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=related_link\">",
"      Closure of skin wounds with sutures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=related_link\">",
"      Minor wound preparation and irrigation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/51/6962?source=related_link\">",
"      Patient information: Stitches (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41478?source=related_link\">",
"      Superficial wound repair with tissue adhesives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=related_link\">",
"      Topical anesthetics in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_22_33125="Sotalol: Patient drug information";
var content_f32_22_33125=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sotalol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     see \"Sotalol: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/26/8617?source=see_link\">",
"     see \"Sotalol: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F222498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Betapace AF&reg;;",
"     </li>",
"     <li>",
"      Betapace&reg;;",
"     </li>",
"     <li>",
"      Sorine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F222499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Sotalol&reg;;",
"     </li>",
"     <li>",
"      CO Sotalol;",
"     </li>",
"     <li>",
"      Dom-Sotalol;",
"     </li>",
"     <li>",
"      Med-Sotalol;",
"     </li>",
"     <li>",
"      Mylan-Sotalol;",
"     </li>",
"     <li>",
"      Novo-Sotalol;",
"     </li>",
"     <li>",
"      Nu-Sotalol;",
"     </li>",
"     <li>",
"      PHL-Sotalol;",
"     </li>",
"     <li>",
"      PMS-Sotalol;",
"     </li>",
"     <li>",
"      PRO-Sotalol;",
"     </li>",
"     <li>",
"      ratio-Sotalol;",
"     </li>",
"     <li>",
"      Rhoxal-sotalol;",
"     </li>",
"     <li>",
"      Riva-Sotalol;",
"     </li>",
"     <li>",
"      Rylosol;",
"     </li>",
"     <li>",
"      Sandoz-Sotalol;",
"     </li>",
"     <li>",
"      ZYM-Sotalol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10024042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700629",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is used to treat unsafe fast heartbeats only. It may cause risky side effects. You will be closely watched when starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700367",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700566",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is more than 1 brand of this drug. One brand cannot safely be used for the other. Your doctor will tell you about any needed change.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Betapace AF&reg; is only for patients with some types of fast heartbeats. Make sure you have the right drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a fast heartbeat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702952",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sotalol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703310",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, poor kidney function, very weak heart, or slow heartbeat without a working pacemaker.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705251",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a long QT on ECG.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may hide the signs of low blood sugar. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698348",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Slow heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11051 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-EFBF5593C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_22_33125=[""].join("\n");
var outline_f32_22_33125=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222498\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222499\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024042\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024044\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024043\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024048\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024049\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024051\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024046\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024047\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024052\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024053\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=related_link\">",
"      Sotalol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/26/8617?source=related_link\">",
"      Sotalol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_22_33126="Lentigo maligna dermoscopy";
var content_f32_22_33126=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dermoscopic features of lentigo maligna",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atypical pseudonetwork, annular-granular pattern and slate-gray areas are characteristics of lentigo maligna.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_22_33126=[""].join("\n");
var outline_f32_22_33126=null;
var title_f32_22_33127="Pelvic floor physical therapy for management of myofascial pelvic pain syndrome in women";
var content_f32_22_33127=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pelvic floor physical therapy for management of myofascial pelvic pain syndrome in women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/22/33127/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/22/33127/contributors\">",
"     Rhonda K Kotarinos, PT, DPT",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/22/33127/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/22/33127/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/22/33127/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/22/33127/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/22/33127/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic floor physical therapy is the general term used to describe a variety of treatments utilized by physical therapists for the management of pelvic floor dysfunction. Pelvic floor dysfunction is a global term used to describe conditions such as pelvic organ prolapse, fecal or urinary incontinence, and chronic pelvic pain. Myofascial pain is one etiology of chronic pelvic pain of a myofascial origin.",
"   </p>",
"   <p>",
"    For women with pelvic organ prolapse and incontinence issues, the therapist develops a treatment program that addresses the weakness of the pelvic floor and related structures [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33127/abstract/1\">",
"     1",
"    </a>",
"    ]. This program may include pelvic floor muscle training, biofeedback, and electrical stimulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=see_link\">",
"     \"An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link\">",
"     \"Treatment of urinary incontinence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22458?source=see_link\">",
"     \"Fecal incontinence in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many experts believe that many, if not most, women with chronic pelvic pain have some degree of myofascial pelvic pain syndrome, a disorder in which pelvic pain is attributed to short, tight, tender pelvic floor muscles, usually with myofascial trigger points. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40389?source=see_link\">",
"     \"Clinical manifestations and diagnosis of myofascial pelvic pain syndrome in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of myofascial pelvic pain syndrome may also utilize pelvic floor muscle training, biofeedback, and electrical stimulation. However, additional forms of pelvic floor physical therapy may be employed secondary to the unique pathophysiology of this syndrome, which involves changes in the length tension relationship of the muscle, as well as changes in neural function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40389?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of myofascial pelvic pain syndrome in women\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic provides an overview of the conceptual framework from which physical therapists approach pelvic pain syndromes. It is intended to inform clinicians who refer patients for this intervention. An overview of multimodal treatment approaches to this disorder is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/11/5305?source=see_link\">",
"     \"Treatment of myofascial pelvic pain syndrome in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES OF MYOFASCIAL PELVIC PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myofascial pelvic pain is most often associated with the presence of myofascial trigger points within local muscles of the pelvis or distant muscles that refer to the pelvis. Conditions associated with pelvic floor tension myalgia can be divided into those that have or do not have urologic symptoms. Pelvic pain syndromes without urologic symptoms include dyspareunia, piriformis syndrome, vulvodynia, pelvic floor tension",
"    <span class=\"nowrap\">",
"     myalgia/levator",
"    </span>",
"    ani spasm, proctalgia fugax, and coccydynia [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33127/abstract/1\">",
"     1",
"    </a>",
"    ]. Urologic chronic pelvic pain syndromes include painful bladder",
"    <span class=\"nowrap\">",
"     syndrome/interstitial",
"    </span>",
"    cystitis",
"    <span class=\"nowrap\">",
"     (PBS/IC)",
"    </span>",
"    in women and men and chronic",
"    <span class=\"nowrap\">",
"     prostatitis/chronic",
"    </span>",
"    pelvic pain syndrome",
"    <span class=\"nowrap\">",
"     (CP/CPPS)",
"    </span>",
"    in men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     REFERRAL TO PHYSICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians can contact the American Physical Therapy Association for a listing of physical therapists in their area that specialize in the management of pelvic floor dysfunction. The clinician and physical therapist should have a good working relationship so that the physical therapist can communicate with the clinician when medical support is required to facilitate treatment, such as with injections or needling procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATIENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three major areas included in the evaluation by the physical therapist are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Musculoskeletal system &mdash; The musculoskeletal evaluation includes assessment of posture, gait, range of motion of the spine and extremities, length and strength relationship of relevant muscles, and documentation of pain distribution. Specific muscles would be assessed for myofascial trigger points.",
"     </li>",
"     <li>",
"      Pelvic floor muscles &mdash; The pelvic floor musculature is evaluated by inserting one or two fingers into the vagina or rectum and palpating the pelvic muscles. An instrumental evaluation of the pelvic floor (eg, surface electromyography - discussed below) may be performed to obtain additional information about strength and tone.",
"     </li>",
"     <li>",
"      Connective tissue &mdash; This soft tissue evaluation involves manually assessing areas of connective tissue for trophic changes and restrictions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pain mapping diagrams",
"    </span>",
"    &nbsp;&mdash;&nbsp;Working with the patient to create a pain map is a useful tool for locating trigger points (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Trigger points'",
"    </a>",
"    below). The patient is asked to draw the locations of her pain on a body diagram. In addition, the character of the pain and other symptoms should be noted using colors or symbols (eg, red or B for burning pain, blue or I for itching, green or A for aching) (",
"    <a class=\"graphic graphic_figure graphicRef80741 \" href=\"UTD.htm?9/23/9586\">",
"     figure 1",
"    </a>",
"    ). Severity of pain is noted using a scale of 0 (no pain) to 10 (excruciating pain). The clinician can use the same type of diagram to document",
"    <span class=\"nowrap\">",
"     her/his",
"    </span>",
"    objective findings of trophic changes, connective tissue restrictions, tenderness, scar tissue and trigger points. This form becomes a permanent part of the medical record and serves as a valuable tool for documenting changes and evaluating progress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Posture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poor posture can lead to excessive strain on muscles and other soft tissues that can predispose the individual to injury and pain. Chronic poor posturing can lead to stretch weakness of muscles and supporting connective tissues, adaptive shortening of muscle and connective tissue structures, and the development of trigger points. Altered neural dynamics may develop as a result of stretch",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    compression of neural tissue in association with pain. Postural dysfunction or movement imbalance can also result from abnormal mechanical tensions (imbalances) in muscles and their related fascia, which can create trigger points and their associated pain [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33127/abstract/2\">",
"     2",
"    </a>",
"    ]. In either case, the postural strain must be identified and resolved.",
"   </p>",
"   <p>",
"    Postural assessment is dynamic, as well as static. From a side standing view, are the ear, shoulder, hip, knee, and ankle on the same vertical line? On frontal and back standing views, are the head and spine held straight and the arms equidistant from the waist? Are the shoulders, hips, and knees at the same height? Does the upper or lower back curve excessively? Do both kneecaps face straight ahead? Static posture evaluation might reveal common structural inadequacies such as leg length discrepancies or shortened muscle groups that maintain poor alignment of body structures. Excessive lumbar spine lordosis with an anterior pelvic tilt has been labeled the \"typical pelvic pain posture\" [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33127/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the dynamic assessment, the patient is observed walking, moving from sit to stand, and ascending and descending stairs. These activities are evaluated to observe dynamic postural adaptations that might be related to pain with movement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Range of motion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of range of motion assessment is to determine whether there is any specific joint structure dysfunction. Evaluation includes both osteokinematic movements (eg, extension, flexion, adduction, abduction, or rotation of bones at joints) and arthrokinematic movements (ie, small gliding, rolling, or spinning movements occurring between joint surfaces).",
"   </p>",
"   <p>",
"    In patients with myofascial pelvic pain, the trunk and lower extremity joints should be evaluated with special attention to the lumbopelvic complex, including the sacrococcygeal joint and hip joints. Muscle length is evaluated simultaneously with range of motion testing, which can be done both actively and passively. Adaptive muscle shortening is one source of decreased range of motion, but trigger points will also limit range of motion through inhibition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Abdominal and pelvic musculature",
"    </span>",
"    &nbsp;&mdash;&nbsp;All muscles that directly relate to the pelvis (28 muscles have direct attachments to the pelvis) and those that refer to the pelvis should be evaluated, with special attention to the abdominal musculature because of its intimate relationship with pelvic floor function. Although coactivation of the abdominal and pelvic muscles is usually normal and advantageous, abnormally overactive or irritated abdominal wall musculature from trigger points such as surgical scars can provoke chronically active pelvic floor musculature [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33127/abstract/1\">",
"     1",
"    </a>",
"    ]. The abdominal wall should also be evaluated for a diastasis of the rectus abdominus muscles.",
"   </p>",
"   <p>",
"    To assess the pelvic floor muscles, one or two of the examiner's fingers are inserted into the",
"    <span class=\"nowrap\">",
"     vagina/rectum",
"    </span>",
"    and brought laterally as they palpate the tissue from the posterior midline to the lateral pelvic side walls and then anteriorly. When the pelvic floor is short and tight, there may be difficulty in admitting the lubricated examining fingers into the vagina, even with full patient cooperation. After entering the",
"    <span class=\"nowrap\">",
"     vagina/rectum,",
"    </span>",
"    the examining finger is palpating for taut bands, scar tissue, and assessing the mobility of the",
"    <span class=\"nowrap\">",
"     vagina/rectum",
"    </span>",
"    on the underlying pelvic floor. Tight pelvic floor muscles form bulky, firm shelves of muscle, often with multiple taut bands that feel like \"violin strings\" which may have trigger points. Pressure onto these bands is usually painful, often with radiation of pain into the lower abdomen or hip,",
"    <span class=\"nowrap\">",
"     vagina/rectum,",
"    </span>",
"    bladder or urethra. This may elicit the patient&rsquo;s pain.",
"   </p>",
"   <p>",
"    Since muscle dysfunction can occur on either end of the length-tension curve of muscle function (the muscle is either too long or too short), it is important to determine where in the contraction-relaxation cycle a problem is occurring before initiating a treatment protocol. To do this, the manual pelvic floor examination is divided into two components: dynamic and passive.",
"   </p>",
"   <p>",
"    The dynamic aspect is the digital palpation of the pelvic floor musculature during an active contraction. Is the patient able to isolate and actively perform a shortening contraction of the levator ani? If so, what is the strength, range of motion, and quality of the contraction? Differences between the two sides should also be noted. The strength can be described by using a manual muscle test scale such as the Brink scale, which is a four-point scale in three categories: contraction pressure, vertical displacement of the examiner's fingers, and duration of the squeeze [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33127/abstract/4\">",
"     4",
"    </a>",
"    ]. The quality of the contraction can be described as smooth, jerky, or cog wheel recruitment of muscle fibers. The range of motion refers to the amount of movement noted during a shortening and lengthening contraction of the pelvic floor.",
"   </p>",
"   <p>",
"    After the shortening contraction, the patient is asked to relax and whether or not she feels the post-shortening contraction muscle relaxation (\"can you feel your muscles letting go?\"). Assessing the lengthening contraction dynamically is done by asking the patient to drop her pelvic floor, as if initiating urination. A Valsalva maneuver or pushing is not acceptable. Assessing post-lengthening contraction relaxation is done passively by digital palpation of the soft tissue structures during the return to the resting position. Again, the patient is questioned as to her awareness of the motion. A thorough soft tissue evaluation includes methodical palpation of the soft tissues, muscles for trigger points, neural irritability, and palpation of connective tissue for restrictions and scars. Palpation normally produces a sensation of pressure; pain upon digital palpation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    passive movement of the soft tissues is abnormal.",
"   </p>",
"   <p>",
"    If available, a biofeedback instrument can be used to supplement this evaluation. Options include surface electromyography or measurement of pressure with transvaginal or transrectal probes. There are no standards for either of these forms of assessment, but the information gained helps to objectively monitor the patient's progress once treatment has been initiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Soft tissue assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of a patient with myofascial pelvic pain syndrome includes a comprehensive palpatory soft tissue assessment of connective tissues of the abdominal wall, inguinal ligaments, suprapubic area, lower back, buttocks, vulva, and lower extremities. Changes in skin color, contour, temperature, elasticity, turgor, and bulk should be noted. A reddish brown discoloration of the skin will occur in viscera-somatic areas of referral secondary to the trophic changes associated with the reflex vasoconstriction. Bright red skin flares, known as dermographia, can occur with the palpation of the abnormal area.",
"   </p>",
"   <p>",
"    Soft tissue palpation is performed with a light and a deep touch. Use of a small amount of massage cream facilitates this examination. The clinician uses a light touch to make a tactile assessment of the quality of the skin and its ability to move, as well as its texture, temperature, and turgor. The skin and soft tissue, including any scars, are also rolled between the examining fingers to assess the mobility between layers.",
"   </p>",
"   <p>",
"    The deeper subcutaneous and muscular tissues are palpated to assess tone, irritability, consistency, viscoelastic properties, shear (ie, the assessment of movement between tissue layers), and fluid content. Any textural changes in the fascial layers should also be noted. The soft tissue layers should be fluid, moving freely with other subcutaneous tissues. Connective tissue restrictions (ie, thickening and resistance to skin rolling), also known as subcutaneous panniculosis, develop in the subcutaneous tissues of the referral zones associated with visceral pain and myofascial trigger points. Trophic changes (ie, changes resulting from interruption of nutrition) in the somatic area of referred pain of a visceral nature or trigger point occur as a result of reflex induced vasoconstriction. Descriptive words, such as compressible-rigid, rough-smooth, and circumscribed-diffuse, are used to document the changes noted in the tissues.",
"   </p>",
"   <p>",
"    Examination of tissues with significant restrictions causes",
"    <span class=\"nowrap\">",
"     sharp/ripping/tearing",
"    </span>",
"    pain despite relatively mild manual pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33127/abstract/1\">",
"     1",
"    </a>",
"    ]. Palpation of a small tender mass (like a wad of chewing gum) within the subcutaneous tissue may produce pain [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33127/abstract/1\">",
"     1",
"    </a>",
"    ]. The location of scar tissue is documented and the scar is assessed for mobility and the production of pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Trigger points",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trigger points are areas of hyperirritability in muscular tissue that produce pain in referral zones when palpated. Muscles containing trigger points are usually short, weak, fatigue easily, and relax slowly [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33127/abstract/1\">",
"     1",
"    </a>",
"    ]. Trigger points can also be found in skin, scar tissue, fascia and ligaments throughout the pelvic floor.",
"   </p>",
"   <p>",
"    Muscles directly related to, or that refer to, the pelvis are assessed for trigger points. The presence of trigger points within the muscles of the pelvic floor, hip girdle, and abdominal wall produces symptoms ranging from vague suprapubic or pelvic discomfort to severe pain. Trigger points within the adductor magnus can refer pain into the central pelvis while a trigger point in the levator ani may refer pain to the vagina. Trigger points in the urogenital diaphragm may refer to the bladder or urethra.",
"   </p>",
"   <p>",
"    To locate a trigger point, the clinician palpates perpendicular to the fiber orientation of the muscle being assessed. When a taut band is felt, the palpating finger is turned to become parallel to the direction of the muscle fibers and used to find the most painful spot within the taut band. Ideally, when the clinician locates the trigger point, a local twitch response is produced in addition to reproduction of the patient's pain. Inter-rater reliability studies suggest that the minimal acceptable criteria for identification of an active trigger point is spot tenderness in a palpable band and patient recognition of pain [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33127/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Peripheral nerves",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific nerves that should be evaluated are the pudendal and the posterior femoral cutaneous nerves. The connective tissues innervated by these nerves may be the most likely source of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33127/abstract/6\">",
"     6",
"    </a>",
"    ]. In the setting of minimal inflammation, pain tends to develop as a result of ischemia. Connective tissue changes resulting from ischemia can cause restrictive processes that may then lead to painful abnormal impulse generating sites. As an example, the cutaneous referral zone for the bladder is the entire saddle area of the lower trunk. When connective tissue changes are present because of the visceral reference to the skin, mechanical compression of the microvasculature by the elastic bands of undergarments at the thigh crease can cause an ischemic compromise to branches of the posterior femoral cutaneous nerve and result in pain.",
"   </p>",
"   <p>",
"    Clinical assessment is accomplished by manually assessing the mobility of the nerve in its anatomical distribution. The pudendal nerve is most easily palpated internally at the ischial spine as it enters Alcock's canal. Some discomfort is normal, but a lowered threshold of pain may indicate that there is some compromise to the nerve's mobility. This could be due to a nerve entrapment or may be related to ischemia of the connective tissue that surrounds it. Irritability of a nerve may also be assessed by distraction of the tissue with active contraction of the related musculature.",
"   </p>",
"   <p>",
"    With the patient in a prone position, distraction of the posterior thigh crease (the normal anatomical path of the perineal branch of the posterior femoral cutaneous nerve on its way to the perineal tissues) away from the body followed by asking the patient to actively simultaneously knee flex and hip extend will assess the ability of the nerve to move. The nervous system should have pain-free mobility 20 percent further than at its resting state.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     REHABILITATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive treatment program of muscle, joint and myofascial techniques should be individualized to address the specific dysfunctions noted during the patient evaluation. Important components of treatment are instruction in a home exercise program and self management techniques. In addition, cognitive behavioral therapy is important to change the conditioned responses that may have developed as a result of the chronic pain state.",
"   </p>",
"   <p>",
"    An individualized therapeutic exercise program is required to address any structural dysfunctions. Treatment sessions typically are one hour on a weekly basis. Re-evaluation is done after 10 treatments to determine if progress has been sufficient for physical therapy to continue [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33127/abstract/7\">",
"     7",
"    </a>",
"    ]. The total duration of treatment often depends on how long the patient has been symptomatic; some patients require a year or more of weekly therapy.",
"   </p>",
"   <p>",
"    Initial treatment can be painful; the pace of treatment should be adjusted to the tolerance of the patient. Patients who are very symptomatic may have more frequent treatments, and patients who travel from far away for treatment can undergo daily treatments of two hours, for a week at a time, if tolerable. Trigger point injections",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dry needling may be useful to facilitate the resolution of the trigger point.",
"   </p>",
"   <p>",
"    Components of treatment include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Myofascial manipulation including manual trigger point release, injections and dry needling",
"     </li>",
"     <li>",
"      Neural mobilization and stretching",
"     </li>",
"     <li>",
"      Rehabilitation of extrapelvic musculoskeletal abnormalities",
"     </li>",
"     <li>",
"      Connective tissue manipulation",
"     </li>",
"     <li>",
"      Scar tissue mobilization",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Transvaginal/transrectal",
"      </span>",
"      manual therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Extrapelvic musculoskeletal abnormalities are addressed using standard physical therapy and orthopedic rehabilitation techniques.",
"   </p>",
"   <p>",
"    During rehabilitation, it is important to avoid activities that are known to exacerbate the patient's condition, such as Kegel exercises, vaginal coitus, prolonged sitting and wearing underwear with elastic legs or tight jeans. If a significant diastasis recti is present (ie, more than 3 cm above the umbilicus and more than a few millimeters apart below the umbilicus [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33127/abstract/1\">",
"     1",
"    </a>",
"    ]), it should be corrected before progressive abdominal strengthening exercises are initiated in the treatment process. A compromised abdominal wall will not react reflexively as it should, thus limiting the ability of strengthening exercises to maximize pelvic floor muscle function [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33127/abstract/8\">",
"     8",
"    </a>",
"    ]. Closure is accomplished by having the patient perform isolated contractions of the rectus abdominis muscles while the muscles are supported by tightly wrapping a sheet around the midsection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myofascial manipulation, trigger point release techniques, connective tissue manipulation and neural mobilization and stretching of the extra-pelvic structures are done first in a prone position and then in supine. During a treatment session, the patient lies in a hook-lying position (supine with the hips and knees bent) as the physical therapist works internally to manually release the trigger points and the restricted movement of the connective tissues and muscles of the vagina,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the rectum. First, short muscle groups in the pelvis or elsewhere are lengthened using soft tissue techniques and passive and active exercises. After the muscles have lengthened, strengthening exercises can be started.",
"   </p>",
"   <p>",
"    Manual joint mobilization techniques are utilized to treat arthrokinematic limitations of specific joints. Areas of structural hypomobility are mobilized while areas of hypermobility are stabilized through exercise and external supports. These interventions should facilitate normalization of osteokinematic movement of the joint.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Connective tissue manipulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Connective tissue restrictions associated with the",
"    <span class=\"nowrap\">",
"     viscero-somatic/somato-visceral",
"    </span>",
"    reflex and trigger points are treated with connective tissue manipulation. This is a superficial form of myofascial manipulation that utilizes pulling strokes on the skin and subcutaneous tissues to achieve reflex and local effects. This manipulation results in improved circulation to viscera, supporting tissues, muscles and nerves. All connective tissue from the nipple line to the knees, anterior and posterior, is treated.",
"   </p>",
"   <p>",
"    Over the course of therapy, subcutaneous connective tissue",
"    <span class=\"nowrap\">",
"     restriction/panniculosis",
"    </span>",
"    becomes progressively softer and increasingly homogeneous to palpation. Dry needling in accordance with traditional Chinese acupuncture can be combined with these manual techniques to facilitate the release of connective tissue restrictions. In the words of the Chinese acupuncturist, this is achieved by releasing &ldquo;stagnant blood.&rdquo; Associated muscle trigger points often respond to the treatment of subcutaneous panniculosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Release of scars",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal and perineal scars with any connective tissue restriction require release. Manual methods for softening and release of scars includes strumming across and stroking along the scar, as well as rolling the scar between fingers and thumbs and adding distraction when possible [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33127/abstract/7\">",
"     7",
"    </a>",
"    ]. Dry needling and local anesthetic injections are also used to facilitate scar tissue mobilization. The scar should be manually manipulated until it is fluid in its movement over underlying tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Transvaginal release of trigger points",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trigger points are treated with transvaginal manual release techniques or in combination with injections or dry needling. Dry needling by the physician is repeated weekly for a total of two to three weeks, usually just prior to manual therapy by the physical therapist [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33127/abstract/7\">",
"     7",
"    </a>",
"    ]. Barrier release is the preferred method for manual trigger point pressure release. Initially, progressive pressure is applied into the trigger point until tissue resistance (barrier) is noted and the patient is uncomfortable; the pressure is maintained until the barrier releases. Pressure is increased again until a new tissue barrier is felt. This technique can be enhanced by combining it with other techniques, such as",
"    <span class=\"nowrap\">",
"     contract/relax,",
"    </span>",
"    postisometric relaxation, and reciprocal inhibition.",
"   </p>",
"   <p>",
"    In the",
"    <span class=\"nowrap\">",
"     contract/relax",
"    </span>",
"    technique, the patient is asked to isotonically contract the levator against the resistance of the therapist's finger; elongation of the muscle is enhanced by the therapist as the patient relaxes the muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33127/abstract/7\">",
"     7",
"    </a>",
"    ]. For postisometric relaxation, the levator ani is contracted isometrically against the resistance of the",
"    <span class=\"nowrap\">",
"     transvaginal/rectal",
"    </span>",
"    finger; this finger then assists with the lengthening process during complete voluntary relaxation. Reciprocal inhibition is the relaxation of an agonist muscle during contraction of the antagonistic muscle. As a pelvic floor trigger point is manipulated, the patient is asked to contract the abdominal wall (antagonist muscle) to initiate a Valsalva maneuver. Asking the patient to inhale while the pelvic floor trigger point is being manually treated may facilitate its release.",
"   </p>",
"   <p>",
"    Injection of an anesthetic solution into the trigger point or dry needling of the trigger point are both equally effective in accomplishing its immediate, but may be temporary, inactivation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33127/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/11/5305?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of myofascial pelvic pain syndrome in women\", section on 'Injections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic exercise to put the muscle through its full available pain-free range is necessary after either manual or dry needle injection treatment techniques. An individualized home exercise program is designed for each patient to utilize the changes made during therapy and facilitate greater changes during the next therapy session. Stretching exercises are the mainstay of an exercise program for abdominal wall muscles with acute trigger points. After the trigger points are resolved, progressive abdominal strengthening is started. Exercises and interventions that may be recommended include reflex pelvic floor inhibition progressing to active pelvic floor lengthening and self myofascial and connective tissue manipulation. Once the pelvic floor is lengthened, a shortening contraction exercise program may be developed. Family members or significant others may be taught to do some of the myofascial and connective tissue manipulation techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given that the resolution of the patient's symptoms is the expected outcome of physical therapy, the clinician should expect positive changes within 10 visits. The therapist reevaluates the patient every 10 visits to assess progress and determine if therapy should continue. When the progress is not as expected, the physical therapist and clinician should collectively analyze the treatment approach.",
"   </p>",
"   <p>",
"    The physical therapist's approach to the evaluation and treatment of chronic pelvic pain has not been evaluated rigorously. Retrospective observational studies on the management of myofascial pelvic pain syndrome with manual techniques report that 50 to 72 percent of patients describe moderate to marked improvement or complete resolution in symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33127/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Data from two randomized trials support manual myofascial physical therapy for the treatment of chronic pelvic pain with urologic symptoms. Both trials found that the positive responder rate was significantly higher with manual myofascial physical therapy compared to therapeutic massage (57 versus 21 percent in one trial) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33127/abstract/12\">",
"     12",
"    </a>",
"    ]. The pilot study that included men and women had a 57 percent positive responder rate for the physical therapy treatment group, while the therapeutic massage treatment arm&rsquo;s positive responder rate was only 21 percent. Study subjects of the second larger trial were only women who had a 59 percent positive responder rate [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33127/abstract/13\">",
"     13",
"    </a>",
"    ]. More trials of the diagnostic and therapeutic approach to these patients are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who do not respond to pelvic floor physical therapy after 8 to 10 weeks should be reevaluated, possibly with additional testing or radiographic imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33127/abstract/7\">",
"     7",
"    </a>",
"    ]. For example, patients with associated urologic symptoms and very little improvement after 10 treatments may be evaluated with cystoscopy or magnetic resonance imaging to rule out an urethral diverticulum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26873?source=see_link\">",
"     \"Urethral diverticulum in women\"",
"    </a>",
"    .) Patients with underlying skeletal abnormalities may benefit from osteopathic manipulation.",
"   </p>",
"   <p>",
"    All patients must be educated about activities to avoid and stretches to do if any latent trigger points become active again or if a painful pelvic stimulus occurs (eg, urinary tract infection) in order to avoid relapsing into the muscle contraction pattern that originally caused the problem. For example, we ask all patients to avoid bearing down to assist bladder emptying.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/36/19009?source=see_link\">",
"       \"Patient information: Vaginismus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pelvic floor physical therapy involves evaluation and treatment of various pelvic floor dysfunctions. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with a diagnosis of myofascial pelvic pain syndrome receive a comprehensive structural and soft tissue evaluation and pain mapping. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Patient evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest pelvic floor physical therapy for relief of myofascial pelvic pain (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Treatment programs are individualized to address the specific dysfunctions noted on the evaluation. Structural dysfunctions are treated primarily with an individualized therapeutic exercise program, while soft tissue dysfunction is managed with manual techniques to treat the connective tissue restrictions, trigger points, and neural restrictions. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Rehabilitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dry needling can be combined with manual techniques to facilitate progress. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Rehabilitation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33127/abstract/1\">",
"      FitzGerald MP, Kotarinos R. Rehabilitation of the short pelvic floor. I: Background and patient evaluation. Int Urogynecol J Pelvic Floor Dysfunct 2003; 14:261.",
"     </a>",
"    </li>",
"    <li>",
"     Cantu, RI, Grodin, AJ. Myofascial Manipulation Theory and Clinical Application, Aspen Publication, Gaithersburg 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33127/abstract/3\">",
"      King, PM, Myers, CA, Ling, FW, Rosenthal, RH. Musculoskeletal factors in chronic pelvic pain. J Psychosom Obstet Gynaecol 1991; 12:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33127/abstract/4\">",
"      Brink CA, Wells TJ, Sampselle CM, et al. A digital test for pelvic muscle strength in women with urinary incontinence. Nurs Res 1994; 43:352.",
"     </a>",
"    </li>",
"    <li>",
"     Mense, S, Simons, DG. Muscle Pain Understanding Its Nature, Diagnosis, and Treatment, Lippincott Williams &amp; Wilkins, Philadelphia 2001. p.211.",
"    </li>",
"    <li>",
"     Butler, DS. The Sensitive Nervous System. Noigroup Publications, Australia 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33127/abstract/7\">",
"      FitzGerald MP, Kotarinos R. Rehabilitation of the short pelvic floor. II: Treatment of the patient with the short pelvic floor. Int Urogynecol J Pelvic Floor Dysfunct 2003; 14:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33127/abstract/8\">",
"      Neumann P, Gill V. Pelvic floor and abdominal muscle interaction: EMG activity and intra-abdominal pressure. Int Urogynecol J Pelvic Floor Dysfunct 2002; 13:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33127/abstract/9\">",
"      Langford CF, Udvari Nagy S, Ghoniem GM. Levator ani trigger point injections: An underutilized treatment for chronic pelvic pain. Neurourol Urodyn 2007; 26:59.",
"     </a>",
"    </li>",
"    <li>",
"     Mitchell, FL. An Endocrine Interpretation of Chapman's reflexes. Academy of Applied Osteopathy, 1963.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33127/abstract/11\">",
"      Weiss JM. Pelvic floor myofascial trigger points: manual therapy for interstitial cystitis and the urgency-frequency syndrome. J Urol 2001; 166:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33127/abstract/12\">",
"      FitzGerald MP, Anderson RU, Potts J, et al. Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes. J Urol 2009; 182:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33127/abstract/13\">",
"      Payne CK. Randomized multicenter clinical trial shows efficacy of myofascial physical therapy in women with interstitial cystitis/painful bladder syndrome (IC/PBS) (abstract). J Urol 2010; 183:e402.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5491 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-4F5D24ED7D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_22_33127=[""].join("\n");
var outline_f32_22_33127=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES OF MYOFASCIAL PELVIC PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      REFERRAL TO PHYSICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATIENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pain mapping diagrams",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Posture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Range of motion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Abdominal and pelvic musculature",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Soft tissue assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Trigger points",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Peripheral nerves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      REHABILITATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Connective tissue manipulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Release of scars",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Transvaginal release of trigger points",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5491\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5491|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/23/9586\" title=\"figure 1\">",
"      Myofascial pelvic pain map",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=related_link\">",
"      An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40389?source=related_link\">",
"      Clinical manifestations and diagnosis of myofascial pelvic pain syndrome in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22458?source=related_link\">",
"      Fecal incontinence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/36/19009?source=related_link\">",
"      Patient information: Vaginismus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/11/5305?source=related_link\">",
"      Treatment of myofascial pelvic pain syndrome in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=related_link\">",
"      Treatment of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26873?source=related_link\">",
"      Urethral diverticulum in women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_22_33128="Approach to the child with peripheral lymphadenopathy";
var content_f32_22_33128=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the child with peripheral lymphadenopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/22/33128/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/22/33128/contributors\">",
"     Kenneth L McClain, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/22/33128/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/22/33128/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/22/33128/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/22/33128/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/22/33128/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/22/33128/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/22/33128/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/22/33128/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic will provide guidelines for evaluating peripheral lymphadenopathy in children. The causes of peripheral lymphadenopathy and cervical lymphadenitis in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30744?source=see_link\">",
"     \"Causes of peripheral lymphadenopathy in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8632?source=see_link\">",
"     \"Etiology and clinical manifestations of cervical lymphadenitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The causes and evaluation of peripheral lymphadenopathy in adults also are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=see_link\">",
"     \"Evaluation of peripheral lymphadenopathy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of lymphadenopathy often is obvious after a complete history and physical examination. Important aspects of the history and examination include symptoms and signs suggestive of infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    systemic disease, and the location, size, consistency, fixation, and tenderness of the lymph nodes.",
"   </p>",
"   <p>",
"    Laboratory testing can be used to confirm a diagnosis that is suspected on the basis of the history and physical examination (eg, throat culture for group A streptococcal pharyngitis, heterophile antibodies or specific titers for Epstein-Barr virus or cytomegalovirus mononucleosis, serology for Bartonella henselae for cat scratch disease). For cases in which the lymphadenopathy remains unexplained after the initial history, examination, and laboratory tests, additional laboratory tests and lymph node biopsy may be necessary (",
"    <a class=\"graphic graphic_algorithm graphicRef52799 \" href=\"UTD.htm?38/49/39710\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef66039 \" href=\"UTD.htm?43/26/44463\">",
"     algorithm 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef73804 \" href=\"UTD.htm?1/5/1105\">",
"     algorithm 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef64444 \" href=\"UTD.htm?7/11/7344\">",
"     algorithm 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Treatment with",
"    <strong>",
"     glucocorticoids must be avoided",
"    </strong>",
"    before a definitive diagnosis is made. Glucocorticoid treatment could mask or delay the histologic diagnosis of leukemia or lymphoma. Glucocorticoids typically are used during the induction phase of chemotherapy for these disorders, and patients who are pre-treated are assigned to a higher risk category or may be ineligible for a clinical trial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=see_link\">",
"     \"Overview of the treatment of acute lymphoblastic leukemia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32874?source=see_link\">",
"     \"Overview of Hodgkin lymphoma in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies have correlated clinical features and biopsy results to predict the risk of malignancy or other treatable etiology in children with peripheral lymphadenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33128/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. A prospective study correlated clinical features with biopsy results in 45 children (&lt;18 years; mean age 7.8 years) with nonfluctuant peripheral adenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33128/abstract/1\">",
"     1",
"    </a>",
"    ]. The risk of malignancy increased with increasing age, size of node, and number of sites of adenopathy. The risk of malignancy was increased in children with supraclavicular nodes, fixed nodes, and abnormal radiographs. Factors that were not helpful for discriminating between benign and malignant causes were fever; cough; splenomegaly; skin erythema, discoloration, or induration; tender nodes; or leukocytosis. A similar study in 123 patients (9 to 25 years of age) found lymph node size &gt;2 cm; abnormal chest radiograph; and lack of ear, nose, and throat symptoms to be correlated with increased risk of malignancy or granulomatous disease (requiring biopsy) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33128/abstract/2\">",
"     2",
"    </a>",
"    ]. Systemic symptoms (eg, night sweats, weight loss, hemoglobin &le;10",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    also were associated with increased risk of malignancy or granulomatous disease.",
"   </p>",
"   <p>",
"    One of the authors of this topic review (KM) used the observations and guidelines from these and other studies to formulate algorithms to guide clinical decision-making in the child with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Generalized lymphadenopathy (",
"      <a class=\"graphic graphic_algorithm graphicRef52799 \" href=\"UTD.htm?38/49/39710\">",
"       algorithm 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Axillary adenopathy (",
"      <a class=\"graphic graphic_algorithm graphicRef66039 \" href=\"UTD.htm?43/26/44463\">",
"       algorithm 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cervical adenopathy (",
"      <a class=\"graphic graphic_algorithm graphicRef73804 \" href=\"UTD.htm?1/5/1105\">",
"       algorithm 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Inguinal adenopathy (",
"      <a class=\"graphic graphic_algorithm graphicRef64444 \" href=\"UTD.htm?7/11/7344\">",
"       algorithm 4",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The algorithms should be used in combination with clinical judgment. They have not been formally validated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history in a patient with lymphadenopathy should focus upon the following [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33128/abstract/4-9\">",
"     4-9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Location, and laterality of adenopathy &ndash; The causes of acute and",
"      <span class=\"nowrap\">",
"       subacute/chronic",
"      </span>",
"      lymphadenopathy differ, although there is some degree of overlap. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8632?source=see_link&amp;anchor=H5#H5\">",
"       \"Etiology and clinical manifestations of cervical lymphadenitis in children\", section on 'Overview'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30744?source=see_link&amp;anchor=H5#H5\">",
"       \"Causes of peripheral lymphadenopathy in children\", section on 'Overview'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Local symptoms suggestive of infection (eg, cough, pharyngitis, dental problems) or malignancy (eg, Horner syndrome, opsoclonus-myoclonus). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32262?source=see_link&amp;anchor=H8#H8\">",
"       \"Horner's syndrome\", section on 'Children'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15609?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical presentation, diagnosis, and staging evaluation of neuroblastoma\", section on 'Paraneoplastic syndromes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Associated constitutional symptoms (fever, weight loss, night sweats, arthralgias, skin rash) may suggest malignancy,",
"      <em>",
"       Mycobacterium tuberculosis",
"      </em>",
"      (TB), or rheumatologic disease. Fever typically accompanies lymphadenopathy caused by infections and is not particularly helpful in discriminating between infectious and noninfectious causes of lymphadenopathy.",
"     </li>",
"     <li>",
"      Contacts (viral respiratory infections, cytomegalovirus [CMV], Epstein-Barr virus [EBV], group A streptococcal infection [GAS,",
"      <em>",
"       Streptococcus pyogenes",
"      </em>",
"      ], TB).",
"     </li>",
"     <li>",
"      Ingestion of unpasteurized animal milk (brucellosis,",
"      <em>",
"       M. bovis",
"      </em>",
"      ) or undercooked meats (toxoplasmosis, tularemia).",
"     </li>",
"     <li>",
"      Dental problems or mouth sores (anaerobes, actinomycosis, enteroviral herpangina, herpes simplex gingivostomatitis).",
"     </li>",
"     <li>",
"      Skin lesions or trauma (",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      , GAS, herpes simplex virus [HSV], cat scratch disease [",
"      <em>",
"       Bartonella henselae",
"      </em>",
"      infection], tularemia, bubonic plague [",
"      <em>",
"       Yersinia pestis",
"      </em>",
"      ]).",
"     </li>",
"     <li>",
"      Animal exposures (cat scratch disease, toxoplasmosis [cats], brucellosis [especially goats], tularemia [especially rabbits], bubonic plague [especially prairie dogs],",
"      <em>",
"       M. marinum",
"      </em>",
"      [fish tanks]).",
"     </li>",
"     <li>",
"      Tick bites, flea bites, exposure to biting flies or mosquitoes (Lyme disease, bubonic plague, tularemia).",
"     </li>",
"     <li>",
"      Immunization status (diphtheria, measles, rubella).",
"     </li>",
"     <li>",
"      Medications (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/36/5706?source=see_link\">",
"       carbamazepine",
"      </a>",
"      &nbsp;(",
"      <a class=\"graphic graphic_table graphicRef61046 \" href=\"UTD.htm?7/17/7451\">",
"       table 1",
"      </a>",
"      )).",
"     </li>",
"     <li>",
"      Geographic location and travel (tularemia, bubonic plague, TB, measles, rubella, filariasis, leishmaniasis, typhoid fever).",
"     </li>",
"     <li>",
"      High-risk behavior (sexually transmitted infections, hepatitis B infection).",
"     </li>",
"     <li>",
"      History of asthma (Churg-Strauss syndrome), recurrent infection, skin abscesses, suppurative adenitis (chronic granulomatous disease), or autoimmune disease (autoimmune lymphoproliferative syndrome).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     General examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete physical examination should be performed to look for signs of systemic disease or infection (eg, ecchymoses, rash, pharyngitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33128/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weight &ndash; Weight loss of &gt;10 percent of body weight may be indicative of malignancy.",
"     </li>",
"     <li>",
"      Head &ndash; Scalp infection (eg, tinea capitis), conjunctival injection (Kawasaki disease, leptospirosis, oculoglandular syndrome [conjunctivitis and preauricular adenopathy]); nasal obstruction or depression of the soft palate (rhabdomyosarcoma, nasopharyngeal carcinoma).",
"     </li>",
"     <li>",
"      Oropharynx &ndash; Dental problems, pharyngitis, herpangina, herpes simplex virus gingivostomatitis.",
"     </li>",
"     <li>",
"      Chest &ndash; Adventitious sounds may indicate a systemic process, such as histoplasmosis or asthma, which may be associated with Churg-Strauss syndrome or diffuse pulmonary Langerhans histiocytosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=see_link\">",
"       \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35592?source=see_link\">",
"       \"Pulmonary Langerhans cell histiocytosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abdomen &ndash; Hepatosplenomegaly (systemic process such as EBV, CMV, HIV, syphilis, neoplastic disease, rheumatologic disease); abdominal mass (eg, neuroblastoma).",
"     </li>",
"     <li>",
"      Skin &ndash; Localized lesions (cat scratch disease (",
"      <a class=\"graphic graphic_picture graphicRef78770 \" href=\"UTD.htm?7/60/8128\">",
"       picture 1",
"      </a>",
"      ), tularemia (",
"      <a class=\"graphic graphic_picture graphicRef51005 \" href=\"UTD.htm?25/51/26418\">",
"       picture 2",
"      </a>",
"      ),",
"      <em>",
"       S. aureus",
"      </em>",
"      or GAS, HSV, etc); generalized rash (viral illness).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Lymph nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lymph nodes should be examined with the following characteristics in mind [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33128/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Location",
"     </li>",
"     <li>",
"      Size (measure them)",
"     </li>",
"     <li>",
"      Consistency",
"     </li>",
"     <li>",
"      Fixation",
"     </li>",
"     <li>",
"      Tenderness",
"     </li>",
"     <li>",
"      <strong>",
"       Location",
"      </strong>",
"      &ndash; Localized lymphadenopathy (present in only one region) suggests local causes and should prompt a search for pathology in the area of node drainage (",
"      <a class=\"graphic graphic_table graphicRef71073 \" href=\"UTD.htm?14/41/15005\">",
"       table 2",
"      </a>",
"      ), although some systemic diseases, such as plague (",
"      <em>",
"       Y. pestis",
"      </em>",
"      ), tularemia, and aggressive lymphomas, can present with local adenopathy. Unilateral localized lymphadenopathy occurs in Hodgkin lymphoma or Rosai-Dorfman disease, whereas bilateral localized lymphadenopathy occurs in non-Hodgkin lymphoma and autoimmune lymphoproliferative disease (ALPS) (",
"      <a class=\"graphic graphic_table graphicRef81033 graphicRef66847 \" href=\"UTD.htm?30/38/31342\">",
"       table 3A-B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Small occipital and postauricular nodes are common in infants, but not in older children [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33128/abstract/7,10\">",
"       7,10",
"      </a>",
"      ]. However, multiple pea-sized occipital nodes are often found in children with acute lymphoblastic leukemia. In contrast, cervical and inguinal nodes are more common after two years of age than in the first six months of life [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33128/abstract/7,10\">",
"       7,10",
"      </a>",
"      ]. Epitrochlear and supraclavicular adenopathy are uncommon at any age.",
"      <br/>",
"      <br/>",
"      Generalized adenopathy (present in two or more noncontiguous regions) usually is a manifestation of systemic disease (",
"      <a class=\"graphic graphic_table graphicRef81033 graphicRef66847 \" href=\"UTD.htm?30/38/31342\">",
"       table 3A-B",
"      </a>",
"      ). Palpation of inguinal, cervical, and axillary nodes, in addition to the liver and spleen, can determine whether lymphadenopathy is localized or generalized.",
"     </li>",
"     <li>",
"      <strong>",
"       Size",
"      </strong>",
"      &ndash; The size of a lymph node that is considered to be normal varies depending upon the lymph node region and age of the child. Lymph nodes in most regions are less than 1 cm in their longest diameter; lymph nodes in the epitrochlear region are usually not palpable.",
"      <br/>",
"      <br/>",
"      Abnormal nodes generally are greater than 2 cm in diameter, but the probability of malignancy varies depending upon the age of the child, size of the node, and number of nodal groups involved (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Overview'",
"      </a>",
"      above). Although malignancy can be found in smaller nodes in 10 to 20 percent of cases, it is more likely to be found in nodes larger than 2 cm [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33128/abstract/1\">",
"       1",
"      </a>",
"      ]. In one series of 75 biopsies performed in children 8 months to 17 years, 15 percent of patients had nodes &gt;3 cm in diameter [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33128/abstract/11\">",
"       11",
"      </a>",
"      ]. Among these, six patients had reactive hyperplasia, seven granulomatous disease, and two lymphomas. In patients with Hodgkin lymphoma being evaluated by CT scans, the threshold for abnormal nodes is 1 to 1.5 cm in transverse diameter (Cotswolds convention) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33128/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Consistency",
"      </strong>",
"      &ndash; Hard nodes are found in cancers that induce fibrosis (scirrhous changes) and when previous inflammation has left fibrosis. Firm, rubbery nodes are found in lymphomas and chronic leukemia; nodes in acute leukemia tend to be softer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=see_link\">",
"       \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Spontaneous drainage of the lymph node",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      formation of a fistulous tract, if it develops over weeks to months, is suggestive of mycobacterial infection. Rapidly developing suppuration and drainage suggests pyogenic infection, usually a staphylococcal or streptococcal infection.",
"     </li>",
"     <li>",
"      <strong>",
"       Fixation",
"      </strong>",
"      &ndash; Normal lymph nodes are freely movable in the subcutaneous space. Abnormal nodes can become fixed to adjacent tissues (eg, deep fascia) by invading cancers or inflammation in tissue surrounding the nodes. They also can become fixed to each other (\"matted\") by the same processes.",
"     </li>",
"     <li>",
"      <strong>",
"       Tenderness",
"      </strong>",
"      &ndash; Tenderness suggests that recent, rapid enlargement has caused tension in the pain receptors in the capsule. Tenderness typically occurs with inflammatory processes, but it also can occur because of hemorrhage into a node, immunologic stimulation, and malignancy [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33128/abstract/1\">",
"       1",
"      </a>",
"      ]. Thus, tenderness is not particularly helpful in discriminating between infectious and noninfectious causes of lymphadenopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Additional evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional tests may be performed to confirm the diagnosis that is suspected on the basis of the history and examination (eg, throat culture for group A streptococcal pharyngitis, EBV serology, serology for",
"    <em>",
"     B. henselae",
"    </em>",
"    for cat scratch disease). Further evaluation may be necessary if the diagnosis remains uncertain after the initial evaluation and laboratory tests.",
"   </p>",
"   <p>",
"    Additional evaluation for patients with peripheral adenopathy may include blood tests, cultures, imaging, a trial of antimicrobial therapy, incision and drainage,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lymph node biopsy. The sequence of the evaluation varies depending upon whether the lymphadenopathy is localized or generalized, and the presence of associated symptoms. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Diagnostic approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Blood tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood tests that may be necessary in the evaluation of a child with lymphadenopathy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count (CBC)",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate (ESR)",
"     </li>",
"     <li>",
"      Serology for EBV (antiviral capsid antigen [anti-VCA] IgG and IgM and EBV nuclear antigens [EBNA]), CMV, HIV, toxoplasmosis,",
"      <em>",
"       B. henselae",
"      </em>",
"      , tularemia, syphilis, and rubella, among others",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Leukopenia and the presence of atypical lymphocytes are important findings, as they may suggest an etiology (eg, malignancy, autoimmune lymphoproliferative disease, EBV). Although the ESR does not help to differentiate infection from malignancy, it tends to be higher (eg, &ge;50",
"    <span class=\"nowrap\">",
"     mm/hr)",
"    </span>",
"    in patients with Hodgkin lymphoma and is helpful in following response to therapy or relapse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32874?source=see_link\">",
"     \"Overview of Hodgkin lymphoma in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cultures of the throat, skin, blood,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lymph node may be indicated in selected circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cultures of the throat or skin lesions may be helpful in confirming the diagnosis that is suspected after the history and examination.",
"     </li>",
"     <li>",
"      Blood cultures should be obtained if the child appears systemically ill and a bacterial infection is suspected.",
"     </li>",
"     <li>",
"      Excisional biopsy (if tuberculous or nontuberculous mycobacterial infection is strongly suspected) or incision and drainage may be indicated in the moderately or severely ill child with acute unilateral lymphadenitis. Abscess fluid should be sent for Gram stain and bacterial culture (aerobic and anaerobic), mycobacterial stain and culture, and fungal stain and culture. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Lymph node biopsy'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24857?source=see_link&amp;anchor=H11#H11\">",
"       \"Diagnostic approach to and initial treatment of cervical lymphadenitis in children\", section on 'Acute unilateral disease'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Tuberculin skin test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculin skin testing (TST) is indicated to exclude",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    infection. TST also may result in reactive induration in children with nontuberculous mycobacterial (NTM) infection, but TST is not sensitive for NTM disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13143?source=see_link\">",
"     \"Latent tuberculosis infection in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23625?source=see_link\">",
"     \"Tuberculosis disease in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13994?source=see_link&amp;anchor=H2443737761#H2443737761\">",
"     \"Overview of nontuberculous mycobacterial lymphadenitis in children\", section on 'Tuberculin skin testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiographs (CXR) and other imaging modalities may be necessary in the evaluation of the child with peripheral lymphadenopathy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CXR are performed to look for mediastinal masses or hilar adenopathy.",
"     </li>",
"     <li>",
"      Ultrasonography may be helpful in defining the presence and extent of an abscess if lymph node fluctuance is not obvious by manual examination.",
"     </li>",
"     <li>",
"      Ultrasonography of the adenopathy also may help to differentiate metastatic from infectious cervical lymph nodes based upon the more circular shape, nodal borders, and distribution of perfusion in the former [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33128/abstract/3,13-16\">",
"       3,13-16",
"      </a>",
"      ]. However, these features do not provide definitive information, so biopsy is often necessary regardless of the results of the ultrasound.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional radiographic techniques may be helpful in discriminating benign from malignant lymphadenopathy. These include diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient maps [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33128/abstract/17\">",
"     17",
"    </a>",
"    ], contrast-enhanced ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33128/abstract/18\">",
"     18",
"    </a>",
"    ], and volumetric computed tomography [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33128/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some children with localized lymphadenopathy, the response to antimicrobial therapy is an important decision point in the diagnostic approach (",
"    <a class=\"graphic graphic_algorithm graphicRef52799 \" href=\"UTD.htm?38/49/39710\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef66039 \" href=\"UTD.htm?43/26/44463\">",
"     algorithm 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef73804 \" href=\"UTD.htm?1/5/1105\">",
"     algorithm 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef64444 \" href=\"UTD.htm?7/11/7344\">",
"     algorithm 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The empiric antibiotic therapy should include coverage for common pathogens such as group A streptococcus and",
"    <em>",
"     S. aureus",
"    </em>",
"    ; the choice is complicated by the increasing prevalence of community-associated methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (CA-MRSA). If the patient resides in an area of high CA-MRSA prevalence,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) as initial treatment is reasonable. Appropriate regimens in areas with low CA-MRSA prevalence may include a first-generation cephalosporin (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/5/30804?source=see_link\">",
"     cephalexin",
"    </a>",
"    ) or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/26/34214?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    . However, if the patient's systemic symptoms (eg, fever) do not improve within 72 hours, a change of antibiotics to clindamycin or TMP-SMX may be warranted (to address the possibility of CA-MRSA). Antimicrobial therapy is usually continued for 10 to 14 days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33290?source=see_link&amp;anchor=H10#H10\">",
"     \"Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children\", section on 'Approach for children &gt;30 days of age'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Lymph node biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although persistent lymph node enlargement prompts clinicians to obtain a biopsy, only 20 percent of biopsies demonstrate a treatable disease. In some reported series, the character or size of the nodes is helpful in deciding when a biopsy is indicated, but location is probably the most important factor [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33128/abstract/1,7,11\">",
"     1,7,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early lymph node biopsy may be indicated in patients with the following clinical features [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33128/abstract/1,2,7,11\">",
"     1,2,7,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Systemic symptoms (fever &gt;1 week, night sweats, weight loss (&gt;10 percent of body weight))",
"     </li>",
"     <li>",
"      Supraclavicular and lower cervical nodes",
"     </li>",
"     <li>",
"      Multiple sites of enlarged lymph nodes",
"     </li>",
"     <li>",
"      Fixed, nontender nodes in the absence of other symptoms",
"     </li>",
"     <li>",
"      Abnormal CXR or CBC",
"     </li>",
"     <li>",
"      Lack of infectious symptoms in the ear, nose, and throat regions",
"     </li>",
"     <li>",
"      Lymph nodes of &gt;1 cm with onset in the neonatal period",
"     </li>",
"     <li>",
"      Lymph nodes &gt;2 cm in diameter that have increased in size from baseline or have not responded to two weeks of antibiotic therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In conjunction with the indications for biopsy listed above, lymph node biopsy also may be indicated in children with persistently elevated ESR or rising ESR despite antibiotic therapy.",
"   </p>",
"   <p>",
"    In addition, excisional biopsy is recommended for patients in whom tuberculous or nontuberculous mycobacterial infection is suspected since simple aspiration may result in the development of a fistulous tract [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33128/abstract/20-23\">",
"     20-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The biopsy should be performed at a medical center specializing in the care of children, and the pathologist should know in advance that there will be a lymph node biopsy. This will ensure that the proper smears, stains, and cultures will be performed. Parts of the sample should not be fixed at the time of excision to allow for sensitive marker studies, such as immunophenotyping, cytogenetics, and molecular studies.",
"   </p>",
"   <p>",
"    Several options are available for direct examination of abnormal lymph nodes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Open biopsy &ndash; Open biopsy generally is the best diagnostic test because histologic examination of intact tissue provides information about both the presence of abnormal cells (carcinoma, microorganisms) and abnormal node architecture, which is necessary for the diagnosis of lymphomas. False-negative results occur if the wrong node is taken, which is not uncommon.",
"      <br/>",
"      <br/>",
"      Biopsy usually is performed on an outpatient basis under local anesthesia. The most abnormal node is selected if multiple node groups are involved. If no single node predominates, the choice in descending order of preference is supraclavicular, neck, axilla, and groin because the chances of a nonspecific result are greatest with axillary and inguinal nodes. In addition, the likelihood of complications of lymph node biopsy, such as infection or damage to the neurovascular structures, is higher in the groin and axilla. The vital structures in the neck are relatively easily identified and avoided during surgery.",
"     </li>",
"     <li>",
"      Fine needle aspiration &ndash; Fine needle aspiration (FNA) for cytology traditionally has been most useful when searching for recurrence of cancer. False-positive results are uncommon, but a substantial false-negative rate exists because of sampling error and difficulty recognizing well-differentiated lymphomas [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33128/abstract/24\">",
"       24",
"      </a>",
"      ]. The technique is particularly limited in children because of the prevalence of benign hyperplasia and the need for molecular studies on malignant tissue. Nevertheless, FNA may assume a larger role in areas where open biopsy is not available and in centers that have a specialized team of pathologists, radiologists, and clinicians [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33128/abstract/25\">",
"       25",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      FNA also has a role in patients with HIV infection for evaluating lymph nodes that are believed to harbor other disease [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33128/abstract/26-28\">",
"       26-28",
"      </a>",
"      ]. In one series of 121 biopsies in 113 patients, 24 were caused by non-Hodgkin lymphoma, 21 mycobacterial infection, 2 Kaposi sarcoma, 1 Hodgkin lymphoma, and 3 cancer; the remaining 60 biopsies showed nonspecific hyperplasia [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33128/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Incision and drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incision and drainage of fluctuant nodes may be necessary to relieve pain and treat obvious infection. However, it is not a particularly effective diagnostic test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic approach to children with peripheral lymphadenopathy varies from observation and reassurance to comprehensive diagnostic testing and aggressive medical and surgical therapy, depending upon the findings from the history and physical examination (",
"    <a class=\"graphic graphic_algorithm graphicRef52799 \" href=\"UTD.htm?38/49/39710\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef66039 \" href=\"UTD.htm?43/26/44463\">",
"     algorithm 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef73804 \" href=\"UTD.htm?1/5/1105\">",
"     algorithm 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef64444 \" href=\"UTD.htm?7/11/7344\">",
"     algorithm 4",
"    </a>",
"    ). It is not necessary to identify the underlying etiology in every patient since most cases are benign and self-limited. The pace of the evaluation is dictated by how ill the patient appears.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Generalized nodes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Initial tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory evaluation for the child with generalized adenopathy varies depending upon the findings in the history and physical examination. The initial evaluation should include viral serology for cytomegalovirus (CMV), Epstein-Barr virus (EBV), and other viral illnesses as warranted by the history and examination. It should also include a complete blood count, erythrocyte sedimentation rate (ESR), and chest radiographs (CXR) (",
"    <a class=\"graphic graphic_algorithm graphicRef52799 \" href=\"UTD.htm?38/49/39710\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Abnormalities on the CXR or complete blood count (CBC) may suggest an underlying etiology and the need for additional evaluation. As an example, hilar adenopathy may indicate sarcoid, tuberculosis, or Hodgkin lymphoma; a mediastinal mass may indicate lymphoma or other malignancy, depending upon its location. Bone marrow aspirate or biopsy may be necessary in patients with cytopenias and negative viral serology. (See individual topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Subsequent tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional tests, which may be indicated in patients in whom the diagnosis remains uncertain after the initial evaluation, are usually of low yield in the absence of a specific indication. These include additional viral, fungal, or other serologic tests (eg, toxoplasmosis, histoplasmosis, coccidiomycosis, brucella, rapid plasma reagin [RPR], and antinuclear antibody).",
"   </p>",
"   <p>",
"    If the diagnosis remains uncertain, or there is no response to therapy suggested by the preceding evaluation, a biopsy of the most abnormal node should be obtained. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Lymph node biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Localized nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of children with localized adenopathy depends upon the location and size of the nodes (",
"    <a class=\"graphic graphic_algorithm graphicRef66039 \" href=\"UTD.htm?43/26/44463\">",
"     algorithm 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef73804 \" href=\"UTD.htm?1/5/1105\">",
"     algorithm 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef64444 \" href=\"UTD.htm?7/11/7344\">",
"     algorithm 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Supraclavicular nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with supraclavicular adenopathy should always be evaluated with CBC, CXR, and biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Axillary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of axillary adenopathy depends upon the size of the nodes (",
"    <a class=\"graphic graphic_algorithm graphicRef66039 \" href=\"UTD.htm?43/26/44463\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children with small axillary adenopathy (&lt;2 cm), bacterial (especially",
"      <em>",
"       B. henselae",
"      </em>",
"      ) and fungal cultures may be obtained and empiric therapy initiated as indicated by the history and examination. Biopsy is indicated for those who fail to respond to appropriate antimicrobial therapy or whose lymphadenopathy persists for &gt;1 month without improvement. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Response to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Large axillary adenopathy (&ge;2 cm) usually requires biopsy if it does not respond to antibiotic therapy or two to three weeks of observation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Cervical or inguinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with localized lymphadenopathy at other sites (eg, cervical, inguinal), can be observed for three to four weeks and treated empirically with antibiotics when appropriate, provided that nothing else in the history and physical examination suggests malignancy (eg, weight loss &gt;10 percent of body weight, abnormal CBC or CXR, elevated ESR, fever, and lack of upper respiratory tract infection symptoms) (",
"    <a class=\"graphic graphic_algorithm graphicRef73804 \" href=\"UTD.htm?1/5/1105\">",
"     algorithm 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef64444 \" href=\"UTD.htm?7/11/7344\">",
"     algorithm 4",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Response to therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Depending upon the location and size of the adenopathy and the presence or absence of infectious symptoms, additional evaluation may be indicated before or after the trial of antibiotics. Additional evaluation may include CXR, ESR, tuberculin skin testing (TST), CBC, and viral studies (eg, for EBV or CMV) (",
"    <a class=\"graphic graphic_algorithm graphicRef73804 \" href=\"UTD.htm?1/5/1105\">",
"     algorithm 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef64444 \" href=\"UTD.htm?7/11/7344\">",
"     algorithm 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This approach is safe and avoids unnecessary biopsies; in many patients, the adenopathy will resolve or the cause will become obvious during the two weeks of observation, with or without therapy. Even with \"can't miss\" diagnoses, such as Hodgkin lymphoma, non-Hodgkin lymphoma, or tuberculosis, the window of opportunity for effective treatment is likely to remain open during this brief period of observation.",
"   </p>",
"   <p>",
"    Biopsy is appropriate if an abnormal node has not resolved after four weeks, or immediately in patients with other findings suggestive of malignancy, including weight loss (&gt;10 percent of body weight), abnormal CBC or CXR, fevers, and lack of upper respiratory tract infection symptoms. It also may be indicated for children with persistently elevated ESR or rising ESR despite antibiotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30744?source=see_link&amp;anchor=H20#H20\">",
"     \"Causes of peripheral lymphadenopathy in children\", section on 'Malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/59/43955?source=see_link\">",
"       \"Patient information: Swollen neck nodes in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The etiology of peripheral lymphadenopathy often is obvious after a complete history and physical examination. Additional evaluation may be necessary to confirm the suspected cause or if the diagnosis remains uncertain after the initial clinical evaluation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The history should focus on symptoms suggestive of infection (eg, exposures, travel, immunization status), malignancy (constitutional symptoms, paraneoplastic syndromes), and medications associated with lymphadenopathy (",
"      <a class=\"graphic graphic_table graphicRef61046 \" href=\"UTD.htm?7/17/7451\">",
"       table 1",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"local\" href=\"#H4\">",
"       'History'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The examination should focus on signs of systemic disease or infection. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'General examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The location of the lymph nodes is the most important feature in generating a differential diagnosis (",
"      <a class=\"graphic graphic_table graphicRef71073 \" href=\"UTD.htm?14/41/15005\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef81033 graphicRef66847 \" href=\"UTD.htm?30/38/31342\">",
"       table 3A-B",
"      </a>",
"      ) and directing the approach to diagnosis (",
"      <a class=\"graphic graphic_algorithm graphicRef52799 \" href=\"UTD.htm?38/49/39710\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef66039 \" href=\"UTD.htm?43/26/44463\">",
"       algorithm 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef73804 \" href=\"UTD.htm?1/5/1105\">",
"       algorithm 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef64444 \" href=\"UTD.htm?7/11/7344\">",
"       algorithm 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Lymph nodes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early lymph node biopsy may be indicated in children with systemic symptoms; supraclavicular and lower cervical nodes; fixed, nontender nodes in the absence of other symptoms; abnormal chest radiograph or complete blood count;",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lack of infectious symptoms. It also may be indicated for children with persistently elevated erythrocyte sedimentation rate (ESR) or rising ESR despite antibiotic therapy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Lymph node biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial laboratory evaluation for the child with unexplained,",
"      <strong>",
"       generalized",
"      </strong>",
"      adenopathy should include viral serology, complete blood count, erythrocyte sedimentation rate, and chest radiograph. Subsequent evaluation depends upon the results of these studies (",
"      <a class=\"graphic graphic_algorithm graphicRef52799 \" href=\"UTD.htm?38/49/39710\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Generalized nodes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The laboratory evaluation for the child with",
"      <strong>",
"       localized",
"      </strong>",
"      adenopathy depends upon the location and size of the nodes (",
"      <a class=\"graphic graphic_algorithm graphicRef66039 \" href=\"UTD.htm?43/26/44463\">",
"       algorithm 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef73804 \" href=\"UTD.htm?1/5/1105\">",
"       algorithm 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef64444 \" href=\"UTD.htm?7/11/7344\">",
"       algorithm 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Localized nodes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment with glucocorticoids must be avoided before a definitive diagnosis is made. Such treatment could mask or delay the histologic diagnosis of leukemia or lymphoma. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/1\">",
"      Soldes OS, Younger JG, Hirschl RB. Predictors of malignancy in childhood peripheral lymphadenopathy. J Pediatr Surg 1999; 34:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/2\">",
"      Slap GB, Brooks JS, Schwartz JS. When to perform biopsies of enlarged peripheral lymph nodes in young patients. JAMA 1984; 252:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/3\">",
"      Niedzielska G, Kotowski M, Niedzielski A, et al. Cervical lymphadenopathy in children--incidence and diagnostic management. Int J Pediatr Otorhinolaryngol 2007; 71:51.",
"     </a>",
"    </li>",
"    <li>",
"     Malley, R. Lymphadenopathy. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher, GR, Ludwig, S, Henretig, FM (Eds), Lippincott Williams and Wilkins, Philadelphia 2006. p.421.",
"    </li>",
"    <li>",
"     Malley R. Lymphadenopathy. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams and Wilkins, Philadelphia 2006. p.421.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/6\">",
"      Margileth AM. Sorting out the causes of lymphadenopathy. Contemp Pediatr 1995; 12:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/7\">",
"      Knight PJ, Mulne AF, Vassy LE. When is lymph node biopsy indicated in children with enlarged peripheral nodes? Pediatrics 1982; 69:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/8\">",
"      Morland B. Lymphadenopathy. Arch Dis Child 1995; 73:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/9\">",
"      Greenfield S, Jordan MC. The clinical investigation of lymphadenopathy in primary care practice. JAMA 1978; 240:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/10\">",
"      Herzog LW. Prevalence of lymphadenopathy of the head and neck in infants and children. Clin Pediatr (Phila) 1983; 22:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/11\">",
"      Lake AM, Oski FA. Peripheral lymphadenopathy in childhood. Ten-year experience with excisional biopsy. Am J Dis Child 1978; 132:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/12\">",
"      Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/13\">",
"      Ying M, Ahuja AT, Evans R, et al. Cervical lymphadenopathy: sonographic differentiation between tuberculous nodes and nodal metastases from non-head and neck carcinomas. J Clin Ultrasound 1998; 26:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/14\">",
"      Steinkamp HJ, Mueffelmann M, B&ouml;ck JC, et al. Differential diagnosis of lymph node lesions: a semiquantitative approach with colour Doppler ultrasound. Br J Radiol 1998; 71:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/15\">",
"      Wu CH, Chang YL, Hsu WC, et al. Usefulness of Doppler spectral analysis and power Doppler sonography in the differentiation of cervical lymphadenopathies. AJR Am J Roentgenol 1998; 171:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/16\">",
"      Tschammler A, Ott G, Schang T, et al. Lymphadenopathy: differentiation of benign from malignant disease--color Doppler US assessment of intranodal angioarchitecture. Radiology 1998; 208:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/17\">",
"      Abdel Razek AA, Soliman NY, Elkhamary S, et al. Role of diffusion-weighted MR imaging in cervical lymphadenopathy. Eur Radiol 2006; 16:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/18\">",
"      Yu M, Liu Q, Song HP, et al. Clinical application of contrast-enhanced ultrasonography in diagnosis of superficial lymphadenopathy. J Ultrasound Med 2010; 29:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/19\">",
"      Puesken M, Buerke B, Gerss J, et al. Prediction of lymph node manifestations in malignant lymphoma: significant role of volumetric compared with established metric lymph node analysis in multislice computed tomography. J Comput Assist Tomogr 2010; 34:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/20\">",
"      Panesar J, Higgins K, Daya H, et al. Nontuberculous mycobacterial cervical adenitis: a ten-year retrospective review. Laryngoscope 2003; 113:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/21\">",
"      Kanlikama M, Mumbu&ccedil; S, Bayazit Y, Sirik&ccedil;i A. Management strategy of mycobacterial cervical lymphadenitis. J Laryngol Otol 2000; 114:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/22\">",
"      Schaad UB, Votteler TP, McCracken GH Jr, Nelson JD. Management of atypical mycobacterial lymphadenitis in childhood: a review based on 380 cases. J Pediatr 1979; 95:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/23\">",
"      Tunkel DE. Surgery for cervicofacial nontuberculous mycobacterial adenitis in children: an update. Arch Otolaryngol Head Neck Surg 1999; 125:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/24\">",
"      Steel BL, Schwartz MR, Ramzy I. Fine needle aspiration biopsy in the diagnosis of lymphadenopathy in 1,103 patients. Role, limitations and analysis of diagnostic pitfalls. Acta Cytol 1995; 39:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/25\">",
"      Zardawi IM. Fine needle aspiration cytology in a rural setting. Acta Cytol 1998; 42:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/26\">",
"      Bottles K, McPhaul LW, Volberding P. Fine-needle aspiration biopsy of patients with acquired immunodeficiency syndrome (AIDS): experience in an outpatient clinic. Ann Intern Med 1988; 108:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/27\">",
"      Reid AJ, Miller RF, Kocjan GI. Diagnostic utility of fine needle aspiration (FNA) cytology in HIV-infected patients with lymphadenopathy. Cytopathology 1998; 9:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33128/abstract/28\">",
"      Ellison E, Lapuerta P, Martin SE. Fine needle aspiration (FNA) in HIV+ patients: results from a series of 655 aspirates. Cytopathology 1998; 9:222.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2867 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-062E1C4994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_22_33128=[""].join("\n");
var outline_f32_22_33128=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - General examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Additional evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Blood tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Cultures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Tuberculin skin test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Response to therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Lymph node biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Incision and drainage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Generalized nodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Initial tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Subsequent tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Localized nodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Supraclavicular nodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Axillary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Cervical or inguinal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/2867\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2867|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?38/49/39710\" title=\"algorithm 1\">",
"      Approach to generalized adenopathy in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?43/26/44463\" title=\"algorithm 2\">",
"      Approach to axillary adenopathy in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?1/5/1105\" title=\"algorithm 3\">",
"      Approach to cervical adenopathy in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?7/11/7344\" title=\"algorithm 4\">",
"      Approach to inguinal adenopathy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2867|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/60/8128\" title=\"picture 1\">",
"      Cat scratch disease typical papular lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/51/26418\" title=\"picture 2\">",
"      Tularemia eschar",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2867|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/17/7451\" title=\"table 1\">",
"      Drugs causing lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/41/15005\" title=\"table 2\">",
"      Causes localized lymphadenopathy in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/44/9933\" title=\"table 3A\">",
"      Infectious causes generalized lymphadenopathy children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/35/31293\" title=\"table 3B\">",
"      Noninfectious causes generalized lymphadenopathy in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30744?source=related_link\">",
"      Causes of peripheral lymphadenopathy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15609?source=related_link\">",
"      Clinical presentation, diagnosis, and staging evaluation of neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24857?source=related_link\">",
"      Diagnostic approach to and initial treatment of cervical lymphadenitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8632?source=related_link\">",
"      Etiology and clinical manifestations of cervical lymphadenitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33290?source=related_link\">",
"      Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=related_link\">",
"      Evaluation of peripheral lymphadenopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32262?source=related_link\">",
"      Horner's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13143?source=related_link\">",
"      Latent tuberculosis infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32874?source=related_link\">",
"      Overview of Hodgkin lymphoma in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13994?source=related_link\">",
"      Overview of nontuberculous mycobacterial lymphadenitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=related_link\">",
"      Overview of the presentation and classification of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=related_link\">",
"      Overview of the treatment of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/59/43955?source=related_link\">",
"      Patient information: Swollen neck nodes in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35592?source=related_link\">",
"      Pulmonary Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23625?source=related_link\">",
"      Tuberculosis disease in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_22_33129="Toxoplasmosis in HIV-infected patients";
var content_f32_22_33129=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Toxoplasmosis in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/22/33129/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/22/33129/contributors\">",
"     Howard M Heller, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/22/33129/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/22/33129/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/22/33129/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/22/33129/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/22/33129/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxoplasmosis, an infection with a worldwide distribution, is caused by the intracellular protozoan parasite, Toxoplasma gondii. Immunocompetent persons with primary infection are usually asymptomatic, but latent infection can persist for the life of the host. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/38/16999?source=see_link\">",
"     \"Toxoplasmosis in immunocompetent hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In immunosuppressed patients, especially patients with the acquired immunodeficiency syndrome (AIDS), the parasite can reactivate and cause disease, usually when the CD4 lymphocyte count falls below 100",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. All patients with human immunodeficiency virus (HIV) infection should be screened for T. gondii antibodies. Counseling on preventing toxoplasmosis should be given to those who are seronegative and prophylaxis initiated, when appropriate, for seropositive patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevalence of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seroprevalence rates of toxoplasmosis vary substantially among different countries (eg, approximately 15 percent in the United States to more than 50 percent in certain European countries) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/4\">",
"     4",
"    </a>",
"    ]. Among HIV-infected patients, seroprevalence of antibodies to T. gondii mirror rates of seropositivity in the general population. Among 2525 women in the United States, for example, the T. gondii seroprevalence was 15 percent and did not differ based upon whether or not the individual had HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/5\">",
"     5",
"    </a>",
"    ]. Those with HIV were more likely to have antibodies to T. gondii if they were &ge;50 years of age or born outside of the United States. In patients with AIDS, there is no higher incidence of toxoplasmosis in cat owners compared to non-cat owners [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with AIDS and &lt;100 CD4",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    who are toxoplasma seropositive, have an approximately 30 percent probability of developing reactivated toxoplasmosis if they are not receiving effective prophylaxis. The most common site of reactivation is the central nervous system (CNS); toxoplasmosis is the most common parasitic CNS opportunistic infection (OI) in AIDS patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/3\">",
"     3",
"    </a>",
"    ], except in patients who are on appropriate prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Toxoplasmic encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of toxoplasmic encephalitis (TE) in AIDS patients reflects seropositivity rates in this population; HIV-infected patients from Florida, for example, had a higher seroprevalence of T. gondii antibodies and a greater prevalence of toxoplasmic encephalitis in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As seen for many other opportunistic infections, the introduction of anti-toxoplasma prophylaxis and potent antiretroviral therapy (ART) has altered the occurrence of toxoplasmic encephalitis. Among HIV-infected patients in the United States, the annual number of toxoplasmosis-related hospitalizations peaked at more than 10,000 in 1995, dropped sharply to 3643 in 2001, and then decreased to 2985 in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13353?source=see_link\">",
"     \"The stages and natural history of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Extracerebral toxoplasmosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is much harder to determine the incidence of extracerebral toxoplasmosis. Most of the available data are from before the introduction of ART and from France where the seroprevalence to T. gondii is high. In one French series of 1699 HIV-infected patients, for example, the overall incidence of toxoplasmosis was 1.53 cases per 100 person-years for the years 1988 to 1995 (compared with 5.4 or 3.8 cases per 1000 person-years in the United States) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/10\">",
"     10",
"    </a>",
"    ]. The distribution of extracerebral cases is illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the series of 1699 patients, 116 cases of confirmed, probable or possible toxoplasmosis were diagnosed; cerebral toxoplasmosis accounted for 89 percent, with pulmonary, ocular, and disseminated infection responsible for 6, 3.5, and 1.7 percent of cases, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another French series of 199 HIV-infected patients with extracerebral toxoplasmosis evaluated between 1990 and 1992 estimated that the prevalence of extracerebral toxoplasmosis among AIDS patients was 1.5 to 2 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/11\">",
"       11",
"      </a>",
"      ]. Among these selected patients, eye involvement occurred in 50 percent, lungs in 26 percent, two or more extracerebral sites in 11.5 percent, and peripheral blood, heart, and bone marrow in 3 percent each. Involvement of the bladder, pharynx, skin, liver, lymph nodes, conus medullaris, and pericardium also were demonstrated in rare cases.",
"     </li>",
"     <li>",
"      Widespread distribution may be more common pathologically than clinically appreciated. This was suggested in an autopsy study in which the most common extracerebral sites of toxoplasmosis in HIV-infected patients were the heart, lungs, and pancreas with 91, 61, and 26 percent of cases, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most prominent risk factor for the development of extracerebral toxoplasmosis is advanced immunosuppression (mean CD4 counts of 57 and 58",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    in two of the French series) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Concurrent CNS disease was present in 41 percent of patients in the report of 199 extracerebral cases [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, when T. gondii reactivates in a patient with AIDS, it most commonly does so in the CNS leading to cerebral abscesses. The clinical manifestations of toxoplasmosis in immunocompetent patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/38/16999?source=see_link\">",
"     \"Toxoplasmosis in immunocompetent hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Toxoplasmic encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cerebral toxoplasmosis typically present with headache. In one retrospective review of 115 cases, 55, 52, and 47 percent had headache, confusion, and fever, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/3\">",
"     3",
"    </a>",
"    ]. Focal neurologic deficits or seizures are also common. Fever is usually, but not reliably, present. Dull affect may be due to global encephalitis but more profound mental status changes, especially accompanied by nausea or vomiting, usually indicates elevated intracranial pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Extracerebral toxoplasmosis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Pneumonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumonitis, as an extracerebral manifestation of toxoplasmosis, presents with fever, dyspnea and non-productive cough [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/13\">",
"     13",
"    </a>",
"    ]. Chest radiographs typically have reticulonodular infiltrates. The clinical picture may be indistinguishable from Pneumocystis jirovecii (formerly carinii) pneumonia (PCP). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=see_link\">",
"     \"Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    .) Toxoplasma tachyzoites can be identified in bronchoalveolar lavage (BAL) fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some have suggested that a blood level of lactate dehydrogenase &gt;600",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    is more likely to be associated with toxoplasmosis than PCP [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/15\">",
"     15",
"    </a>",
"    ]. However, others have found that LDH is elevated in both of these infections [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Chorioretinitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with toxoplasmic chorioretinitis (a posterior uveitis) usually present with eye pain and decreased visual acuity. These symptoms and signs do not distinguish this entity from other ocular infections in HIV, especially cytomegalovirus (CMV) retinitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Toxoplasmic chorioretinitis appears as raised yellow-white, cottony lesions in a non-vascular distribution, unlike the perivascular exudates of CMV retinitis. Vitreal inflammation is usually present in contrast to ocular toxoplasmosis in immunocompetent patients. Chorioretinitis due to T. gondii can rarely mimic acute retinal necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/17\">",
"     17",
"    </a>",
"    ]. Up to 63 percent of AIDS patients with toxoplasma chorioretinitis will have concurrent CNS lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Other manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxoplasmosis can rarely present with involvement of a variety of other sites in patients with AIDS including: gastrointestinal tract, liver, musculoskeletal system, heart, bone marrow, bladder, spinal cord, and orchitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/11,18,19\">",
"     11,18,19",
"    </a>",
"    ]. In the French series, toxoplasmosis of the pancreas or muscular system did not occur in the absence of involvement at other sites [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/11\">",
"     11",
"    </a>",
"    ]. Nine patients with disseminated toxoplasmosis presenting with septic shock were reported from France; in two patients this appeared to be primary infection [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definitive diagnosis of TE requires a compatible clinical syndrome; identification of one or more mass lesions by brain imaging; and detection of the organism in a biopsy specimen [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/4\">",
"     4",
"    </a>",
"    ]. However, the majority of clinicians prefer to initially treat a seropositive patient with compatible symptoms, signs, and imaging for presumptive TE; a biopsy is performed in those who do not improve (clinically or radiographically) with directed therapy.",
"   </p>",
"   <p>",
"    To establish a definitive diagnosis in patients with extracerebral toxoplasmosis, the demonstration of tachyzoites in tissue or fluid, such as BAL, is usually required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of patients with toxoplasma encephalitis are seropositive for anti-toxoplasma IgG antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/21\">",
"     21",
"    </a>",
"    ]. Anti-toxoplasma IgM antibodies are usually absent; quantitative IgG antibody titers are not helpful.",
"   </p>",
"   <p>",
"    The absence of antibodies to toxoplasma makes the diagnosis less likely, but does not exclude the possibility of TE [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most AIDS patients with cerebral toxoplasmosis have multiple, ring-enhancing brain lesions often associated with edema. In a report of 45 patients who underwent computed tomography (CT) or magnetic resonance imaging (MRI), 31 (69 percent) had multiple lesions and 14 had single lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/22\">",
"     22",
"    </a>",
"    ]. There is a predilection for involvement of the basal ganglia [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=see_link\">",
"     \"Approach to HIV-infected patients with central nervous system lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     MRI versus CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is more sensitive than computed tomography (CT) for identifying these lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In one prospective study of 50 AIDS patients with neurologic symptoms, for example, MRI detected abnormalities that influenced diagnosis and treatment in 40 percent, which were not characterized by CT [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there is an extensive differential diagnosis for brain lesions in AIDS patients and the appearance by either CT or MRI does not adequately distinguish among these. Toxoplasmosis and CNS lymphoma are the two most common entities (representing 50 and 30 percent, respectively, in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/24\">",
"     24",
"    </a>",
"    ], but other infections, including cryptococcosis, histoplasmosis, aspergillosis, tuberculosis and trypanosomiasis may also cause brain abscesses in patients with AIDS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=see_link\">",
"     \"Approach to HIV-infected patients with central nervous system lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     SPECT imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thallium single photon emission computed tomography (SPECT) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/25\">",
"     25",
"    </a>",
"    ] and positron emission tomography (PET) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/26\">",
"     26",
"    </a>",
"    ] can be useful in distinguishing toxoplasmosis or other infections from CNS lymphoma. Lymphoma has greater thallium uptake on SPECT and greater glucose and methionine metabolism on PET than neurotoxoplasmosis or other infections [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Brain biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive diagnosis of cerebral toxoplasmosis is made by pathologic examination of brain tissue obtained by open or stereotactic brain biopsy. Organisms are demonstrated on hematoxylin and eosin stains; some laboratories also use immunoperoxidase staining which may increase diagnostic sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there is morbidity and even mortality associated with the procedure. In one series of 136 patients in Rome, morbidity and mortality of brain biopsy was 12 and 2 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/30\">",
"     30",
"    </a>",
"    ]. Morbidity rates have been reported to be 3 to 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/31\">",
"     31",
"    </a>",
"    ]. Due to these concerns, it is common practice to presumptively diagnose and treat cerebral toxoplasmosis in AIDS patients if the clinical suspicion is high. A presumptive diagnosis can be made if the patient has a CD4 cell count",
"    <span class=\"nowrap\">",
"     &lt;100/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    and:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is seropositive for T. gondii IgG antibody",
"     </li>",
"     <li>",
"      Has not been receiving effective prophylaxis for toxoplasma",
"     </li>",
"     <li>",
"      Brain imaging demonstrates a typical radiographic appearance (eg, multiple ring-enhancing lesions)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If these three criteria are present, there is a 90 percent probability that the diagnosis is toxoplasmosis, and thus, it is common practice to treat empirically for toxoplasmosis. If a solitary lesion is detected, even if toxoplasma serology is positive, CNS lymphoma rises on the differential diagnosis list [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/32\">",
"     32",
"    </a>",
"    ]. If all three of the above criteria are not met, biopsy or other diagnostic tests should be performed. Brain biopsy should also be performed if the patient does not respond to empiric therapy, on the basis on clinical or radiographic improvement (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=see_link&amp;anchor=H13#H13\">",
"     \"Approach to HIV-infected patients with central nervous system lesions\", section on 'Diagnostic approach'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An Italian group has questioned the reliability of the presumptive diagnostic approach in favor of earlier biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In one study, the positive predictive value of the Centers for Disease Control and Prevention (CDC) criteria for the diagnosis of toxoplasmic encephalitis declined from 100 to 39 percent from 1991 to 1996 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/33\">",
"     33",
"    </a>",
"    ]. An increase in use of prophylaxis against toxoplasmosis and increases in other causes of CNS focal lesions were deemed largely responsible for this difference.",
"   </p>",
"   <p>",
"    Polymerase chain reaction (PCR) testing for other pathogens (eg, Epstein-Barr virus [EBV], JC virus, Mycobacterium tuberculosis, Cryptococcus neoformans) can be considered in patients with focal brain lesions who were already taking prophylactic antibiotics for toxoplasmosis or were seronegative [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/30\">",
"     30",
"    </a>",
"    ]. The prevalence of these other infections in HIV-infected patients and other clinical clues from the presentation should influence which specific tests are ordered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     CSF analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebrospinal fluid (CSF) may have mild mononuclear pleocytosis and elevated protein in patients with TE. Tachyzoites can occasionally be seen on cytocentrifuged cerebrospinal fluid samples stained with Giemsa.",
"   </p>",
"   <p>",
"    Detection of T. gondii by PCR has demonstrated high specificity (96 to 100 percent) but variable sensitivity (50 to 98 percent) depending on the primers used [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Treatment also affects diagnostic sensitivity. Thus, a positive PCR result establishes the diagnosis, but a negative one does not rule it out.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of TE includes CNS lymphoma, mycobacterial infection, cryptococcosis, bacterial abscess, and uncommonly, progressive multifocal leukoencephalopathy. The approach to the differential diagnosis of focal brain lesions is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=see_link\">",
"     \"Approach to HIV-infected patients with central nervous system lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial drug regimen of choice is the combination of [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/4,22,38-40\">",
"     4,22,38-40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       Pyrimethamine",
"      </a>",
"      (200 mg loading dose followed by 50 mg PO daily among patients &lt;60 kg or 75 mg daily among patients &gt;60 kg)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    plus",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"       Sulfadiazine",
"      </a>",
"      (1000 mg four times PO daily among patients &lt;60 kg to 1500 mg four times PO daily among patients &gt;60 kg)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    plus",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       Leucovorin",
"      </a>",
"      10 to 25 mg PO daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One study documented equivalent pharmacokinetic parameters for 2000 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    administered twice daily compared to 1000 mg given four times a day and may be a consideration if there is concern regarding nonadherence [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For those patients who cannot take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    due to intolerance or history of allergy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    <strong>",
"     plus",
"    </strong>",
"    &nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (600 mg IV or PO four times a day) is recommended.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    has a higher incidence of cutaneous hypersensitivity reactions, this is the preferred first-line regimen due to a lower incidence of relapse compared with pyrimethamine plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    -containing regimens should also include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (folinic acid, 10 to 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    PO) to prevent drug-induced hematologic toxicity. Patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    therapy do not require additional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) for PCP prophylaxis.",
"   </p>",
"   <p>",
"    Extracerebral toxoplasmosis is treated with the same regimens as toxoplasmic encephalitis, although the response may not be as favorable [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Alternative regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several alternative regimens have been used, generally in patients who are unable to tolerate either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/42-45\">",
"     42-45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      and 25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      sulfamethoxazole given IV or PO twice daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       Pyrimethamine",
"      </a>",
"      <strong>",
"       plus",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (900 to 1200 mg PO once daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       Pyrimethamine",
"      </a>",
"      <strong>",
"       plus",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"       atovaquone",
"      </a>",
"      (1500 mg PO twice daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"       Sulfadiazine",
"      </a>",
"      (1000 to 1500 mg PO four times a day) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"       atovaquone",
"      </a>",
"      (1500 mg PO twice daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"       Atovaquone",
"      </a>",
"      (1500 mg PO twice daily)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    therapy should always be accompanied by the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    calcium (10 to 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    PO). Some of these regimens, especially those using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    , have been tried as salvage therapy in patients failing to respond to a first-line regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/43\">",
"     43",
"    </a>",
"    ]. However, reconsideration of the diagnosis should be the first response to a patient who appears to be failing therapy (see",
"    <a class=\"local\" href=\"#H26\">",
"     'Response to therapy'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    is used, measuring plasma levels might be helpful since there is significant individual variation in drug absorption and higher plasma concentrations are associated with better outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) has also been evaluated in two small studies due to its low cost and preliminary data suggesting similar efficacy to first line agents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A pilot, multicenter, randomized prospective trial evaluated the efficacy and safety of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      (TMP) and sulfamethoxazole (SMX) compared with standard therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"       sulfadiazine",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/47\">",
"       47",
"      </a>",
"      ]. Seventy-seven patients were randomly assigned to receive TMP (10",
"      <span class=\"nowrap\">",
"       mg/kg/day)",
"      </span>",
"      and SMX (50",
"      <span class=\"nowrap\">",
"       mg/kg/day)",
"      </span>",
"      as acute therapy for four weeks followed by maintenance therapy for three months at half of the original dose. There was no statistically significant difference in clinical efficacy between the two arms. Adverse effects were more common in the patients treated with pyrimethamine-sulfadiazine.",
"     </li>",
"     <li>",
"      An observational cohort study in France of 83 patients showed clinical improvement among 86 percent of the patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      ; 22 percent had adverse events although only 7 percent discontinued treatment due to side effects [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/48\">",
"       48",
"      </a>",
"      ]. The relapse rate was 30 percent a mean of eight months after the initial diagnosis. There was a higher relapse rate in patients treated prior to 1996 compared with those treated after 1996, but the difference was not statistically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    TMP-SMX may be an effective alternative treatment regimen, particularly in resource-poor settings [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/49\">",
"     49",
"    </a>",
"    ]. In critically ill patients, some experts consider intravenous administration of TMP 10",
"    <span class=\"nowrap\">",
"     mg/kg/d",
"    </span>",
"    + SMX 50",
"    <span class=\"nowrap\">",
"     mg/kg/d",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who respond, the duration of therapy is typically six weeks at the doses recommended above. Following that treatment, it is usually safe to decrease to a lower dose for secondary prophylaxis (chronic suppressive therapy). (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Secondary prophylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Steroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjunctive corticosteroids should be used for patients with radiographic evidence of midline shift, signs of critically elevated intracranial pressure or clinical deterioration within the first 48 hours of therapy.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    (4 mg every six hours) is usually chosen and is generally tapered over several days.",
"   </p>",
"   <p>",
"    When corticosteroids are used, it may be difficult to assess the clinical response to antibiotics since the rapid improvement in symptoms may be due to steroid therapy. Radiographic assessment is also affected since the corticosteroids will reduce the intensity of ring-enhancement and the amount of surrounding edema. If steroids are used, patients should also be carefully monitored for the development of other opportunistic infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Monitoring of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring of patients includes careful clinical evaluations, serial brain imaging, and assessment of any adverse effects of therapy. There is no value to serial assessment of IgG toxoplasma antibody titers.",
"   </p>",
"   <p>",
"    Common side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    include rash, nausea, and bone marrow suppression. Higher doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    calcium up to 50 to 100 mg daily can be considered for management of hematologic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/4\">",
"     4",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"     Sulfadiazine",
"    </a>",
"    use can lead to rash, fever, leukopenia, hepatitis, nausea, vomiting, diarrhea, and crystalluria.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    use can also lead to fever, rash, nausea and diarrhea related to production of Clostridium difficile toxin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical improvement usually precedes radiographic improvement. Thus, a careful daily neurologic examination is more important than radiographic studies in assessing the response to therapy during the first two weeks of treatment. Radiographic reassessment should be deferred for two to three weeks unless the patient has not demonstrated clinical improvement within the first week or has shown any worsening.",
"   </p>",
"   <p>",
"    The literature on response to therapy is hampered by presumptive diagnoses, cross-over treatments, and discontinuation for toxicity rather than lack of clinical response. There are no randomized, double-blind trials. The comparative trials on different treatment regimens suggest that approximately 80 percent of patients demonstrate clinical and radiologic responses [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/22,44\">",
"     22,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study focused on the timing of the response in 49 patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/22\">",
"     22",
"    </a>",
"    ]. Seventy-one percent responded overall with 32 of the 35 patients demonstrating improvement of at least 50 percent of baseline abnormalities by day 14 of therapy. The authors concluded that early neurologic deterioration or lack of neurologic improvement (except for headache and seizures) by day 10 to 14 should raise the possibility of an alternative diagnosis and such patients should be considered for brain biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=see_link\">",
"     \"Approach to HIV-infected patients with central nervous system lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lack of either clinical or radiographic improvement within 10 to 14 days of empiric therapy for toxoplasmosis should raise the possibility of an alternative diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Anticonvulsants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticonvulsants should be administered to patients with a history of seizures, but should not be given routinely for prophylaxis to all patients with the presumed diagnosis of TE [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/4\">",
"     4",
"    </a>",
"    ]. Careful attention needs to be paid to any potential drug interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Special considerations during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to treatment of the pregnant woman should be the same as the nonpregnant adult [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/4\">",
"     4",
"    </a>",
"    ]. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    has been associated with birth defects in animals, limited human data have not suggested an increased risk for defects [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/4,51\">",
"     4,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perinatal transmission of toxoplasma usually occurs only in the setting of acute infection [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/52\">",
"     52",
"    </a>",
"    ]; however, there have been a few case reports of transmission from HIV-infected women with significant immunosuppression and symptomatic reactivation disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/53\">",
"     53",
"    </a>",
"    ]. Ultrasound examination of the fetus should be performed during pregnancy to assess evidence of congenital infection (eg, hydrocephalus), although the overall risk appears very low [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10923597\">",
"    <span class=\"h1\">",
"     TOXOPLASMOSIS AND IMMUNE RECONSTITUTION SYNDROME (IRIS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"immune reconstitution inflammatory syndrome\" (IRIS) describes a collection of inflammatory disorders associated with paradoxical worsening of preexisting infectious processes following the initiation of potent antiretroviral therapy (ART) in HIV-infected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/55-60\">",
"     55-60",
"    </a>",
"    ]. If immune function improves rapidly following the commencement of ART, systemic or local inflammatory reactions may occur at the site or sites of the preexisting infection. This inflammatory reaction is usually self-limited, especially if the infection is effectively treated. However, long-term sequelae and fatal outcomes may rarely occur, particularly when neurologic structures are involved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IRIS may complicate CNS infections, as has been well described for mycobacteria and cryptococcal infections; however, fewer cases of IRIS related to CNS toxoplasmosis have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. IRIS in association with toxoplasmosis can lead to a paradoxical worsening of symptoms with worsening edema surrounding brain lesions as CD4 cell counts rapidly improve [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/62\">",
"     62",
"    </a>",
"    ]. Management includes continuing treatment for TE and HIV and increasing the dose of steroids as needed to control symptoms. A biopsy may be needed to rule out other similar appearing processes, especially lymphoma, if the diagnosis in unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sometimes IRIS can also lead to an &ldquo;unmasking&rdquo; of an infection that previously existed, but was not diagnosed until the onset of immune recovery. In one case series of 65 cases of TE, 3 patients were diagnosed with CNS disease only after the initiation of ART [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/63\">",
"     63",
"    </a>",
"    ]. Symptoms occurred within a median time of 41 days after starting antiretroviral medications and at a median CD4 count of 222",
"    <span class=\"nowrap\">",
"     cells/mL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients seropositive for T. gondii should receive prophylaxis according to the guidelines of the Centers for Disease Control and Prevention (CDC), United States Public Health Service (USPHS) and the Infectious Diseases Society of America (IDSA) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Primary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylaxis is indicated for patients with HIV and CD4 counts &lt;100",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    who are T. gondii IgG-positive [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/4,64\">",
"     4,64",
"    </a>",
"    ]. Patients who have negative toxoplasma serology should be counseled to avoid eating undercooked meats and to use gloves when carefully cleaning cat litter boxes. They do not need to avoid contact with household cats entirely. The choice of agents and dosing is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who experience immune reconstitution on ART can safely discontinue prophylaxis for toxoplasmosis when their CD4 counts are &gt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    for greater than three months. However, prophylaxis should be reinstated if the CD4 cell count drops below 200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Secondary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above in the treatment section, following six weeks of therapy, patients can receive lower doses of drugs, which is considered secondary prophylaxis or chronic suppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"     Sulfadiazine",
"    </a>",
"    (2000 to 4000 mg daily in two or four divided doses) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    (25 to 50 mg daily) is the first choice for secondary prophylaxis.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     Leucovorin",
"    </a>",
"    (folinic acid 10 mg to 25 mg orally every day) is also given concurrently [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternative regimens include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      (600 mg PO every eight hours) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      (25 to 50 mg PO daily) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      (10 to 25 mg PO daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/4,39\">",
"       4,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"       Atovaquone",
"      </a>",
"      750 mg PO 2 to 4 times daily with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      25 mg PO daily plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      10 mg PO daily [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/4,43,65\">",
"       4,43,65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"       Atovaquone",
"      </a>",
"      750 mg PO two to four times daily with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"       sulfadiazine",
"      </a>",
"      2000 to 4000 mg PO daily in two or four divided doses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     Atovaquone",
"    </a>",
"    monotherapy 750 mg PO four times daily can be considered for patients who cannot tolerate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    but the one-year relapse rate is 26 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Discontinuation of prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the CD4 count rises above 200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    for three months, primary prophylaxis for both PCP and toxoplasmosis can be safely discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/4,66,67\">",
"     4,66,67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The issue of secondary prophylaxis is more complex. Patients appear to be at low risk for recurrence of TE if they have completed therapy, remain asymptomatic, and have a sustained increase in their CD4 cell counts greater than 200 cells for more than six months [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/4\">",
"     4",
"    </a>",
"    ]. One study of 90 HIV-infected patients demonstrated that ART was associated with restoration of T. gondii-specific CD4 T cell responses in patients with a prior history of TE [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/68\">",
"     68",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     CDC/NIH/HIVMA",
"    </span>",
"    guidelines state that if immune reconstitution is maintained for six months, then secondary prophylaxis for TE can be discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/4\">",
"     4",
"    </a>",
"    ]. Some experts also suggest obtaining an MRI of the brain to determine whether it is appropriate to stop therapy based on any residual disease.",
"   </p>",
"   <p>",
"    The clinician needs to remember that the number of patients who have been evaluated with this approach is limited and the patient should be educated about symptoms that should lead to a prompt medical evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/68-72\">",
"     68-72",
"    </a>",
"    ]. Secondary prophylaxis should be re-initiated if the CD4+ T lymphocyte count declines to less than 200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initiation of antiretroviral therapy has also been shown to improve T-cell lymphoproliferative responses to toxoplasma antigens in patients with baseline CD4 counts &lt;200 cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33129/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seroprevalence to T. gondii depends upon the part of the world in which the patient was born and resided more than upon the patient's HIV status.",
"     </li>",
"     <li>",
"      Toxoplasma encephalitis is the most common presentation of toxoplasmosis as an opportunistic infection among AIDS patients and occurs most commonly in those with a CD4 count &lt;100",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       .",
"      </span>",
"     </li>",
"     <li>",
"      Prophylaxis against Pneumocystis jirovecii (formerly carinii) pneumonia (PCP) and the widespread use of antiretroviral therapy (ART) in developed countries has greatly decreased the incidence of this infection.",
"     </li>",
"     <li>",
"      The diagnosis of toxoplasma encephalitis is usually made presumptively in an AIDS patient with CD4 count",
"      <span class=\"nowrap\">",
"       &lt;100/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      a positive T. gondii IgG antibody, no recent prophylaxis against toxoplasmosis, and multiple ring-enhancing lesions on brain imaging.",
"     </li>",
"     <li>",
"      Brain biopsy can yield the diagnosis in patients who don't meet the above criteria or whose lesions fail to respond to presumptive therapy.",
"     </li>",
"     <li>",
"      First-line therapies for cerebral toxoplasmosis include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"       sulfadiazine",
"      </a>",
"      or pyrimethamine plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Alternatives include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      , pyrimethamine plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"       atovaquone",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"       sulfadiazine",
"      </a>",
"      plus atovaquone.",
"     </li>",
"     <li>",
"      Folinic acid (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      ) must always accompany",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      therapy.",
"     </li>",
"     <li>",
"      Corticosteroids are often administered in conjunction with antibiotics in patients with signs of significant increased intracranial pressure.",
"     </li>",
"     <li>",
"      The doses of",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"        pyrimethamine",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"        sulfadiazine",
"       </a>",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       pyrimethamine/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"        clindamycin",
"       </a>",
"      </span>",
"      are usually lowered for maintenance treatment after approximately six weeks of therapy.",
"     </li>",
"     <li>",
"      Primary prophylaxis against toxoplasmosis is usually given to patients with CD4 counts &lt;100",
"      <span class=\"nowrap\">",
"       cell/mm",
"       <sup>",
"        3",
"       </sup>",
"       .",
"      </span>",
"      TMP-SMX in the doses given for PCP prophylaxis is the usual choice to accomplish prevention of both OIs.",
"     </li>",
"     <li>",
"      Both primary and secondary prophylaxis (maintenance therapy) can be discontinued in patients who achieve immune reconstitution with ART.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/1\">",
"      Renold C, Sugar A, Chave JP, et al. Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome. Medicine (Baltimore) 1992; 71:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/2\">",
"      Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 1992; 15:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/3\">",
"      Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med 1992; 327:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/4\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/5\">",
"      Falusi O, French AL, Seaberg EC, et al. Prevalence and predictors of Toxoplasma seropositivity in women with and at risk for human immunodeficiency virus infection. Clin Infect Dis 2002; 35:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/6\">",
"      Wallace MR, Rossetti RJ, Olson PE. Cats and toxoplasmosis risk in HIV-infected adults. JAMA 1993; 269:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/7\">",
"      San-Andr&eacute;s FJ, Rubio R, Castilla J, et al. Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989-1997. Clin Infect Dis 2003; 36:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/8\">",
"      Levy RM, Janssen RS, Bush TJ, Rosenblum ML. Neuroepidemiology of acquired immunodeficiency syndrome. J Acquir Immune Defic Syndr 1988; 1:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/9\">",
"      Jones JL, Roberts JM. Toxoplasmosis hospitalizations in the United States, 2008, and trends, 1993-2008. Clin Infect Dis 2012; 54:e58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/10\">",
"      Belanger F, Derouin F, Grangeot-Keros L, Meyer L. Incidence and risk factors of toxoplasmosis in a cohort of human immunodeficiency virus-infected patients: 1988-1995. HEMOCO and SEROCO Study Groups. Clin Infect Dis 1999; 28:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/11\">",
"      Rabaud C, May T, Amiel C, et al. Extracerebral toxoplasmosis in patients infected with HIV. A French National Survey. Medicine (Baltimore) 1994; 73:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/12\">",
"      Hofman P, Bernard E, Michiels JF, et al. Extracerebral toxoplasmosis in the acquired immunodeficiency syndrome (AIDS). Pathol Res Pract 1993; 189:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/13\">",
"      Rabaud C, May T, Lucet JC, et al. Pulmonary toxoplasmosis in patients infected with human immunodeficiency virus: a French National Survey. Clin Infect Dis 1996; 23:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/14\">",
"      Pomeroy C, Filice GA. Pulmonary toxoplasmosis: a review. Clin Infect Dis 1992; 14:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/15\">",
"      Pugin J, Vanhems P, Hirschel B, et al. Extreme elevations of serum lactic dehydrogenase differentiating pulmonary toxoplasmosis from Pneumocystis pneumonia. N Engl J Med 1992; 326:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/16\">",
"      Butt AA, Michaels S, Kissinger P. The association of serum lactate dehydrogenase level with selected opportunistic infections and HIV progression. Int J Infect Dis 2002; 6:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/17\">",
"      Moshfeghi DM, Dodds EM, Couto CA, et al. Diagnostic approaches to severe, atypical toxoplasmosis mimicking acute retinal necrosis. Ophthalmology 2004; 111:716.",
"     </a>",
"    </li>",
"    <li>",
"     Montoya JG, Remington JS. Toxoplasma gondii. In: Principals and Practice of Infectious Diseases, 5th Edition, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2000. p.2858.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/19\">",
"      Vyas R, Ebright JR. Toxoplasmosis of the spinal cord in a patient with AIDS: case report and review. Clin Infect Dis 1996; 23:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/20\">",
"      Lucet JC, Bailly MP, Bedos JP, et al. Septic shock due to toxoplasmosis in patients infected with the human immunodeficiency virus. Chest 1993; 104:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/21\">",
"      Luft BJ, Brooks RG, Conley FK, et al. Toxoplasmic encephalitis in patients with acquired immune deficiency syndrome. JAMA 1984; 252:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/22\">",
"      Luft BJ, Hafner R, Korzun AH, et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. N Engl J Med 1993; 329:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/23\">",
"      Levy RM, Mills CM, Posin JP, et al. The efficacy and clinical impact of brain imaging in neurologically symptomatic AIDS patients: a prospective CT/MRI study. J Acquir Immune Defic Syndr 1990; 3:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/24\">",
"      Ciricillo SF, Rosenblum ML. Use of CT and MR imaging to distinguish intracranial lesions and to define the need for biopsy in AIDS patients. J Neurosurg 1990; 73:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/25\">",
"      Lorberboym M, Wallach F, Estok L, et al. Thallium-201 retention in focal intracranial lesions for differential diagnosis of primary lymphoma and nonmalignant lesions in AIDS patients. J Nucl Med 1998; 39:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/26\">",
"      O'Doherty MJ, Barrington SF, Campbell M, et al. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med 1997; 38:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/27\">",
"      Miller RF, Hall-Craggs MA, Costa DC, et al. Magnetic resonance imaging, thallium-201 SPET scanning, and laboratory analyses for discrimination of cerebral lymphoma and toxoplasmosis in AIDS. Sex Transm Infect 1998; 74:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/28\">",
"      Skiest DJ, Erdman W, Chang WE, et al. SPECT thallium-201 combined with Toxoplasma serology for the presumptive diagnosis of focal central nervous system mass lesions in patients with AIDS. J Infect 2000; 40:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/29\">",
"      Conley FK, Jenkins KA, Remington JS. Toxoplasma gondii infection of the central nervous system. Use of the peroxidase-antiperoxidase method to demonstrate toxoplasma in formalin fixed, paraffin embedded tissue sections. Hum Pathol 1981; 12:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/30\">",
"      Antinori A, Ammassari A, De Luca A, et al. Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. Neurology 1997; 48:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/31\">",
"      Skiest DJ. Focal neurological disease in patients with acquired immunodeficiency syndrome. Clin Infect Dis 2002; 34:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/32\">",
"      Andrews BT, Kenefick TP. Neurosurgical management of the acquired immunodeficiency syndrome. An update. West J Med 1993; 158:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/33\">",
"      Ammassari A, Scoppettuolo G, Murri R, et al. Changing disease patterns in focal brain lesion-causing disorders in AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/34\">",
"      Roberts TC, Storch GA. Multiplex PCR for diagnosis of AIDS-related central nervous system lymphoma and toxoplasmosis. J Clin Microbiol 1997; 35:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/35\">",
"      Cinque P, Scarpellini P, Vago L, et al. Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction. AIDS 1997; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/36\">",
"      Nogui FL, Mattas S, Turcato J&uacute;nior G, Lewi DS. Neurotoxoplasmosis diagnosis for HIV-1 patients by real-time PCR of cerebrospinal fluid. Braz J Infect Dis 2009; 13:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/37\">",
"      Mesquita RT, Ziegler AP, Hiramoto RM, et al. Real-time quantitative PCR in cerebral toxoplasmosis diagnosis of Brazilian human immunodeficiency virus-infected patients. J Med Microbiol 2010; 59:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/38\">",
"      Dannemann B, McCutchan JA, Israelski D, et al. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med 1992; 116:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/39\">",
"      Katlama C, De Wit S, O'Doherty E, et al. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 1996; 22:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/40\">",
"      Nath A, Sinai AP. Cerebral Toxoplasmosis. Curr Treat Options Neurol 2003; 5:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/41\">",
"      Jordan MK, Burstein AH, Rock-Kress D, et al. Plasma pharmacokinetics of sulfadiazine administered twice daily versus four times daily are similar in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/42\">",
"      Jacobson JM, Hafner R, Remington J, et al. Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS. AIDS 2001; 15:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/43\">",
"      Torres RA, Weinberg W, Stansell J, et al. Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Atovaquone/Toxoplasmic Encephalitis Study Group. Clin Infect Dis 1997; 24:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/44\">",
"      Chirgwin K, Hafner R, Leport C, et al. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039. Clin Infect Dis 2002; 34:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/45\">",
"      Kovacs JA. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program. Lancet 1992; 340:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/46\">",
"      Torres RA, Weinberg W, Stansell J, et al. Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Atovaquone/Toxoplasmic Encephalitis Study Group. Clin Infect Dis 1997; 24:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/47\">",
"      Torre D, Casari S, Speranza F, et al. Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group. Antimicrob Agents Chemother 1998; 42:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/48\">",
"      B&eacute;raud G, Pierre-Fran&ccedil;ois S, Foltzer A, et al. Cotrimoxazole for treatment of cerebral toxoplasmosis: an observational cohort study during 1994-2006. Am J Trop Med Hyg 2009; 80:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/49\">",
"      Dedicoat M, Livesley N. Management of toxoplasmic encephalitis in HIV-infected adults (with an emphasis on resource-poor settings). Cochrane Database Syst Rev 2006; :CD005420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/50\">",
"      Torre D, Speranza F, Martegani R, et al. A retrospective study of treatment of cerebral toxoplasmosis in AIDS patients with trimethoprim-sulphamethoxazole. J Infect 1998; 37:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/51\">",
"      Deen JL, von Seidlein L, Pinder M, et al. The safety of the combination artesunate and pyrimethamine-sulfadoxine given during pregnancy. Trans R Soc Trop Med Hyg 2001; 95:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/52\">",
"      Lago EG, Conrado GS, Piccoli CS, et al. Toxoplasma gondii antibody profile in HIV-infected pregnant women and the risk of congenital toxoplasmosis. Eur J Clin Microbiol Infect Dis 2009; 28:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/53\">",
"      Bachmeyer C, Mouchnino G, Thulliez P, Blum L. Congenital toxoplasmosis from an HIV-infected woman as a result of reactivation. J Infect 2006; 52:e55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/54\">",
"      Low incidence of congenital toxoplasmosis in children born to women infected with human immunodeficiency virus. European Collaborative Study and Research Network on Congenital Toxoplasmosis. Eur J Obstet Gynecol Reprod Biol 1996; 68:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/55\">",
"      DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000; 133:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/56\">",
"      French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000; 1:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/57\">",
"      Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002; 81:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/58\">",
"      Michelet C, Arvieux C, Fran&ccedil;ois C, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998; 12:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/59\">",
"      Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004; 38:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/60\">",
"      Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 2006; 57:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/61\">",
"      Lawn SD. Immune reconstitution disease associated with parasitic infections following initiation of antiretroviral therapy. Curr Opin Infect Dis 2007; 20:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/62\">",
"      Tremont-Lukats IW, Garciarena P, Juarbe R, El-Abassi RN. The immune inflammatory reconstitution syndrome and central nervous system toxoplasmosis. Ann Intern Med 2009; 150:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/63\">",
"      Martin-Blondel G, Alvarez M, Delobel P, et al. Toxoplasmic encephalitis IRIS in HIV-infected patients: a case series and review of the literature. J Neurol Neurosurg Psychiatry 2011; 82:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/64\">",
"      Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000; 342:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/65\">",
"      Katlama C, Mouthon B, Gourdon D, et al. Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group. AIDS 1996; 10:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/66\">",
"      Furrer H, Opravil M, Bernasconi E, et al. Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. Swiss HIV Cohort Study. Lancet 2000; 355:2217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/67\">",
"      Mussini C, Pezzotti P, Govoni A, et al. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study. J Infect Dis 2000; 181:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/68\">",
"      Lejeune M, Mir&oacute; JM, De Lazzari E, et al. Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis. Clin Infect Dis 2011; 52:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/69\">",
"      Guex AC, Radziwill AJ, Bucher HC. Discontinuation of secondary prophylaxis for toxoplasmic encephalitis in human immunodeficiency virus infection after immune restoration with highly active antiretroviral therapy. Clin Infect Dis 2000; 30:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/70\">",
"      Soriano V, Dona C, Rodr&iacute;guez-Rosado R, et al. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2000; 14:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/71\">",
"      Zeller V, Truffot C, Agher R, et al. Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis. Clin Infect Dis 2002; 34:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/72\">",
"      Kirk O, Reiss P, Uberti-Foppa C, et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002; 137:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33129/abstract/73\">",
"      Furco A, Carmagnat M, Chevret S, et al. Restoration of Toxoplasma gondii-specific immune responses in patients with AIDS starting HAART. AIDS 2008; 22:2087.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3710 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-FFFC22E1CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_22_33129=[""].join("\n");
var outline_f32_22_33129=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevalence of infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Toxoplasmic encephalitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Extracerebral toxoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Toxoplasmic encephalitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Extracerebral toxoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Pneumonitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Chorioretinitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Other manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - MRI versus CT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - SPECT imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Brain biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CSF analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Alternative regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Steroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Monitoring of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Response to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Anticonvulsants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Special considerations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10923597\">",
"      TOXOPLASMOSIS AND IMMUNE RECONSTITUTION SYNDROME (IRIS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Secondary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Discontinuation of prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=related_link\">",
"      Approach to HIV-infected patients with central nervous system lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=related_link\">",
"      Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=related_link\">",
"      Primary prevention of opportunistic infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13353?source=related_link\">",
"      The stages and natural history of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/38/16999?source=related_link\">",
"      Toxoplasmosis in immunocompetent hosts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_22_33130="Overview of geriatric rehabilitation: Program components and settings for rehabilitation";
var content_f32_22_33130=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of geriatric rehabilitation: Program components and settings for rehabilitation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/22/33130/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/22/33130/contributors\">",
"     Helen Hoenig, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/22/33130/contributors\">",
"     Patrick M. Kortebein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/22/33130/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/22/33130/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/22/33130/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/22/33130/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/22/33130/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H4419917\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary purpose of rehabilitation is to enable people to function at the highest possible level despite physical impairment. Rehabilitation includes a vast array of interventions provided by a diverse group of providers across the entire continuum of care. While rehabilitation may be provided to all age groups, the fastest growing population of persons requiring rehabilitation services is adults over 65 years of age. This is because of the aging of the US and worldwide population [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Improvements in both medical and rehabilitative care have helped to reduce prevalence of old age disability [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/3\">",
"     3",
"    </a>",
"    ], but it comes with a substantive price in demands for both medical and rehabilitation care [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/4\">",
"     4",
"    </a>",
"    ]. Moreover, there is concern that improvements in health and disability gained over the last several decades may not impact the generation just entering retirement. The increasing numbers in this population, and the apparent increases in disability related to musculoskeletal disorders (as well as depression, diabetes, and neurological disorders) affecting mobility-related activities in particular, will likely further drive needs for rehabilitation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Making good use of rehabilitation resources is facilitated by an appreciation for how disability occurs and the mechanisms by which rehabilitation is effective. This knowledge leads to understanding of which specific rehabilitation services might best be provided, where to provide them, and by whom. This topic will review aspects of geriatric rehabilitation related to types of involved providers, interventions, and settings. Indications for rehabilitation and patient assessment are addressed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4419924\">",
"    <span class=\"h1\">",
"     CONCEPTUAL MODELS FOR DISABILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major conceptual models for understanding disability and where rehabilitation services can be most effective:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The International Classification of Function, Disability, and Health (ICF), developed by the World Health Organization [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/6\">",
"       6",
"      </a>",
"      ], and",
"     </li>",
"     <li>",
"      A model variably known as the &ldquo;Environmental Press,&rdquo; &ldquo;Ecological,&rdquo; or &ldquo;Person-Environment Fit&rdquo; model, originally described by Lawton [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4419931\">",
"    <span class=\"h2\">",
"     The World Health Organization model (ICF)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Classification of Function, Disability, and Health (ICF) model indicates that an individual&rsquo;s level of function (body function, ability to execute a task [activity], and participate in life activities) is determined by his or her health condition(s) within the context of environmental and personal factors. Medical and surgical interventions are directed at the underlying health conditions causing disability; rehabilitation services target the impairment, activities, and participation levels of the disablement process, as well as personal and environmental contextual factors that influence activity and participation.",
"   </p>",
"   <p>",
"    Multiple health conditions or comorbidities, with concomitant impairments, are common in older persons and influence the disablement process. Effective treatment of late-life disability, therefore, is typically multimodal [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/8\">",
"     8",
"    </a>",
"    ]. Decline in late-life disability from 1980 to 2010 can be attributed to the combination of advances in medical care, improved socioeconomic factors, and innovations in mainstream and assistive technology [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/3,9\">",
"     3,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4419938\">",
"    <span class=\"h2\">",
"     The ecological model",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disability results from a mismatch between individual capacity and task demands, which in turn are influenced by the environment and the way in which tasks are performed [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. For example, walking imposes different physical demands when performed atop Mt. Everest versus at sea level. Thus, the ecological model helps to explain how personal and particularly environmental contextual factors described in the WHO ICF model interact with physical limitations to result in disability [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In the ecological model, remediation of disability occurs through treatments that either increase individual capacity or reduce task demand.",
"   </p>",
"   <p>",
"    Medical treatment (eg, oxygen supplementation or medication) or surgical treatment (eg, cataract surgery, joint replacement) have the potential to increase capacity. Rehabilitation interventions may improve capacity, reduce task demands, or accomplish both. Examples of such interventions follow [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improve capacity:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Exercise",
"     </li>",
"     <li>",
"      Hearing aids, reading magnifiers",
"     </li>",
"     <li>",
"      Artificial limbs",
"     </li>",
"     <li>",
"      Orthotics (ie, braces, splints)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduce task demands:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A raised toilet seat or bath bench, which reduce the effort required to rise to a standing position",
"     </li>",
"     <li>",
"      A ramp or elevator to replace stairs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both increase capacity and reduce demand:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A cane that can enhance sensory capacity by providing proprioceptive feedback to improve balance, and it can reduce demand, for example, by offloading body weight from the leg to the arm to relieve arthritic joints or weak lower extremities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4419952\">",
"    <span class=\"h1\">",
"     TYPES OF REHABILITATION PROVIDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disability has many diverse causes and often occurs through the interaction of one or more medical conditions with both personal and environmental contextual factors. Therefore, a wide variety of providers may be involved in treating rehabilitation.",
"   </p>",
"   <p>",
"    A list of types of rehabilitation providers, the typical rehabilitation interventions used by various disciplines, and the aspect(s) of the disablement process targeted by the provider types is provided in a table (",
"    <a class=\"graphic graphic_table graphicRef86413 \" href=\"UTD.htm?25/20/25933\">",
"     table 1",
"    </a>",
"    ). Treatment by a provider in a single discipline is often sufficient for patients with uncomplicated conditions or with minimal disability (eg, physical therapy for osteoarthritis of the knee or a home safety evaluation by an occupational therapist for a patient with fear of falling). However, for more complex or catastrophic disability, a multidisciplinary team of providers is optimal to address the rehabilitation needs related to progressive disability and the interaction of multiple contributing conditions and contextual factors.",
"   </p>",
"   <p>",
"    Multidisciplinary care is a cornerstone of rehabilitation. The efficacy of coordinated multidisciplinary rehabilitation for a number of conditions affecting older adults, including stroke, rheumatoid arthritis, falls, and frailty, is supported by numerous studies [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/13-19\">",
"     13-19",
"    </a>",
"    ]. Geriatric evaluation and treatment units provide multidisciplinary care with medical, social service, nursing, and rehabilitation personnel (typically physical and occupational therapy) working together in a coordinated fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/13\">",
"     13",
"    </a>",
"    ]. Inpatient stroke rehabilitation teams include a variety of rehabilitation personnel (eg, speech therapy, occupational therapy, physical therapy) to target rehabilitation therapies to the specific stroke-related deficits, as well as medical, nursing, and other staff [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/14\">",
"     14",
"    </a>",
"    ]. Coordination of care may be achieved with weekly team meetings",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    scripted protocols to facilitate care coordination.",
"   </p>",
"   <p>",
"    Benefits from coordinated multidisciplinary rehabilitation accrue from systematically targeting the multiple factors that interact to cause and exacerbate disability. For example, stroke may adversely affect visual perception, speech, and cognition as well as cause paralysis. Members of the multidisciplinary team often have both unique and overlapping expertise, reinforcing the interventions of each other.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4419959\">",
"    <span class=\"h1\">",
"     INTERVENTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4419967\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical activity is defined as bodily movement that is produced by skeletal muscle contraction and that substantially increases energy expenditure. Exercise, a type of physical activity, is defined as a planned, structured, and repetitive bodily movement done to improve or maintain one or more components of physical fitness (eg, muscle strength, flexibility, balance).",
"   </p>",
"   <p>",
"    Physical activity is beneficial for reducing overall morbidity and mortality in older adults (",
"    <a class=\"graphic graphic_table graphicRef51565 \" href=\"UTD.htm?10/2/10283\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/20\">",
"     20",
"    </a>",
"    ]. Exercise recommendations for all individuals &gt;65 years of age are shown in a table (",
"    <a class=\"graphic graphic_table graphicRef82111 \" href=\"UTD.htm?9/29/9694\">",
"     table 3",
"    </a>",
"    ) and discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/60/9161?source=see_link\">",
"     \"Physical activity and exercise in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The physical activity recommendations intended for all older adults may need to be modified for particular medical disorders, using specific types of exercise to correct or ameliorate identified impairments and functional limitations. Common conditions in older adults that would necessitate exercise modification include acute cardiac conditions (eg, cardiac rehabilitation), orthopedic and neurosurgery procedures, osteoporosis,",
"    <span class=\"nowrap\">",
"     acute/postacute",
"    </span>",
"    stroke, or chronic respiratory disease (eg, pulmonary rehabilitation). Physical therapists, exercise physiologists, and physicians specializing in rehabilitation (&ldquo;physiatrists&rdquo;) can help to tailor the exercise prescription to meet particular patient needs.",
"   </p>",
"   <p>",
"    Certain types of exercise may be particularly beneficial for specific patient populations. As an example, resistive exercise and power training have been found to improve function in frail older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/21\">",
"     21",
"    </a>",
"    ]. A systematic review found that progressive resistance exercise (ie, weightlifting) can significantly improve muscle strength and, to a lesser extent, functional activities such as rising from a chair and ambulation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During acute hospitalization, early mobilization seems to offer particular benefit, improving outcomes in multiple patient populations, including patients with hip fracture, acute pneumonia, or critical illness in the intensive care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4419974\">",
"    <span class=\"h2\">",
"     Assistive technology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assistive technology and adaptive methods encompass a diverse group of interventions designed to enable people with physical limitations to participate in a broad range of activities.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assistive technology refers to devices that may be used to make tasks easier or safer (eg, a reacher can be used by someone with limited upper or lower extremity range of motion to make it easier to pick something up).",
"     </li>",
"     <li>",
"      Adaptive methods refers to changing the way a task is done so as to make it safer or easier (eg, a stroke patient might don a sweater more easily by putting the sleeve on the paralyzed arm first, then on the non-paralyzed arm, and then over the head).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Often the two methods are used together. These interventions can act at all levels of the disablement process, targeting particular organ system impairments (eg, a prosthetic leg after an amputation), particular types of activities (eg, a cane used when walking), or broadly enhancing access and opportunities for participation (eg, ramps allowing access to public buildings).",
"   </p>",
"   <p>",
"    Assistive technology is a particularly common way of coping with disability [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/26\">",
"     26",
"    </a>",
"    ]. Assistive technology includes mobility aids such as canes and walkers, bathroom safety devices such as raised toilet seats and grab bars, self-care devices such as reachers and built up utensils, as well sophisticated computerized and electronic technology. Use of assistive technology has increased substantially in recent years, far exceeding the growth and aging of the US populations [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. By some reports, technological advances may account for half of the decline in disability in recent years [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/3\">",
"     3",
"    </a>",
"    ]. There has been both an increase in evidence to support its effectiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/29-31\">",
"     29-31",
"    </a>",
"    ] as well as major improvements in the technology itself, with improved ergonomics, ease of use, and durability [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/32\">",
"     32",
"    </a>",
"    ]. The internet provides a wealth of information about diverse assistive devices.",
"    <a class=\"external\" href=\"file://www.abledata.com/\">",
"     Abledata",
"    </a>",
"    is one such resource, providing objective information on assistive technology and rehabilitation equipment available from sources within the United States and internationally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4419988\">",
"    <span class=\"h3\">",
"     Mobility aids",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the aging of the population, there is increasing need for mobility aids. In the United States in 2000, among adults 65 years and older, 10 percent used canes and 4.6 percent used walkers [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/33\">",
"     33",
"    </a>",
"    ]. Mobility devices may be used for diverse types of physical limitations affecting mobility, including weakness, sensory limitations (vision or proprioception), impaired balance,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    limited endurance. While such devices are intended to improve mobility, activity, foster independence, and provide some protection against falls, evidence from high-quality studies on the impact of these devices is sparse.",
"   </p>",
"   <p>",
"    There are multiple options for mobility aids, and their appropriate use is outlined below. An algorithm for selecting among mobility aids and a table that reviews indications and the relative pros and cons of various mobility aids are provided (",
"    <a class=\"graphic graphic_algorithm graphicRef86446 \" href=\"UTD.htm?31/17/32018\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef86414 \" href=\"UTD.htm?38/39/39548\">",
"     table 4",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    Despite availability of insurance coverage, many older adults purchase mobility aids over the counter on their own or borrow them from friends or relatives without professional guidance, which can lead to problems using the device [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/34\">",
"     34",
"    </a>",
"    ]. Mobility aids that are not properly fit or are used incorrectly can increase the risk of falls and injury. Falls directly related to mobility devices account for over 50,000 visits annually to emergency departments in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/35\">",
"     35",
"    </a>",
"    ]. Moreover, 30 to 50 percent of wheelchair users report tips and falls [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/36\">",
"     36",
"    </a>",
"    ]. It is vital to observe older patients actually using their mobility aid to verify proper fit and correct use and to refer the patient to expert consultation with a certified Assistive Technology Provider (ATP), physical therapist (PT), or occupational therapist (OT) if there is any question.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3285546\">",
"    <span class=\"h4\">",
"     Canes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Canes are the most commonly used type of mobility device [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Most persons are not properly instructed in cane use, and up to 70 percent of canes are used incorrectly or are the wrong height or design [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/33\">",
"     33",
"    </a>",
"    ]. As a result, almost 30 to 50 percent of individuals abandon use of the cane after receiving it.",
"   </p>",
"   <p>",
"    Typically, canes are used to reduce the weight borne across an arthritic joint, thereby reducing pain, or to assist with balance when the balance problem is due to impaired sensation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mild leg weakness. A cane can transmit proprioceptive input to the hand and arm, which can be helpful to people with neuropathic problems or visual deficit. Canes are lightweight and versatile, but require good hand and arm strength and provide only minimal support. Canes are most useful when the gait problem is unilateral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mild.",
"    <br/>",
"    <br/>",
"    A variety of options are available in canes. For most patients, a simple cane with an ergonomic grip is most effective [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/39\">",
"     39",
"    </a>",
"    ]. A quad cane with four tips provides a broader base of support but is clumsier to use. A cane with a pistol grip handle can increase weight support.",
"    <br/>",
"    <br/>",
"    The cane needs to be at the right height so as not to throw off balance and to provide proper biomechanical support, with the handle of the cane at the level of the wrist with the arm fully extended. Most canes can be adjusted by cutting the cane at the tip or, for adjustable canes, with the button on the side of the cane. Most canes have a rubber tip to improve traction that should be inspected for wear and replaced when worn.",
"   </p>",
"   <p>",
"    <br/>",
"    A cane should be used in the hand opposite to the affected limb to preserve a normal gait pattern and keep the body weight over the base of support to ensure good balance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176091046\">",
"    <span class=\"h4\">",
"     Crutches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like canes, crutches come with various options (eg, axillary, forearm, and platform crutches). However, as all crutches require excellent arm strength and coordination for effective use, they are seldom used with older patients. Improper use of crutches, especially the more common axillary crutches, can result in injury to the shoulder (eg, brachial plexopathy and rotator cuff tendinitis). There are several different ways to use crutches (eg, swing through gait, touch-down, etc.) and most require learning a novel gait pattern, which can be challenging in the presence of even mild cognitive impairment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3285554\">",
"    <span class=\"h4\">",
"     Walkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Walkers are the second most commonly used type of mobility aid [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Walkers generally are used to treat bilateral gait problems or when more body-weight support or balance support is needed than a cane can provide. Walkers come with many options in the number of wheels and type of support.",
"   </p>",
"   <p>",
"    One of the most commonly used types of walker is a two-wheel or front-wheel walker. A four-point or pick-up walker is seldom used any more, as it is harder to use and offers little additional stability [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/40\">",
"     40",
"    </a>",
"    ]. Forearm supports can be attached to a two-wheel walker to enable use by persons with weak grip or hand deformities.",
"   </p>",
"   <p>",
"    Increasingly common is a four-wheel walker with brakes located on the handles like a bicycle (sometimes called a &ldquo;rollator&rdquo; or &ldquo;Canadian walker&rdquo;). Four-wheel walkers come with and without a seat and with or without a basket. A four-wheel walker is less stable than a two-wheel walker. It requires good hand coordination to use the brakes and is more expensive than a two-wheel walker; but it is more maneuverable, and the seat affords an opportunity to rest at will. It is a good choice for someone whose main problem is poor endurance from pain or shortness of breath (such patients often have the necessary balance and hand coordination to safely use this type of walker, and the seat allows for rest breaks). A three-wheel walker can provide similar balance support as a four-wheel walker, but it is lighter weight and more maneuverable so it is particularly useful for patients dealing with mobility in narrow confines (eg, a trailer) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/41\">",
"     41",
"    </a>",
"    ]; however, it is does not come with a seat or basket so it is less useful for people with limited endurance or who need to transport items while walking (eg, shopping).",
"   </p>",
"   <p>",
"    <br/>",
"    A &ldquo;Merry Walker&rdquo; has four wheels, a sling seat, and railings on four sides so that the patient is protected from falling yet can propel themselves. The Merry Walker is larger than other walkers and is best used in an institutional setting with wide",
"    <span class=\"nowrap\">",
"     doorways/hallways.",
"    </span>",
"   </p>",
"   <p>",
"    A &ldquo;Knee Walker&rdquo; is a relatively new wheeled mobility device. It is similar to the foot-propelled or kick scooters used by children but with a platform on which the patient can rest their knee while walking. It is especially useful for people who must be non-weight-bearing after surgery or injury to the foot or ankle as it is easy to use and it avoids the need for a wheelchair or crutches. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3285569\">",
"    <span class=\"h4\">",
"     Wheelchairs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wheelchairs may be used when weightbearing is prohibited or in patients with significant functional impairments (eg, bilateral leg weakness, impaired balance,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    motor coordination too severely impaired for safe use of a walker). The most commonly used wheelchair is a manual wheelchair with a sling seat that folds and has removable footrests and armrests.",
"   </p>",
"   <p>",
"    Many older individuals pay for wheelchairs and other assistive devices themselves [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/42\">",
"     42",
"    </a>",
"    ] and may be tempted to save money by use of non-removable foot rests or by using a second-hand wheelchair. Fixed foot rests are a fall hazard and make it harder to get in and out of the chair and should be avoided. Borrowing a wheelchair can be problematic if the fit is not adequate or the seat is worn, reducing comfort and increasing the risk of pressure ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Important aspects of wheelchair fit for all wheelchair users include seat width and height. The seat width should allow about one inch between the thighs and the armrests, such that there is no pressure or rubbing on the lateral thighs while still allowing good biomechanics when propelling the chair. The seat length should allow about two inches between the end of the seat and the knees, and the foot rests are positioned so the thighs are slightly elevated or level such that the seat provides even support to the buttocks and thighs. Patients who use their feet to propel the wheelchair (eg, stroke patients) require a &ldquo;hemi-height&rdquo; wheelchair with a seat height that is lower to the ground. A seat cushion generally should be used with a wheelchair and a specialized pressure-reducing cushion is appropriate for persons in the wheelchair full-time or who have difficulty with limited ability to shift their weight while seated [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Specialized seating systems can be provided for persons with truncal instability. &nbsp;",
"   </p>",
"   <p>",
"    Shoulder pain is common in manual wheelchair users, and it is likely that elders with arthritic joints and women whose upper extremities are weaker are at particular risk for developing shoulder problems with prolonged manual wheelchair use [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/46\">",
"     46",
"    </a>",
"    ]. Patients who develop shoulder pain with wheelchair use should be evaluated for rotator cuff tendinitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link\">",
"     \"Evaluation of the patient with shoulder complaints\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of options are available to treat shoulder pain in manual wheelchair users, including exercises to strengthen the shoulder musculature, training on how to most efficiently propel the wheelchair,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    providing a lightweight wheelchair that is easier to propel or even a power wheelchair [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Ultra lightweight manual wheelchairs can be adjusted for optimal biomechanical advantage when propelling the wheelchair, and interchangeable power assist wheels are available that can reduce the force needed to propel the wheelchair. Wheelchairs with special adaptations to meet specialized needs (eg, ultra lightweight, elevating leg rests, reclining backrests, power wheelchairs, etc.) may require additional justification to ensure reimbursement [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/49\">",
"     49",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Motorized wheelchairs and scooters are increasingly common and are most helpful for community mobility [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/50\">",
"     50",
"    </a>",
"    ]. Even the most compact motorized wheelchair has a larger footprint than a manual wheelchair, making it hard to maneuver in the home. The cost-benefit trade-offs for these devices need to be considered carefully: financial costs include not only the device, but a car lift to transport the device and an entry ramp if it is to be used in the home. There also is a risk of accidents (collisions, tipping over); however, the risk of deconditioning appears minimal.",
"    <br/>",
"    <br/>",
"    At least in the short term, power scooters do not appear to be overused or to cause deconditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/51\">",
"     51",
"    </a>",
"    ]. It appears that most wheelchair users pick and choose locations where they use their wheelchair depending on needs, abilities, and environmental constraints [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/52\">",
"     52",
"    </a>",
"    ]. Benefits from wheelchairs relate to increased mobility and participation in activities that would be prohibitive otherwise [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/53\">",
"     53",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    A systematic review of the evidence regarding the best way to obtain the optimal wheelchair found that there is only limited evidence to determine best practices [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/54\">",
"     54",
"    </a>",
"    ]. There is some evidence that expert assistance, fitting, and training is helpful for improving wheelchair use [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. For patients with complex rehabilitation and seating needs (eg, deformities, increased muscle",
"    <span class=\"nowrap\">",
"     tone/spasticity),",
"    </span>",
"    a multidisciplinary team can be helpful, including a rehabilitation physician (physiatrist), an occupational therapist (OT) or physical therapist (PT) with expertise in wheelchairs, a certified rehabilitation technology supplier,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a rehabilitation technician [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/54\">",
"     54",
"    </a>",
"    ]. For individuals with complex needs, several components of a wheelchair program will help to assure a good outcome: education to reduce accidents and maximize mobility; involving the individual in the prescription process; and active follow-up to reduce accidents and make adjustments, as needed, to improve fit and usage [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/54\">",
"     54",
"    </a>",
"    ]. Expert evaluation and training is also important for patients who will use the wheelchair full-time, who are at increased risk for pressure sores (eg, due to incontinence or inability to weight shift), for persons with postural problems, or if a motorized wheelchair or scooter is being considered. However, even short-term and intermittent wheelchair users likely benefit from fitting and training by an OT or PT in use of the device, with beneficial effects related to comfort and ability to safely navigate with the wheelchair [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4662577\">",
"    <span class=\"h4\">",
"     Reimbursement for mobility aids in the US",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medicare (Centers for Medicare and Medicaid [CMS]) will pay for &ldquo;durable medical equipment&rdquo; (DME), including all types of mobility aids, but it is important to follow their guidelines to ensure coverage (",
"    <a class=\"graphic graphic_table graphicRef86415 \" href=\"UTD.htm?2/23/2429\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/58\">",
"     58",
"    </a>",
"    ]. Medicare guidelines for Mobility Assistive Equipment (MAE) favor use of a cane or walker over a manual wheelchair and a manual wheelchair over a power wheelchair scooter, approving the higher-level device only if the patient has a mobility limitation that is not adequately compensated with the lower-level device [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/59\">",
"     59",
"    </a>",
"    ]. Generally, Medicare reimbursement is limited to one type of mobility aid per qualifying illness (ie, the patient isn&rsquo;t provided both a quad cane and a wheelchair for mobility needs after a stroke). Face-to-face evaluation by a physician or midlevel provider and substantive medical justification is required by CMS for power mobility devices [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/60\">",
"     60",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Some medical supply stores and vendors employ a certified Assistive Technology Professional (ATP) especially for provision of complex devices (eg, power wheelchairs).",
"    <span class=\"nowrap\">",
"     Medicare/CMS",
"    </span>",
"    covers consultation with an OT or PT for fitting and training in use of any type of durable medical equipment, including mobility aids.",
"   </p>",
"   <p>",
"    <br/>",
"    The Veterans Health Administration (VHA) will also cover most types of mobility aids and without some of the restrictions in the Medicare system (eg, more than one type of mobility aid may be provided for a particular medical problem so long as it is medical necessary), although medical justification by a VHA medical provider is required and training in use of the device by a VHA rehabilitation provider is also usually required.",
"    <br/>",
"    <br/>",
"    Typically, Medicare will pay for rental of a standard manual wheelchair, with the patient owning the wheelchair after 13 months of rental [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/61\">",
"     61",
"    </a>",
"    ]. Wheelchairs for nursing home residents are provided by the institution rather than",
"    <span class=\"nowrap\">",
"     Medicare/CMS,",
"    </span>",
"    so it can be difficult to obtain a specialized wheelchair in that setting. Veterans own the mobility aids provided to them by the VHA, and they do not need to be returned when they are no longer needed, although they may need to be returned to get a new or replacement device. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4419995\">",
"    <span class=\"h3\">",
"     Bathroom and self-care aids",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of devices and environmental modifications can be used to make self-care tasks easier and improve safety, particularly in the bathroom. While the evidence to support the efficacy of particular bathroom devices is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/62\">",
"     62",
"    </a>",
"    ], the theoretical rationale for their provision is strong. Several randomized clinical trials have demonstrated beneficial clinical outcomes (eg, physical function,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    balance confidence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduced falls) from home health interventions that include provision of assistive devices, environmental modifications, and home visits by rehabilitation therapists [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/63-67\">",
"     63-67",
"    </a>",
"    ]. Evidence suggests that simply providing home safety assessments and equipment without involvement of a professional such as an OT is less effective [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Useful information on bathroom design and other types of environmental modification to enhance independence and safety is available at the websites for the Center for Inclusive Design and Environmental Access (",
"    <a class=\"external\" href=\"file://www.ap.buffalo.edu/idea/home/index.asp\">",
"     www.ap.buffalo.edu/idea/home/index.asp",
"    </a>",
"    ) and the Center for Universal Design (",
"    <a class=\"external\" href=\"file://www.design.ncsu.edu/cud/index.html\">",
"     www.design.ncsu.edu/cud/index.html",
"    </a>",
"    ). Commonly-used bathroom equipment includes raised toilet seats, seats in the",
"    <span class=\"nowrap\">",
"     tub/shower,",
"    </span>",
"    hand-held showers, and grab bars.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Raised toilet seats &mdash;",
"      </strong>",
"      It is easier to rise to standing when starting from a higher level than a lower level [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/69\">",
"       69",
"      </a>",
"      ], so a raised toilet seat or",
"      <span class=\"nowrap\">",
"       tub/shower",
"      </span>",
"      bench may be helpful to someone with weak legs, painful joints, or poor balance. Raised toilet seats may be free standing (eg, bedside commode) or attached directly to the toilet.",
"      <span class=\"nowrap\">",
"       Tub/shower",
"      </span>",
"      benches also come in a variety of shapes and sizes.",
"     </li>",
"     <li>",
"      <strong>",
"       Grab bars &mdash;",
"      </strong>",
"      Bars may allow patients to rise more safely by enabling use of the arms to compensate for weak legs or limited sensation. Patients may rely on items already in their home such as a nearby sink or towel bar for this purpose, which is fine if they are stable or securely attached to the wall, but can be dangerous if the item is unstable. Placement of grab bars can eliminate some of the risk.",
"      <br/>",
"      <br/>",
"      There is considerable variety in grab-bar technology [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/70\">",
"       70",
"      </a>",
"      ], with options such as direct attachment to the toilet or a raised toilet seat, swing away bars, attachment to the side of the tub, or directly to the wall itself.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who need help from another person for transfers, use of a gait belt can improve safety, and hydraulic lifts are available that can be easily used even by quite frail caregivers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4420002\">",
"    <span class=\"h3\">",
"     Prosthetics and orthotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prosthesis is an artificial device that replaces a missing body part (eg, artificial limb) while an orthosis is an external device applied to the body to support or improve the function of that body",
"    <span class=\"nowrap\">",
"     segment/joint",
"    </span>",
"    (eg, ankle foot orthosis, carpal tunnel splint).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1174926\">",
"    <span class=\"h4\">",
"     Prostheses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prosthetic devices require detailed patient evaluation for optimal prescription. Careful consideration of medical comorbidities and the premorbid functional status is required, particularly in older persons. Such factors may be of lesser importance for younger patients with traumatic amputation.",
"   </p>",
"   <p>",
"    Lower extremity amputations are the second most common type of amputation (with digit amputation most common), and up to 90 percent are due to peripheral vascular disease in diabetic patients. The underlying disease that resulted in an amputation (eg, diabetes, peripheral vascular disease) often affects the function of other organ systems and the patient&rsquo;s ability to cope with the increased work of walking required with a prosthesis. Comorbid conditions such as cognitive impairment, arthritis, pulmonary disease, or stroke can also affect the use of a prosthesis. A systematic review noted that the following factors were most predictive of functional walking ability after a prosthetic limb: cognition, fitness, preoperative mobility, ability to stand on one leg, and independence in activities of daily living [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For some severely debilitated amputees, a manual or power wheelchair with a cosmetic leg may provide the best functional outcome. For other amputees, functional needs may be met with a low-tech prosthesis, such as a simple knee or ankle joint rather than a computerized knee or multiaxial ankle joint. In contrast, those with an above-knee amputation who are likely to be able to ambulate in the community may benefit from a high-tech prosthesis with a computerized knee [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multidisciplinary amputee clinic including a physiatrist, a physical therapist, and a prosthetist is the optimal resource for determining the proper prosthesis and assuring correct fit and function. If this is not available, it is vital for the ordering physician to work closely with a certified prosthetist and include a PT early in the process. In general, obtaining proper prosthetic fit and function requires a skilled prosthetist. Unfortunately, there is limited research available to assist in determining the optimal prosthesis for an individual patient [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/73\">",
"     73",
"    </a>",
"    ]. Prosthetic training is typically completed on an outpatient basis by a physical therapist who may then work with the prosthetist to modify the prosthesis if abnormal gait patterns or skin breakdown are noted; ideally, there are intermittent evaluations and supervision by a physiatrist skilled in amputee rehabilitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1174941\">",
"    <span class=\"h4\">",
"     Orthoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthoses (ie, splints and braces) are available for virtually every joint in the body including the spine. There are a number of prefabricated, &ldquo;off the shelf&rdquo; orthoses (eg, carpal tunnel splints, soft cervical collar). Custom orthoses are generally fabricated by an orthotist although occupational therapists may also perform this function, particularly for upper-extremity joints. Prefabricated splints and braces are most appropriate for uncomplicated conditions that don&rsquo;t have substantial deformity.",
"   </p>",
"   <p>",
"    Commonly used prefabricated lower-extremity braces in the geriatric population include those for the knee (eg, knee sleeve, knee unloader braces), ankle foot orthoses for foot drop, and heel cushions for plantar",
"    <span class=\"nowrap\">",
"     fasciitis/heel",
"    </span>",
"    pain. There are few randomized trials with any braces. The available evidence indicates that knee braces may reduce pain and improve function for patients with osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Knee sleeves may be used for mild to moderate severity knee osteoarthritis (OA); devices to control patellar motion (eg, patellar cutout) may be beneficial for patellofemoral OA. Due to the limited evidence of benefit for any particular knee sleeve, patient preference should be the deciding factor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=see_link&amp;anchor=H6#H6\">",
"       \"Nonpharmacologic therapy of osteoarthritis\", section on 'Braces'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Knee unloader braces are designed to alleviate pain by unloading the osteoarthritic medial or lateral compartment of the knee.",
"      <span class=\"nowrap\">",
"       Medial/lateral",
"      </span>",
"      unloader braces should be reserved for patients with more severe knee OA and are best prescribed by an orthopedic surgeon, rehabilitation",
"      <span class=\"nowrap\">",
"       physician/physiatrist,",
"      </span>",
"      or with input from a physical therapist. Patients with knee instability may be prescribed a hinged knee brace that can be set to limit range of motion to a particular arc; however, such braces should only be prescribed under the direction of a rehabilitation or orthopedic provider as they should be used in conjunction with a rehabilitation program.",
"     </li>",
"     <li>",
"      Foot drop occurs most commonly after a stroke but may also be seen with a neuropathy affecting the",
"      <span class=\"nowrap\">",
"       fibular/peroneal",
"      </span>",
"      nerve. Ankle foot orthoses (AFOs) maintain the foot in a neutral position during ambulation and can improve gait speed and self-confidence in patients with foot drop [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/76,77\">",
"       76,77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is fair evidence that heel cushions may be beneficial for plantar fasciitis, and pre-fabricated heel cushions appear to be just as effective as higher-cost custom-molded foot orthoses [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/78,79\">",
"       78,79",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44681?source=see_link&amp;anchor=H8#H8\">",
"       \"Plantar fasciitis and other causes of heel pain\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients at prolonged bedrest benefit from a protective orthosis to maintain the foot in a neutral position, preventing Achilles tendon contractures and protecting the heels from skin",
"      <span class=\"nowrap\">",
"       breakdown/pressure",
"      </span>",
"      ulcers.",
"     </li>",
"     <li>",
"      For the upper extremity, carpal tunnel functional wrist splints are effective for reducing numbness and pain [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/80\">",
"       80",
"      </a>",
"      ]; over the counter splints are as effective for treating carpal tunnel syndrome symptoms as custom fit splints [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/81\">",
"       81",
"      </a>",
"      ]. However, the patient should be referred for neurological evaluation (eg, electrodiagnostic testing) and possible surgery if there is any evidence of thenar muscle weakness or atrophy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44008?source=see_link&amp;anchor=H6#H6\">",
"       \"Treatment of carpal tunnel syndrome\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Osteoarthritis of the first metacarpal phalangeal joint is common and it can be effectively treated with an opponens splint. These splints typically are hand crafted by an occupational therapist, hand therapist (PT or OT), or prosthetist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4420009\">",
"    <span class=\"h2\">",
"     Environmental modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;&ldquo;Environmental modification&rdquo; and &ldquo;universal design&rdquo; describe interventions and methods to minimize the effects of the environment in exacerbating disability and enhance &ldquo;accessibility&rdquo; for all persons irrespective of their abilities. The term &ldquo;universal design&rdquo; highlights an overarching goal of enabling access for the widest possible breadth of physical abilities. However, the effects of medical conditions on physical function are variable among individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/82\">",
"     82",
"    </a>",
"    ]; similarly, interactions with the environment are not uniform across conditions and impairments. The",
"    <span class=\"nowrap\">",
"     environment/person",
"    </span>",
"    interface can be particularly important for persons with impairments affecting mobility and also for persons with low vision.",
"   </p>",
"   <p>",
"    Environmental modification may be used in isolation or in conjunction with assistive technology to enhance access and utility of both public and private spaces for persons with disability [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/64\">",
"     64",
"    </a>",
"    ]. Increasing evidence supports the influence of the physical environment (ie, terrain, housing) on functional outcomes in older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/83\">",
"     83",
"    </a>",
"    ]. For example, elders who live in neighborhoods with a mixture of residential and business facilities (ie, &ldquo;mixed use&rdquo;) and higher-density neighborhoods report greater independence with Instrumental ADLs, with the effect most prominent among those with greater physical limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Americans with Disabilities Act (ADA) of 1990 directed that new public and private business construction must be accessible, and it supports widely used guidelines for accessibility. Technical information on the ADA is available at",
"    <a class=\"external\" href=\"file://www.adata.org/\">",
"     www.adata.org",
"    </a>",
"    , and information on accessibility is available from the US Access Board (",
"    <a class=\"external\" href=\"file://www.access-board.gov/about.htm\">",
"     www.access-board.gov/about.htm",
"    </a>",
"    ). Helpful information on environmental modification and universal design pertinent to both public and private spaces can be found at the websites for the Center for Inclusive Design and Environmental Access (",
"    <a class=\"external\" href=\"file://www.ap.buffalo.edu/idea/home/index.asp\">",
"     www.ap.buffalo.edu/idea/Home/index.asp",
"    </a>",
"    ) and the Center for Universal Design (",
"    <a class=\"external\" href=\"file://www.design.ncsu.edu/cud/index.html\">",
"     www.design.ncsu.edu/cud/index.html",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Occupational therapists have particular expertise in the person-environment interface within the home environment and can work in conjunction with architects and structural engineers to recommend the most beneficial modifications; physical therapists are particularly helpful with mobility impairments, equipment, and methods for coping with environmental challenges both inside and especially outside the home; low-vision specialist provide unique expertise for these same kinds of problems in older adults coping with low vision (eg, macular degeneration).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4420016\">",
"    <span class=\"h2\">",
"     Modalities for pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several therapeutic modalities are available for the treatment of pain.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Heat/Cold",
"       </strong>",
"      </span>",
"      &mdash; Two of the most commonly used therapeutic modalities are heat and cold. Both heat and cold may be delivered to the patient in several different ways. Mechanisms of thermal transfer include conduction (eg, hot or cold pack), convection (eg, whirlpool bath), and conversion (eg, ultrasound, diathermy). The effect of commonly used modalities for delivering heat and cold is at the superficial level of the body; core temperature is altered very little by localized thermal modalities. Ultrasound, particularly low-frequency ranges, is used to heat deeper tissues (up to several cm in depth). Heating modalities include heating",
"      <span class=\"nowrap\">",
"       pads/hydrocollator",
"      </span>",
"      packs, heat lamps, hot",
"      <span class=\"nowrap\">",
"       tub/whirlpool,",
"      </span>",
"      paraffin baths (paraffin mixed in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"       mineral oil",
"      </a>",
"      heated to 45 to 54&deg;C), and ultrasound (0.5 to 3.0 MHz). Heat causes local vasodilatation and hyperemia. Cooling modalities for rehabilitation include ice",
"      <span class=\"nowrap\">",
"       cubes/packs/wraps",
"      </span>",
"      (recommended duration 10 to 20 minutes per session; thin damp towel between skin and ice), ice massage, and whirlpool baths.",
"      <br/>",
"      <br/>",
"      While both heat and cold are most frequently utilized for their pain relieving effects, other indications include muscle relaxation for heat, and relief of swelling and edema for cold (",
"      <a class=\"graphic graphic_table graphicRef86679 \" href=\"UTD.htm?13/30/13803\">",
"       table 6",
"      </a>",
"      ). Contraindications for thermal modalities must be considered (",
"      <a class=\"graphic graphic_table graphicRef86678 \" href=\"UTD.htm?21/23/21883\">",
"       table 7",
"      </a>",
"      ). Heat is generally contraindicated in patients with acute injury and application of cold is to be avoided for patients with insensate skin or Raynaud phenomenon.",
"      <br/>",
"      <br/>",
"      Evidence for the relative benefits of different methods to provide heat is limited and comparisons of modalities (eg, hot pack versus diathermy) appear to show equal benefit for pain relief [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/85\">",
"       85",
"      </a>",
"      ]. Although one study showed more rapid resolution of calcific rotator cuff tendinitis with ultrasound compared to exercise alone, there was no difference between the groups at nine months [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Transcutaneous electrical nerve stimulation (TENS)",
"      </strong>",
"      &mdash; TENS is primarily used for musculoskeletal pain relief. The mechanism of action for TENS is uncertain, although it has been postulated that TENS modulates pain perception through the gate control pain theory. Well-controlled investigations have not demonstrated significant benefit of TENS for musculoskeletal pain disorders beyond placebo or heat alone [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/87,88\">",
"       87,88",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Iontophoresis/Phonophoresis",
"       </strong>",
"      </span>",
"      &mdash;",
"      These modalities utilize electric current (iontophoresis) or ultrasound energy (phonophoresis) to force a therapeutic medication (eg, glucocorticoid) into tissues. Both are used to treat soft tissue musculoskeletal injuries. Although evidence is limited, the few randomized controlled trials indicate that these modalities are generally no more effective than placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/89,90\">",
"       89,90",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4663283\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persons with dysphagia may be helped by special feeding techniques (eg, tucking the chin, swallowing a second time after every bite)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dietary modifications (eg, use of gelatin to thicken liquids) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/91\">",
"     91",
"    </a>",
"    ]. A speech language pathologist (speech therapist) can use radiographic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endoscopic studies to clarify the nature of the dysphagia and fine-tune recommendations. Treatment of dysphagia may be directed by the speech language pathologist individually or in collaboration with a nutritionist",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    occupational therapist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2267490\">",
"    <span class=\"h2\">",
"     Reimbursement (US, other than mobility aids)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Veterans Health Administration (VHA), but not",
"    <span class=\"nowrap\">",
"     Medicare/CMS,",
"    </span>",
"    will pay for bathroom safety devices such as raised toilet seats,",
"    <span class=\"nowrap\">",
"     tub/shower",
"    </span>",
"    seats, or grab bars, considering these items not medical equipment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    needed for &ldquo;personal convenience;&rdquo; however, Medicare will pay for a free-standing &ldquo;bedside&rdquo; commode (",
"    <a class=\"graphic graphic_table graphicRef86415 \" href=\"UTD.htm?2/23/2429\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Medicare/CMS",
"    </span>",
"    will not pay for other assistive devices related to self-care (eg, specialized eating utensils), although the VHA does provide these items. Consultation with a rehabilitation therapist (eg, OT, PT) for evaluation, fitting, and training in use of any type of assistive devices is paid for by both Medicare and the VHA, and such consultation can help assure the prescribed device will meet the patient&rsquo;s needs and that they can use it safely [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Medicare/CMS",
"    </span>",
"    provides coverage for many prosthetic and orthotic devices, although generally the patient is responsible for a 20 percent co-pay (",
"    <a class=\"graphic graphic_table graphicRef86415 \" href=\"UTD.htm?2/23/2429\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/58\">",
"     58",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medicare will cover fabrication of a prosthetic limb and related follow-up visits with a prosthetist, as does the Veterans Health Administration (VHA). Per Medicare guidelines, the functional level of the amputee must be considered and specified in the prescription for the prosthetic limb.",
"     </li>",
"     <li>",
"      Typically both Medicare and the VHA will pay for a splint fabricated by an orthotist or occupational therapist and many prefabricated braces as well.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The VHA will pay for ramps and some home renovations (with a monetary cap that varies with &ldquo;service connection&rdquo;), and some veterans are eligible for a &ldquo;specially adapted housing&rdquo; grant [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/94\">",
"     94",
"    </a>",
"    ]. Medicare does not cover environmental modifications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4420023\">",
"    <span class=\"h1\">",
"     REHABILITATION SETTINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rehabilitation therapy services can be delivered in a wide variety of settings across the care continuum. Settings for rehabilitation include the acute hospital (eg, critical care units, general medical or surgical units) and postacute locations including transitional care units in hospitals, rehabilitation hospitals, nursing",
"    <span class=\"nowrap\">",
"     homes/skilled",
"    </span>",
"    nursing facilities, outpatient facilities, and the patient&rsquo;s home. The intensity and nature of services that can be delivered differ across the settings.",
"   </p>",
"   <p>",
"    When not delivered in a dedicated rehabilitation unit, rehabilitation treatment is often limited to services by a single discipline (eg, physical therapy [PT] or occupational therapy [OT]). Even when more than one rehabilitation service is involved, the degree of coordination that is possible (ie, in the hospital, largely through progress notes or discharge planning rounds) is less optimal than the coordination through in-person contact and physician-led weekly conferences that is required in an inpatient rehabilitation facility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18332705\">",
"    <span class=\"h2\">",
"     Rehabilitation therapy in the acute hospital",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rehabilitation therapy in the intensive care unit (ICU) is relatively new [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/25\">",
"     25",
"    </a>",
"    ]. Early mobilization, beginning the first day of ICU hospitalization and while the patient is still on a ventilator, can shorten length of stay and improve functional outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/95-97\">",
"     95-97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rehabilitative services for patients on medical and surgical wards typically focus on mobilization and discharge planning. Data are accruing showing the merits of early mobilization for diverse acutely-ill patient populations [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. There is good evidence showing benefit from early intensive",
"    <span class=\"nowrap\">",
"     PT/OT",
"    </span>",
"    in the hospital for stroke patients, and for patients with a total joint replacement or hip fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/23,98\">",
"     23,98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For example, early intensive rehabilitative therapy for stroke patients improves functional outcomes (eg, ability to walk and to use the toilet independently) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/99\">",
"     99",
"    </a>",
"    ]. As another example, hip fracture patients with fewer days of immobility post-operatively (ie, mobilized to be out of bed beyond a chair) had better ability to walk at two months and lower six-month mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/98\">",
"     98",
"    </a>",
"    ]. However, it is necessary to determine if a patient has the capacity, both physically and mentally, to participate in PT or OT. Close coordination of medical care can help, for example, by reducing delirium and by ensuring optimal pain management [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/23,100\">",
"     23,100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=see_link\">",
"     \"Prevention and treatment of delirium and confusional states\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=see_link\">",
"     \"Management of postoperative pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Suggestions for parameters to determine the hospitalized patient&rsquo;s ability to participate in PT or OT are shown in a table, with focus on the patient&rsquo;s cognitive, hemodynamic, musculoskeletal, and pain status (",
"    <a class=\"graphic graphic_table graphicRef86416 \" href=\"UTD.htm?37/23/38267\">",
"     table 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Even for patients who can&rsquo;t participate in therapy, involvement of PT and OT is a necessary component of discharge planning in any adult for whom there is concern about the ability to return home (eg, limitations in self-care or mobility are present). This is particularly important for older adults as they are vulnerable to adverse effects from care transitions and often require care in multiple settings over the course of illness and recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/101\">",
"     101",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18332847\">",
"    <span class=\"h2\">",
"     Post-acute hospital rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common critical decision for inpatient providers is determining the type of setting in which post-acute rehabilitation will be delivered. Ideally, rehabilitation during the post-acute period will help to ensure maximal recovery for patients after an acute illness.",
"   </p>",
"   <p>",
"    Post-acute rehabilitation may take place in a number of different venues with differing advantages for various types of geriatric patients. These sites include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inpatient rehabilitation facilities (IRF or &ldquo;acute&rdquo; rehabilitation)",
"     </li>",
"     <li>",
"      Long-term acute care hospitals (LTACH)",
"     </li>",
"     <li>",
"      Skilled nursing facilities (SNF) with Medicare certified therapy services (sometimes referred to as &ldquo;subacute&rdquo; or &ldquo;transitional care&rdquo; units)",
"     </li>",
"     <li>",
"      The Geriatric Evaluation and Management inpatient rehabilitation program (within the Veterans Administration)",
"     </li>",
"     <li>",
"      Home health",
"     </li>",
"     <li>",
"      Outpatient therapy services",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Post-acute settings differ in the types of available rehabilitation therapies, intensity of therapy, the level of medical and nursing support, and reimbursement. The options and considerations when considering continued rehabilitation upon discharge from the acute hospital setting are summarized in a table (",
"    <a class=\"graphic graphic_table graphicRef86677 \" href=\"UTD.htm?28/56/29580\">",
"     table 9",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Multiple factors are to be considered when determining an appropriate location for post-acute rehabilitation for a particular geriatric patient. Definitive research is lacking to guide decisions. Key factors to consider include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Medical diagnosis",
"     </li>",
"     <li>",
"      Functional abilities (pre-morbid, admission and current)",
"     </li>",
"     <li>",
"      Medical stability",
"     </li>",
"     <li>",
"      Cognition",
"     </li>",
"     <li>",
"      Therapy tolerance and motivation",
"     </li>",
"     <li>",
"      Types of therapy services needed",
"     </li>",
"     <li>",
"      Psychosocial factors such as",
"      <span class=\"nowrap\">",
"       patient/family",
"      </span>",
"      preference, geographic location",
"     </li>",
"     <li>",
"      Third party reimbursement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/2/12330?source=see_link&amp;anchor=H4#H4\">",
"     \"Hospital discharge\", section on 'Determining the post-discharge site of care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4420030\">",
"    <span class=\"h3\">",
"     Medical diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical diagnosis is an important determinant of eligibility for admission to an inpatient rehabilitation facility (IRF or acute rehabilitation hospital). Under the Centers for Medicare and Medicaid (CMS) guidelines, 60 percent of patients admitted to an IRF must have 1 of 13 medical diagnoses (",
"    <a class=\"graphic graphic_table graphicRef86417 \" href=\"UTD.htm?29/26/30123\">",
"     table 10",
"    </a>",
"    ). These guidelines therefore influence the availability of beds and acceptance of particular patients referred for IRF care.",
"   </p>",
"   <p>",
"    Diagnoses that often warrant a higher level of post-acute care (ie, intensive rehabilitation in an IRF) include stroke, spinal cord injury, and traumatic brain injury. General orthopedic patients (eg, patients recovering from hip fracture, ischemic amputation, or total joint replacement) may not gain particular benefit from intensive rehabilitation, and may recover function just as well with rehabilitation in a subacute or skilled nursing facility [",
"    <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/102-104\">",
"     102-104",
"    </a>",
"    ]; each patient should be evaluated individually to determine their most appropriate postacute rehabilitation setting. Frailty in patients with hip fracture or ischemic amputation may limit their ability to tolerate more intensive rehabilitation while patients with an elective total joint replacement may have good general health and be able to rehabilitate with home health therapy followed by therapy in an outpatient facility. In contrast, patients with traumatic amputation often have other concomitant injuries requiring intensive rehabilitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18333177\">",
"    <span class=\"h3\">",
"     Optimal level of post-acute rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even within groups of patients who can benefit from intensive post-acute inpatient rehabilitation, a variety of considerations are important when determining the optimal level of post-acute care. The following describes some key considerations across most diagnostic groups that pertain to determining the optimal level of post-acute rehabilitation. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Prehospital and current functional abilities",
"      </strong>",
"      &mdash; Information about functional abilities may be obtained from PT",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      OT evaluations and from the nursing service, although a history of prehospital function is best obtained from the",
"      <span class=\"nowrap\">",
"       patient/family",
"      </span>",
"      directly.",
"      <span class=\"nowrap\">",
"       PT/OT",
"      </span>",
"      consultations should be made early on during an acute hospitalization. This will help to ensure optimal clinical outcomes and allow sufficient time for the evaluation, equipment to be obtained if needed, and the patient trained in its use.",
"      <br/>",
"      <br/>",
"      Therapy assessments should include an evaluation of ambulatory function and the patient&rsquo;s ability to perform basic activities of daily living (ADLs) (",
"      <a class=\"graphic graphic_table graphicRef66451 \" href=\"UTD.htm?2/13/2269\">",
"       table 11",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef63647 \" href=\"UTD.htm?43/3/44093\">",
"       table 12",
"      </a>",
"      ). At a minimum, it should be determined whether the patient is independent or requires assistance from another person. For example, most individuals who resided in a nursing home setting pre-hospitalization will return to a nursing home, as it is unlikely they would make sufficient functional gains to become independent again and would be unlikely to have an independent living situation to return to after rehabilitation. Rehabilitation for such patients would best be met in a skilled nursing facility&ndash;level setting, rather than in an IRF or with a home health service.",
"     </li>",
"     <li>",
"      <strong>",
"       Medical stability",
"      </strong>",
"      &mdash; Medical stability assists in determining both the patient&rsquo;s ability to participate in therapy while in the hospital and the type of post-acute setting needed after discharge. Inpatient rehabilitation facilities have physicians on staff to see patients daily and treat complex rehabilitation medical problems (eg, spasticity, autonomic dysreflexia); in contrast, a skilled nursing facility has skilled nurses on staff to monitor patients&rsquo; conditions and provide skilled nursing services with intermittent support (eg, once weekly) from medical staff who typically have general expertise in geriatric medicine. Thus, patients with active medical problems requiring close physician and nursing care are best discharged to either a long-term acute care hospital (LTACH) or an inpatient rehabilitation facility (IRF).",
"     </li>",
"     <li>",
"      <strong>",
"       Cognition",
"      </strong>",
"      &mdash; Participation in therapy is dependent, at a minimum, on the ability to follow one-step commands and to sufficiently recall so that learning is possible and therapists are not repetitively instructing the same task. Therapeutic goals are constrained when such abilities aren&rsquo;t present, with interventions limited to recommendations for equipment, environmental modifications, and caregiver training to enhance safety with functional tasks (eg, ambulation and bathing) and caregiver training on interventions to help maintain",
"      <span class=\"nowrap\">",
"       physical/functional",
"      </span>",
"      abilities (eg, range of motion exercises, proper use of splints and braces).",
"     </li>",
"     <li>",
"      <strong>",
"       Therapy tolerance and motivation",
"      </strong>",
"      &mdash; While rehabilitation therapy in and of itself can help reduce depression and restore confidence, patients must be willing to participate. The patients&rsquo; motivation may be gleaned from their participation and motivation during therapy sessions in the acute hospital setting and their willingness to work with nursing staff during daily care. Tolerance for the more intensive therapy program required in an IRF (three hours of therapy per day, five days per week) also may be inferred from patient participation with",
"      <span class=\"nowrap\">",
"       PT/OT",
"      </span>",
"      during their acute hospitalization.",
"     </li>",
"     <li>",
"      <strong>",
"       Types of needed therapy services",
"      </strong>",
"      &mdash; Patients discharged to an IRF must have a demonstrated need for at least two therapy disciplines (ie,",
"      <span class=\"nowrap\">",
"       PT/OT/speech",
"      </span>",
"      therapy). These services may be offered in other settings, but anticipated use of these therapies is not a requirement for admission to other settings.",
"     </li>",
"     <li>",
"      <strong>",
"       Psychosocial factors",
"      </strong>",
"      &mdash; Social support, financial",
"      <span class=\"nowrap\">",
"       resources/insurance,",
"      </span>",
"      and personal preference (eg, facility close to home) are important considerations in determining the best location for post-acute rehabilitation.",
"     </li>",
"     <li>",
"      <strong>",
"       Reimbursement (US)",
"      </strong>",
"      &mdash; Medicare uses a &ldquo;prospective payment&rdquo; for rehabilitation in many postacute settings, for which a predetermined amount is provided for particular diagnoses, with consideration for the severity of the condition and comorbid conditions (eg, mild stroke versus severe stroke with diabetes and hypertension). Social workers can often provide helpful information about available payment rates.",
"      <br/>",
"      <br/>",
"      A general example of these considerations for a stroke patient are as follows: Medicare prospective payment for intensive inpatient rehabilitation after an acute stroke (without additional comorbid conditions) is approximately 12 to 14 days. In contrast, the same stroke patient may receive up to 100 days of therapy (20 days at 100 percent coverage and 80 days at 80 percent coverage) in a skilled nursing facility. Thus, if the patient is likely to benefit from prolonged therapy, but at a lower intensity, a skilled nursing home for rehabilitation might be the best choice.",
"      <br/>",
"      <br/>",
"      Prospective payment is also in place for home health services. In that setting, a stroke patient might receive three weeks of therapy (physical therapy, occupational therapy,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      speech therapy) up to three times per week with another one to two weeks with less frequent visits per week. Preceding treatment in an inpatient setting does not preclude payment for home health therapies or outpatient therapies after discharge home.",
"      <br/>",
"      <br/>",
"      In all three of these settings (inpatient rehabilitation, skilled nursing, home health), the patient must require &lsquo;skilled&rsquo; services to qualify for Medicare payment. For home health coverage in particular, a single visit by an occupational therapist (eg, for a home safety and falls assessment) would not be covered. Home health aid services, in the absence of other skilled nursing or therapy series, would also not be reimbursed. In addition, home health services are only covered for &ldquo;homebound&rdquo; patients, defined as being unable to leave home except for medical care and infrequent non-medical reasons such as to go to religious services; the ordering physician must have had a face-to-face visit with the patient in the preceding 30 days and document this [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/105\">",
"       105",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Outpatient rehabilitation services continue to be paid for by Medicare as &ldquo;fee for service&rdquo; but the total number of visits for all conditions are limited (to a total of",
"      <span class=\"nowrap\">",
"       $1870/year",
"      </span>",
"      for PT plus speech therapy with an additional",
"      <span class=\"nowrap\">",
"       $1870/year",
"      </span>",
"      for OT in 2012). These limits may be exceeded for some medically necessary therapies with appropriate justification from the medical provider",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      when provided in hospital emergency rooms or outpatient departments [",
"      <a class=\"abstract\" href=\"UTD.htm?32/22/33130/abstract/106,107\">",
"       106,107",
"      </a>",
"      ]. There is no requirement for &lsquo;skilled services&rsquo; by physical therapy or nursing for outpatient therapy services to be covered.",
"      <br/>",
"      <br/>",
"      Medicaid also covers rehabilitation services with variation from state to state. The VHA provides rehabilitation throughout the continuum of care with either no charge for services or a modest co-pay (depending on level of service connection",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      finances).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2267440\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A model from the World Health Organization describes disability as determined by an individual&rsquo;s health condition(s) within the context of environmental and personal factors; rehabilitation services target the impairment as well as personal and environmental contextual factors that influence activity and participation. In another model, disability results from a mismatch between individual capacity and task demands; remediation of disability occurs through treatments that either increase individual capacity or reduce task demand. (See",
"      <a class=\"local\" href=\"#H4419924\">",
"       'Conceptual models for disability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rehabilitation treatment by a provider in a single discipline is often sufficient for patients with uncomplicated conditions or with minimal disability. For more complex or catastrophic disability (eg, stroke, amputation), a multidisciplinary team of providers as part of inpatient rehabilitation is optimal to address the interaction of multiple contributing conditions and contextual factors. (See",
"      <a class=\"local\" href=\"#H4419952\">",
"       'Types of rehabilitation providers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physical activity recommendations intended for all older adults may need to be adapted to meet particular needs, using specific types of exercise to correct or ameliorate identified impairments and functional limitations. Physical therapists, exercise physiologists, and physicians specializing in rehabilitation (&ldquo;physiatrists&rdquo;) can help to tailor the exercise prescription to meet particular patient needs. (See",
"      <a class=\"local\" href=\"#H4419967\">",
"       'Exercise'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An increasing variety of patient assistive technology aids can improve capacity for activity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      reduce task demands, but they can be hazardous if not used properly. Physical and occupational therapists can provide prescription guidance as well as fitting and training in use of these devices to enhance functional benefits and safety. Mobility aids (canes, crutches, walkers, wheelchairs) meet different needs (",
"      <a class=\"graphic graphic_table graphicRef86414 \" href=\"UTD.htm?38/39/39548\">",
"       table 4",
"      </a>",
"      ) and, in the US, are variably reimbursed depending upon insurance and the patient&rsquo;s qualifying illness. (See",
"      <a class=\"local\" href=\"#H4419988\">",
"       'Mobility aids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4662577\">",
"       'Reimbursement for mobility aids in the US'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Orthoses (ie, splints and braces) are available for virtually every joint in the body including the spine; prefabricated splints and braces are most appropriate for uncomplicated conditions that don&rsquo;t have substantial deformity. A multidisciplinary team including a physical therapist, prosthetist,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      physiatrist can provide guidance and fitting as may be needed for more complex devices such as a prosthetic limb. (See",
"      <a class=\"local\" href=\"#H4420002\">",
"       'Prosthetics and orthotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Occupational therapists (OTs) have particular expertise on the self-care skills, person-environment interface within the home environment, and can recommend the most beneficial assistive devices and home modifications; physical therapists (PTs) are particularly helpful with mobility impairments and equipment, as well as exercise interventions to treat physical impairment; speech therapists have expertise in treatment of impaired speech and swallowing; low vision specialists provide unique expertise for older adults coping with low vision; a variety of other specialized personnel may provide rehabilitation care in particular settings (eg, recreational therapists, rehabilitation nursing). (See",
"      <a class=\"local\" href=\"#H4420009\">",
"       'Environmental modification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rehabilitation therapy services can be delivered in a wide variety of settings across the care continuum. Early mobilization, beginning the first day of ICU hospitalization and while the patient is still on a ventilator, can shorten length of stay and improve functional outcomes. Involvement of PT and OT is a necessary component of hospital discharge planning, particularly for older adults, in patients for whom there is concern about the ability to return home (eg, limitations in self-care or mobility are present). The options and considerations when considering continued rehabilitation upon discharge from the acute hospital setting are summarized in a table (",
"      <a class=\"graphic graphic_table graphicRef86677 \" href=\"UTD.htm?28/56/29580\">",
"       table 9",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18332847\">",
"       'Post-acute hospital rehabilitation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/1\">",
"      Manton KG, Gu X, Lowrimore GR. Cohort changes in active life expectancy in the U.S. elderly population: experience from the 1982-2004 National Long-Term Care Survey. J Gerontol B Psychol Sci Soc Sci 2008; 63:S269.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.who.int/topics/ageing/en/ (Accessed on June 18, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/3\">",
"      Schoeni RF, Freedman VA, Martin LG. Why is late-life disability declining? Milbank Q 2008; 86:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/4\">",
"      Freedman VA, Martin LG, Schoeni RF. Recent trends in disability and functioning among older adults in the United States: a systematic review. JAMA 2002; 288:3137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/5\">",
"      Martin LG, Freedman VA, Schoeni RF, Andreski PM. Trends in disability and related chronic conditions among people ages fifty to sixty-four. Health Aff (Millwood) 2010; 29:725.",
"     </a>",
"    </li>",
"    <li>",
"     International Classification of Function, Disability, and Health, World Health Organization. 2002. Available at: file://www3.who.int/icf/icftemplate.cfm (Accessed on November 30, 2011).",
"    </li>",
"    <li>",
"     Lawton MP. Competence, environmental press, and the adaptation of older people. In: Aging and the environment, Lawton MP, Windley PG, Byerts TO (Eds), Springer, New York 1982. p.33.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/8\">",
"      Hoenig H, Siebens H. Research agenda for geriatric rehabilitation. Am J Phys Med Rehabil 2004; 83:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/9\">",
"      Freedman VA, Schoeni RF, Martin LG, Cornman JC. Chronic conditions and the decline in late-life disability. Demography 2007; 44:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/10\">",
"      Wahl HW, F&auml;nge A, Oswald F, et al. The home environment and disability-related outcomes in aging individuals: what is the empirical evidence? Gerontologist 2009; 49:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/11\">",
"      Weiner DK, Long R, Hughes MA, et al. When older adults face the chair-rise challenge. A study of chair height availability and height-modified chair-rise performance in the elderly. J Am Geriatr Soc 1993; 41:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/12\">",
"      Hughes MA, Myers BS, Schenkman ML. The role of strength in rising from a chair in the functionally impaired elderly. J Biomech 1996; 29:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/13\">",
"      Cohen HJ, Feussner JR, Weinberger M, et al. A controlled trial of inpatient and outpatient geriatric evaluation and management. N Engl J Med 2002; 346:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/14\">",
"      Prvu Bettger JA, Stineman MG. Effectiveness of multidisciplinary rehabilitation services in postacute care: state-of-the-science. A review. Arch Phys Med Rehabil 2007; 88:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/15\">",
"      Stroke Unit Trialists' Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev 2007; :CD000197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/16\">",
"      Govan L, Weir CJ, Langhorne P, for the Stroke Unit Trialists' Collaboration. Organized Inpatient (Stroke Unit) Care for Stroke. Stroke 2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/17\">",
"      Ahlmen M, Sullivan M, Bjelle A. Team versus non-team outpatient care in rheumatoid arthritis. A comprehensive outcome evaluation including an overall health measure. Arthritis Rheum 1988; 31:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/18\">",
"      Ahlm&eacute;n M, Bjelle A, Sullivan M. Prediction of team care effects in outpatients with rheumatoid arthritis. J Rheumatol 1991; 18:1655.",
"     </a>",
"    </li>",
"    <li>",
"     Michael YL, Lin JS, Whitlock EP,  et al. Interventions to Prevent Falls in Older Adults: An Updated Systematic Review. Evidence Syntheses, No. 80.  Agency for Healthcare Research and Quality 2010. Available at: file://www.ncbi.nlm.nih.gov/books/NBK51686/ (Accessed on November 30, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/20\">",
"      Nelson ME, Rejeski WJ, Blair SN, et al. Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc 2007; 39:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/21\">",
"      Cuoco A, Callahan DM, Sayers S, et al. Impact of muscle power and force on gait speed in disabled older men and women. J Gerontol A Biol Sci Med Sci 2004; 59:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/22\">",
"      Liu CJ, Latham NK. Progressive resistance strength training for improving physical function in older adults. Cochrane Database Syst Rev 2009; :CD002759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/23\">",
"      Morrison RS, Flanagan S, Fischberg D, et al. A novel interdisciplinary analgesic program reduces pain and improves function in older adults after orthopedic surgery. J Am Geriatr Soc 2009; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/24\">",
"      Mundy LM, Leet TL, Darst K, et al. Early mobilization of patients hospitalized with community-acquired pneumonia. Chest 2003; 124:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/25\">",
"      Needham DM. Mobilizing patients in the intensive care unit: improving neuromuscular weakness and physical function. JAMA 2008; 300:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/26\">",
"      Hoenig H, Ganesh SP, Taylor DH Jr, et al. Lower extremity physical performance and use of compensatory strategies for mobility. J Am Geriatr Soc 2006; 54:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/27\">",
"      Russell JN, Hendershot GE, LeClere F, et al. Trends and differential use of assistive technology devices: United States, 1994. Adv Data 1997; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/28\">",
"      Freedman VA, Agree EM, Martin LG, Cornman JC. Trends in the use of assistive technology and personal care for late-life disability, 1992-2001. Gerontologist 2006; 46:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/29\">",
"      Verbrugge LM, Rennert C, Madans JH. The great efficacy of personal and equipment assistance in reducing disability. Am J Public Health 1997; 87:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/30\">",
"      Mann WC, Ottenbacher KJ, Fraas L, et al. Effectiveness of assistive technology and environmental interventions in maintaining independence and reducing home care costs for the frail elderly. A randomized controlled trial. Arch Fam Med 1999; 8:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/31\">",
"      Hoenig H, Taylor DH Jr, Sloan FA. Does assistive technology substitute for personal assistance among the disabled elderly? Am J Public Health 2003; 93:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/32\">",
"      Cooper RA. A perspective on the ultralight wheelchair revolution. Technol Disabil 1996; 5:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/33\">",
"      Bradley SM, Hernandez CR. Geriatric assistive devices. Am Fam Physician 2011; 84:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/34\">",
"      Mann WC, Hurren D, Charvat B, Tomita M. Problems with wheelchairs experienced by frail elders. Technol Diabil 1996; 5:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/35\">",
"      Stevens JA, Thomas K, Teh L, Greenspan AI. Unintentional fall injuries associated with walkers and canes in older adults treated in U.S. emergency departments. J Am Geriatr Soc 2009; 57:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/36\">",
"      Chen WY, Jang Y, Wang JD, et al. Wheelchair-related accidents: relationship with wheelchair-using behavior in active community wheelchair users. Arch Phys Med Rehabil 2011; 92:892.",
"     </a>",
"    </li>",
"    <li>",
"     Kaye HS, Kang T, LaPlante MP. Disability Statistics Report: Mobility device use in the United States. National Institute of Disability and Rehabilitation Research; US Department of Special Education and Rehabilitative Services, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/38\">",
"      Winkler SL, Vogel B, Hoenig H, et al. Cost, utilization, and policy of provision of assistive technology devices to veterans poststroke by Medicare and VA. Med Care 2010; 48:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/39\">",
"      Allet L, Leemann B, Guyen E, et al. Effect of different walking aids on walking capacity of patients with poststroke hemiparesis. Arch Phys Med Rehabil 2009; 90:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/40\">",
"      Holder CG, Haskvitz EM, Weltman A. The effects of assistive devices on the oxygen cost, cardiovascular stress, and perception of nonweight-bearing ambulation. J Orthop Sports Phys Ther 1993; 18:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/41\">",
"      Mahoney J, Euhardy R, Carnes M. A comparison of a two-wheeled walker and a three-wheeled walker in a geriatric population. J Am Geriatr Soc 1992; 40:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/42\">",
"      Wolff JL, Agree EM, Kasper JD. Wheelchairs, walkers, and canes: what does Medicare pay for, and who benefits? Health Aff (Millwood) 2005; 24:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/43\">",
"      Ganesh S, Hayter A, Kim J, et al. Wheelchair use by veterans newly prescribed a manual wheelchair. Arch Phys Med Rehabil 2007; 88:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/44\">",
"      Brienza D, Kelsey S, Karg P, et al. A randomized clinical trial on preventing pressure ulcers with wheelchair seat cushions. J Am Geriatr Soc 2010; 58:2308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/45\">",
"      Beeckman D, Vanderwee K. Skin protection wheelchair cushions for older nursing home residents reduce 6-month incidence of ischial tuberosity pressure ulcers compared with segmented foam cushions. Evid Based Nurs 2011; 14:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/46\">",
"      Finley MA, Rodgers MM. Prevalence and identification of shoulder pathology in athletic and nonathletic wheelchair users with shoulder pain: A pilot study. J Rehabil Res Dev 2004; 41:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/47\">",
"      Collinger JL, Boninger ML, Koontz AM, et al. Shoulder biomechanics during the push phase of wheelchair propulsion: a multisite study of persons with paraplegia. Arch Phys Med Rehabil 2008; 89:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/48\">",
"      Boninger ML, Souza AL, Cooper RA, et al. Propulsion patterns and pushrim biomechanics in manual wheelchair propulsion. Arch Phys Med Rehabil 2002; 83:718.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical Criteria Algorithm for Wheelchair Prescribing. Centers for Medicare &amp; Medicaid. Available at: https://www.cms.gov/determinationprocess/downloads/id143c.pdf (Accessed on December 05, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/50\">",
"      Dicianno BE, Tovey E. Power mobility device provision: understanding Medicare guidelines and advocating for clients. Arch Phys Med Rehabil 2007; 88:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/51\">",
"      Hoenig H, Pieper C, Branch LG, Cohen HJ. Effect of motorized scooters on physical performance and mobility: a randomized clinical trial. Arch Phys Med Rehabil 2007; 88:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/52\">",
"      Hoenig H, Pieper C, Zolkewitz M, et al. Wheelchair users are not necessarily wheelchair bound. J Am Geriatr Soc 2002; 50:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/53\">",
"      Mortenson WB, Miller WC, Backman CL, Oliffe JL. Predictors of mobility among wheelchair using residents in long-term care. Arch Phys Med Rehabil 2011; 92:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/54\">",
"      Greer N, Brasure M, Wilt TJ. Wheeled mobility (wheelchair) service delivery: scope of the evidence. Ann Intern Med 2012; 156:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/55\">",
"      Trefler E, Fitzgerald SG, Hobson DA, et al. Outcomes of wheelchair systems intervention with residents of long-term care facilities. Assist Technol 2004; 16:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/56\">",
"      Hoenig H, Landerman LR, Shipp KM, et al. A clinical trial of a rehabilitation expert clinician versus usual care for providing manual wheelchairs. J Am Geriatr Soc 2005; 53:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/57\">",
"      Best KL, Kirby RL, Smith C, MacLeod DA. Wheelchair skills training for community-based manual wheelchair users: a randomized controlled trial. Arch Phys Med Rehabil 2005; 86:2316.",
"     </a>",
"    </li>",
"    <li>",
"     Center for Medicare &amp; Medicaid Services. Medicare Coverage for Durable Medical Equipment and Other Devices. Department of Health and Human Services. p. 7. Available at: file://www.medicare.gov/publications/pubs/pdf/11045.pdf (Accessed on January 28, 2012).",
"    </li>",
"    <li>",
"     Clinical Criteria for MAE Coverage. Centers for Medicare &amp; Medicaid Services. Available at: https://www.cms.gov/determinationprocess/downloads/id143c.pdf (Accessed on December 05, 2011).",
"    </li>",
"    <li>",
"     Power Wheelchair Coverage Overview. Centers for Medicare &amp; Medicaid. Available at: file://www.cms.gov/MLNProducts/downloads/PowerWheelchair.pdf (Accessed on December 05, 2011).",
"    </li>",
"    <li>",
"     Chapter 20: Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS). In: Medicare Claims Processing Manual. Available at: https://www.cms.gov/manuals/downloads/clm104c20.pdf (Accessed on December 05, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/62\">",
"      Gill TM, Han L, Allore HG. Bath aids and the subsequent development of bathing disability in community-living older persons. J Am Geriatr Soc 2007; 55:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/63\">",
"      Mann WC, Ottenbacher KJ, Fraas L, et al. Effectiveness of assistive technology and environmental interventions in maintaining independence and reducing home care costs for the frail elderly. A randomized controlled trial. Arch Fam Med 1999; 8:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/64\">",
"      Sanford JA, Griffiths PC, Richardson P, et al. The effects of in-home rehabilitation on task self-efficacy in mobility-impaired adults: A randomized clinical trial. J Am Geriatr Soc 2006; 54:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/65\">",
"      Gitlin LN, Winter L, Dennis MP, et al. A randomized trial of a multicomponent home intervention to reduce functional difficulties in older adults. J Am Geriatr Soc 2006; 54:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/66\">",
"      Wahl HW, F&auml;nge A, Oswald F, et al. The home environment and disability-related outcomes in aging individuals: what is the empirical evidence? Gerontologist 2009; 49:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/67\">",
"      Petersson I, Lilja M, Hammel J, Kottorp A. Impact of home modification services on ability in everyday life for people ageing with disabilities. J Rehabil Med 2008; 40:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/68\">",
"      Pighills AC, Torgerson DJ, Sheldon TA, et al. Environmental assessment and modification to prevent falls in older people. J Am Geriatr Soc 2011; 59:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/69\">",
"      Alexander NB, Koester DJ, Grunawalt JA. Chair design affects how older adults rise from a chair. J Am Geriatr Soc 1996; 44:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/70\">",
"      Sanford JA, Arch M, Megrew MB. An evaluation of grab bars to meet the needs of elderly people. Assist Technol 1995; 7:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/71\">",
"      Sansam K, Neumann V, O'Connor R, Bhakta B. Predicting walking ability following lower limb amputation: a systematic review of the literature. J Rehabil Med 2009; 41:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/72\">",
"      Highsmith MJ, Kahle JT, Bongiorni DR, et al. Safety, energy efficiency, and cost efficacy of the C-Leg for transfemoral amputees: A review of the literature. Prosthet Orthot Int 2010; 34:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/73\">",
"      Cumming JC, Barr S, Howe TE. Prosthetic rehabilitation for older dysvascular people following a unilateral transfemoral amputation. Cochrane Database Syst Rev 2006; :CD005260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/74\">",
"      Brouwer RW, Jakma TS, Verhagen AP, et al. Braces and orthoses for treating osteoarthritis of the knee. Cochrane Database Syst Rev 2005; :CD004020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/75\">",
"      Rannou F, Poiraudeau S, Beaudreuil J. Role of bracing in the management of knee osteoarthritis. Curr Opin Rheumatol 2010; 22:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/76\">",
"      de Wit DC, Buurke JH, Nijlant JM, et al. The effect of an ankle-foot orthosis on walking ability in chronic stroke patients: a randomized controlled trial. Clin Rehabil 2004; 18:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/77\">",
"      Nolan KJ, Savalia KK, Lequerica AH, Elovic EP. Objective assessment of functional ambulation in adults with hemiplegia using ankle foot orthotics after stroke. PM R 2009; 1:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/78\">",
"      Baldassin V, Gomes CR, Beraldo PS. Effectiveness of prefabricated and customized foot orthoses made from low-cost foam for noncomplicated plantar fasciitis: a randomized controlled trial. Arch Phys Med Rehabil 2009; 90:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/79\">",
"      Hawke F, Burns J, Radford JA, du Toit V. Custom-made foot orthoses for the treatment of foot pain. Cochrane Database Syst Rev 2008; :CD006801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/80\">",
"      Burke DT, Burke MM, Stewart GW, Cambr&eacute; A. Splinting for carpal tunnel syndrome: in search of the optimal angle. Arch Phys Med Rehabil 1994; 75:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/81\">",
"      Tijhuis GJ, Vliet Vlieland TP, Zwinderman AH, Hazes JM. A comparison of the Futuro wrist orthosis with a synthetic ThermoLyn orthosis: utility and clinical effectiveness. Arthritis Care Res 1998; 11:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/82\">",
"      Fried LP, Bandeen-Roche K, Kasper JD, Guralnik JM. Association of comorbidity with disability in older women: the Women's Health and Aging Study. J Clin Epidemiol 1999; 52:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/83\">",
"      Zeng Y, Gu D, Purser J, et al. Associations of environmental factors with elderly health and mortality in China. Am J Public Health 2010; 100:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/84\">",
"      Clarke P, George LK. The role of the built environment in the disablement process. Am J Public Health 2005; 95:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/85\">",
"      Atamaz FC, Durmaz B, Baydar M, et al. Comparison of the efficacy of transcutaneous electrical nerve stimulation, interferential currents, and shortwave diathermy in knee osteoarthritis: a double-blind, randomized, controlled, multicenter study. Arch Phys Med Rehabil 2012; 93:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/86\">",
"      Ebenbichler GR, Erdogmus CB, Resch KL, et al. Ultrasound therapy for calcific tendinitis of the shoulder. N Engl J Med 1999; 340:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/87\">",
"      Mulvey MR, Bagnall AM, Johnson MI, Marchant PR. Transcutaneous electrical nerve stimulation (TENS) for phantom pain and stump pain following amputation in adults. Cochrane Database Syst Rev 2010; :CD007264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/88\">",
"      Khadilkar A, Odebiyi DO, Brosseau L, Wells GA. Transcutaneous electrical nerve stimulation (TENS) versus placebo for chronic low-back pain. Cochrane Database Syst Rev 2008; :CD003008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/89\">",
"      Kroeling P, Gross A, Goldsmith CH, et al. Electrotherapy for neck pain. Cochrane Database Syst Rev 2009; :CD004251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/90\">",
"      Andres BM, Murrell GA. Treatment of tendinopathy: what works, what does not, and what is on the horizon. Clin Orthop Relat Res 2008; 466:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/91\">",
"      Robbins J, Gensler G, Hind J, et al. Comparison of 2 interventions for liquid aspiration on pneumonia incidence: a randomized trial. Ann Intern Med 2008; 148:509.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Medicare &amp; Medicaid Services. Durable Medical Equipment (DME) Center. Department of Health and Human Services. Available at: https://www.cms.gov/center/dme.asp (Accessed on December 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/93\">",
"      Chamberlain MA, Thornley G, Wright V. Evaluation of aids and equipment for bath and toilet. Rheumatol Rehabil 1978; 17:187.",
"     </a>",
"    </li>",
"    <li>",
"     Home Modification Programs.  United States Department of Veterans Affairs. Available at: www.vba.va.gov/VBA/benefits/factsheets/homeloans/homemods.doc (Accessed on February 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/95\">",
"      Morris PE, Goad A, Thompson C, et al. Early intensive care unit mobility therapy in the treatment of acute respiratory failure. Crit Care Med 2008; 36:2238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/96\">",
"      Schweickert WD, Pohlman MC, Pohlman AS, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet 2009; 373:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/97\">",
"      Needham DM, Korupolu R, Zanni JM, et al. Early physical medicine and rehabilitation for patients with acute respiratory failure: a quality improvement project. Arch Phys Med Rehabil 2010; 91:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/98\">",
"      Siu AL, Penrod JD, Boockvar KS, et al. Early ambulation after hip fracture: effects on function and mortality. Arch Intern Med 2006; 166:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/99\">",
"      Horn SD, DeJong G, Smout RJ, et al. Stroke rehabilitation patients, practice, and outcomes: is earlier and more aggressive therapy better? Arch Phys Med Rehabil 2005; 86:S101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/100\">",
"      Duncan PW, Zorowitz R, Bates B, et al. Management of Adult Stroke Rehabilitation Care: a clinical practice guideline. Stroke 2005; 36:e100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/101\">",
"      Jenq G, Tinetti ME. The journey across the health care (dis)continuum for vulnerable patients: policies, pitfalls, and possibilities. JAMA 2012; 307:2157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/102\">",
"      Dejong G, Horn SD, Smout RJ, et al. Joint replacement rehabilitation outcomes on discharge from skilled nursing facilities and inpatient rehabilitation facilities. Arch Phys Med Rehabil 2009; 90:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/103\">",
"      DeJong G, Tian W, Smout RJ, et al. Long-term outcomes of joint replacement rehabilitation patients discharged from skilled nursing and inpatient rehabilitation facilities. Arch Phys Med Rehabil 2009; 90:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/22/33130/abstract/104\">",
"      Bachmann S, Finger C, Huss A, et al. Inpatient rehabilitation specifically designed for geriatric patients: systematic review and meta-analysis of randomised controlled trials. BMJ 2010; 340:c1718.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Medicare &amp; Medicaid Services. Medicare and Home Health Care. Department of Health and Human Services. Available at: file://www.medicare.gov/publications/pubs/pdf/10969.pdf (Accessed on January 28, 2012).",
"    </li>",
"    <li>",
"     Medicare Limits on Therapy Services. Centers for Medicare &amp; Medicaid Services. Available at: file://www.medicare.gov/publications/pubs/pdf/10988.pdf (Accessed on February 06, 2012).",
"    </li>",
"    <li>",
"     Will Medicare pay for outpatient physical, occupational or speech therapy? MedicareInteractive.org 2011. Available at: file://www.medicareinteractive.org/page2.php?topic=counselor&amp;page=script&amp;slide_id=353 (Accessed on September 11, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16852 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-210.101.131.232-895BD5A23F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_22_33130=[""].join("\n");
var outline_f32_22_33130=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2267440\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4419917\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4419924\">",
"      CONCEPTUAL MODELS FOR DISABILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4419931\">",
"      The World Health Organization model (ICF)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4419938\">",
"      The ecological model",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4419952\">",
"      TYPES OF REHABILITATION PROVIDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4419959\">",
"      INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4419967\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4419974\">",
"      Assistive technology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4419988\">",
"      - Mobility aids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3285546\">",
"      Canes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H176091046\">",
"      Crutches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3285554\">",
"      Walkers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3285569\">",
"      Wheelchairs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4662577\">",
"      Reimbursement for mobility aids in the US",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4419995\">",
"      - Bathroom and self-care aids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4420002\">",
"      - Prosthetics and orthotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1174926\">",
"      Prostheses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1174941\">",
"      Orthoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4420009\">",
"      Environmental modification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4420016\">",
"      Modalities for pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4663283\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2267490\">",
"      Reimbursement (US, other than mobility aids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4420023\">",
"      REHABILITATION SETTINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18332705\">",
"      Rehabilitation therapy in the acute hospital",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18332847\">",
"      Post-acute hospital rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4420030\">",
"      - Medical diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18333177\">",
"      - Optimal level of post-acute rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2267440\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/16852\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/16852|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?31/17/32018\" title=\"algorithm 1\">",
"      Selecting gait aid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/16852|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/20/25933\" title=\"table 1\">",
"      Member roles and functions for rehab team",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/2/10283\" title=\"table 2\">",
"      Benefits physical activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/29/9694\" title=\"table 3\">",
"      Older adult activity counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/39/39548\" title=\"table 4\">",
"      Comparison of mobility aids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/23/2429\" title=\"table 5\">",
"      Medicare coverage of medical equipment and prosthetic items",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/30/13803\" title=\"table 6\">",
"      Heat and cold therapy indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/23/21883\" title=\"table 7\">",
"      Heat or cold therapy contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/23/38267\" title=\"table 8\">",
"      Criteria for OT and PT in acute hospital setting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/56/29580\" title=\"table 9\">",
"      Characteristics US postacute rehab settings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/26/30123\" title=\"table 10\">",
"      Medicare qualifying conditions for intensive rehab facility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/13/2269\" title=\"table 11\">",
"      Katz daily living scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/3/44093\" title=\"table 12\">",
"      Lawton daily living scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=related_link\">",
"      Evaluation of the patient with shoulder complaints",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/2/12330?source=related_link\">",
"      Hospital discharge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=related_link\">",
"      Nonpharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/60/9161?source=related_link\">",
"      Physical activity and exercise in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44681?source=related_link\">",
"      Plantar fasciitis and other causes of heel pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=related_link\">",
"      Prevention and treatment of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44008?source=related_link\">",
"      Treatment of carpal tunnel syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_22_33131="Immunohistochemistry of GISTs";
var content_f32_22_33131=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F79128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F79128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Immunohistochemical schema for the differential diagnosis of spindle cell tumors of the gastrointestinal tract",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Type",
"      </td>",
"      <td class=\"subtitle1\">",
"       CD117",
"      </td>",
"      <td class=\"subtitle1\">",
"       CD34",
"      </td>",
"      <td class=\"subtitle1\">",
"       SMA*",
"      </td>",
"      <td class=\"subtitle1\">",
"       S100 Protein",
"      </td>",
"      <td class=\"subtitle1\">",
"       Desmin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"1\">",
"       GISTs",
"      </td>",
"      <td>",
"       + (&gt;95 percent)",
"      </td>",
"      <td>",
"       + (60-70 percent)",
"      </td>",
"      <td>",
"       +/- (30-40 percent)",
"      </td>",
"      <td>",
"       - (5 percent +)",
"      </td>",
"      <td>",
"       Very rare",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"1\">",
"       Leiomyoma",
"      </td>",
"      <td colspan=\"1\" rowspan=\"1\">",
"       -",
"      </td>",
"      <td>",
"       + (10-15 percent)",
"      </td>",
"      <td colspan=\"1\" rowspan=\"1\">",
"       +",
"      </td>",
"      <td colspan=\"1\" rowspan=\"1\">",
"       -",
"      </td>",
"      <td colspan=\"1\" rowspan=\"1\">",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Leiomyosarcoma",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Schwannoma",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       _",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Alpha smooth muscle actin.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from Fletcher, CD, et al. Int J Surg Pathol 2002; 10:81 and Mietennen, M, et al. Mod Pathol 2000; 10:1134.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_22_33131=[""].join("\n");
var outline_f32_22_33131=null;
var title_f32_22_33132="Absorbable sutures";
var content_f32_22_33132=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Absorbable sutures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Suture material",
"       </td>",
"       <td class=\"subtitle1\">",
"        Knot security",
"       </td>",
"       <td class=\"subtitle1\">",
"        Wound tensile strength",
"       </td>",
"       <td class=\"subtitle1\">",
"        Security (days)*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Tissue reactivity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Anatomic site",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fast-absorbing gut",
"       </td>",
"       <td>",
"        Poor",
"       </td>",
"       <td>",
"        Least",
"       </td>",
"       <td>",
"        4 to 6",
"       </td>",
"       <td>",
"        Most",
"       </td>",
"       <td>",
"        Face",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vicryl Rapide",
"       </td>",
"       <td>",
"        Good",
"       </td>",
"       <td>",
"        Fair",
"       </td>",
"       <td>",
"        5 to 7",
"       </td>",
"       <td>",
"        Minimal",
"       </td>",
"       <td>",
"        Face, scalp, under cast/splint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surgical gut",
"       </td>",
"       <td>",
"        Poor",
"       </td>",
"       <td>",
"        Fair",
"       </td>",
"       <td>",
"        5 to 7",
"       </td>",
"       <td>",
"        Most",
"       </td>",
"       <td>",
"        Face (rarely used)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poliglecaprone 25 (Monocryl)",
"       </td>",
"       <td>",
"        Good",
"       </td>",
"       <td>",
"        Fair",
"       </td>",
"       <td>",
"        7 to 10",
"       </td>",
"       <td>",
"        Minimal",
"       </td>",
"       <td>",
"        Face, consider in contaminated wounds needing deep closure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chromic gut",
"       </td>",
"       <td>",
"        Fair",
"       </td>",
"       <td>",
"        Fair",
"       </td>",
"       <td>",
"        10 to 14",
"       </td>",
"       <td>",
"        Most",
"       </td>",
"       <td>",
"        Mouth, tongue, nailbed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyglactin (Vicryl)",
"       </td>",
"       <td>",
"        Good",
"       </td>",
"       <td>",
"        Good",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        Minimal",
"       </td>",
"       <td>",
"        Deep closure, nailbed, mouth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyglycolic acid (Dexon)",
"       </td>",
"       <td>",
"        Best",
"       </td>",
"       <td>",
"        Good",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        Minimal",
"       </td>",
"       <td>",
"        Deep closure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polydioxanone (PDS)",
"       </td>",
"       <td>",
"        Fair",
"       </td>",
"       <td>",
"        Best",
"       </td>",
"       <td>",
"        45 to 60",
"       </td>",
"       <td>",
"        Least",
"       </td>",
"       <td>",
"        Deep closure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyglyconate (Maxon)",
"       </td>",
"       <td>",
"        Fair",
"       </td>",
"       <td>",
"        Best",
"       </td>",
"       <td>",
"        45 to 60",
"       </td>",
"       <td>",
"        Least",
"       </td>",
"       <td>",
"        Deep closure",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Retention of 50 percent of tensile strength.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Hollander, JE, Singer, AJ. Laceration management. Ann Emerg Med 1999; 34:356. Copyright &copy; 1999 The American College of Emergency Physicians.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_22_33132=[""].join("\n");
var outline_f32_22_33132=null;
var title_f32_22_33133="RUTF";
var content_f32_22_33133=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of the F100 liquid diet with ready-to-use therapeutic food for treatment of malnutrition",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Per 100 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        F100",
"       </td>",
"       <td class=\"subtitle2\">",
"        RUTF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Macronutrients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Energy (kJ)",
"       </td>",
"       <td class=\"sublist_other\">",
"        414",
"       </td>",
"       <td class=\"sublist_other\">",
"        2281",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Protein (g)",
"       </td>",
"       <td class=\"sublist_other\">",
"        2.5",
"       </td>",
"       <td class=\"sublist_other\">",
"        13.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lipid (g)",
"       </td>",
"       <td class=\"sublist_other\">",
"        5",
"       </td>",
"       <td class=\"sublist_other\">",
"        35.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Minerals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Potassium (mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        212",
"       </td>",
"       <td class=\"sublist_other\">",
"        1111",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Calcium (mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        58",
"       </td>",
"       <td class=\"sublist_other\">",
"        320",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Phosphorus (mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        58",
"       </td>",
"       <td class=\"sublist_other\">",
"        349",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Magnesium (mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        15",
"       </td>",
"       <td class=\"sublist_other\">",
"        92",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Zinc (mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        2.1",
"       </td>",
"       <td class=\"sublist_other\">",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Copper (mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.3",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Iodine (microgram)",
"       </td>",
"       <td class=\"sublist_other\">",
"        14",
"       </td>",
"       <td class=\"sublist_other\">",
"        110",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Selenium (microgram)",
"       </td>",
"       <td class=\"sublist_other\">",
"        4",
"       </td>",
"       <td class=\"sublist_other\">",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Iron (mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.4",
"       </td>",
"       <td class=\"sublist_other\">",
"        11.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Vitamins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Thiamine (mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.1",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Riboflavin (mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.3",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vitamin B-6 (mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.1",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vitamin B-12 (microgram)",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.3",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vitamin C (mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        9.7",
"       </td>",
"       <td class=\"sublist_other\">",
"        53",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Folic acid (microgram)",
"       </td>",
"       <td class=\"sublist_other\">",
"        39",
"       </td>",
"       <td class=\"sublist_other\">",
"        210",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Niacin (mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        5.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Biotin (microgram)",
"       </td>",
"       <td class=\"sublist_other\">",
"        12",
"       </td>",
"       <td class=\"sublist_other\">",
"        65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pantothenic acid (mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.6",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Retinol (microgram)",
"       </td>",
"       <td class=\"sublist_other\">",
"        154",
"       </td>",
"       <td class=\"sublist_other\">",
"        910",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vitamin D (microgram)",
"       </td>",
"       <td class=\"sublist_other\">",
"        2.9",
"       </td>",
"       <td class=\"sublist_other\">",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vitamin K (microgram)",
"       </td>",
"       <td class=\"sublist_other\">",
"        2.9",
"       </td>",
"       <td class=\"sublist_other\">",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vitamin E (mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.9",
"       </td>",
"       <td class=\"sublist_other\">",
"        20",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Comparison of the nutritional composition of the F100 diet and solid ready-to-use therapeutic food (RUTF), used for the treatment of malnutrition in children.",
"    <div class=\"footnotes\">",
"     F100: liquid, milk-based diet; RUTF: solid ready-to-use therapeutic food.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Diop el HI, Dossou NI, Ndour MM, et al. Comparison of the efficacy of a solid ready-to-use food and a liquid, milk-based diet for the rehabilitation of severely malnourished children: a randomized trial. Am J Clin Nutr 2003; 78:302. Copyright &copy;2003 American Society for Nutrition.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_22_33133=[""].join("\n");
var outline_f32_22_33133=null;
var title_f32_22_33134="Dialysis patients with ICDs";
var content_f32_22_33134=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F69902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F69902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Cumulative number and percent of dialysis patients receiving ICDs/CRT-Ds",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 300px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Period prevalent dialysis patients.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: US Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2010. Full report available at:",
"     <a href=\"file://www.usrds.org/adr.htm\" target=\"_blank\">",
"      file://www.usrds.org/adr.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_22_33134=[""].join("\n");
var outline_f32_22_33134=null;
var title_f32_22_33135="Protamine reversal in HD";
var content_f32_22_33135=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F74909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F74909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schematic diagram showing protamine reversal regimen for regional anticoagulation in hemodialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of protamine reversal regimen for regional anticoagulation during hemodialysis. Protamine is infused into the venous return line to lower the ACT to its predialysis baseline level.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_22_33135=[""].join("\n");
var outline_f32_22_33135=null;
